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Summary 
 
 
 
Neurodegenerative disorders with abnormal accumulation of tau protein are termed 
“tauopathies”. These disorders, including Alzheimer’s disease, are affecting more than 20 
million people worldwide. Although their pathogenesis is related to the formation of tau 
aggregates, the exact molecular mechanisms underlying these disorders are still not well 
understood. The main aim of my thesis was to characterize the mechanisms of tau 
accumulation and removal. I therefore studied the role of truncated tau in the development of 
taupathies and tested whether induction of autophagy, a well-known catabolic process, may 
be sufficient to reverse tau accumulation and ameliorate tau-induced pathology.  
In the first part of our studies, we analyzed a novel inducible transgenic mouse model 
(TAU62 mice), expressing a truncated form of human wild-type tau (tau151-421, noted Δtau). 
TAU62 mice displayed axonal dysfunction and slowly progressive motor phenotype. 
Importantly, the neurotoxicity of Δtau was strongly enhanced when full-length P301S tau was 
co-expressed. In particular, P301SxTAU62 (abbreviated P62) double transgenic mice showed 
rapidly progressive, severe motor impairment, which was reversed by stopping the Δtau 
expression. Consistently, neuronal dysfunction and tau hyperphosphorylation were reversed in 
P62 mice when expression of Δtau was switched-off. These results demonstrate that Δtau 
exacerbates the toxicity of full-length tau and thereby induces severe but reversible neuronal 
dysfunction associated with structural changes. In parallel, we showed that induction of 
autophagy, using the mTORC1 inhibitor rapamycin, is sufficient to improve tau clearance in a 
transgenic mouse model of tauopathy (P301S mice). Rapamycin significantly delayed the 
progression of tau pathology in P301S mice, which was associated with a reduction in the 
accumulation of insoluble tau. 
Together, these data provide novel insights into the pathogenesis of tauopathies. They 
pave new ways for novel therapeutic strategies, which can prevent the fragmentation of tau 
and/or promote the process of autophagy. 
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PREFACE 
 
"Men ought to know that from nothing else but the brain come joys, delights, laughter and 
sports, and sorrows, griefs, despondency, and lamentations. And by the same organ we 
become mad and delirious, and fears and terrors assail us, some by night, and some by day, 
and dreams and untimely wanderings, and cares that are not suitable, and ignorance of 
present circumstances, desuetude, and unskillfulness. All these things we endure from the 
brain, when it is not healthy..." [1]  
 
By these words, Hippocrates in 400 B.C. unequivocally identified and defined the 
brain as the center of mind and soul, while earlier and contemporary philosophers favored the 
heart and considered the brain only as an accessory organ. During the following centuries, 
improvement of the techniques allowed to better identify the structures of the brain, the 
anatomical connections between nerves and organs, as well as some pathological features 
within the brain [2]. New methods of staining and development of advanced microscopy, 
imaging, and electrochemistry, in the 20th century, lead to a precise description of the different 
types of neurons, their connectivity and properties, and to a better understanding of the brain 
functions.  
 
The brain is the main constituent of the nervous system in all vertebrate and most 
invertebrate animals [3]. In vertebrates, it is composed of the cerebral hemispheres (or 
cerebrum), which are organized in the frontal, parietal, occipital and temporal lobes. Together 
with the cerebellum, they control all voluntary actions of the body. The cerebral cortex of 
human and some other vertebrates includes the hippocampal structure, which is involved in 
the acquisition of new memories, in the consolidation from short- to long-term memory, as 
well as in spatial memory. In the brain, one can also distinguish the thalamus and 
hypothalamus, which are associated with the regulation of various behaviours, such as 
drinking or sleeping (Figure 1A). Neurons are the basic excitating cells constituting the 
nervous system and are characterized by their ability to conduct the electrical signal, called 
nervous influx. Neurons are composed of one cellular body (or soma) with multiple dendrites 
and with a long axon, conducting the nervous influx (Figure 1B). Neurons are tightly linked 
together by an intricate network of connections established by synapses. These complex 
 8 
 
interconnections allow for the development of various functions, such as muscle activity or 
secretion of hormones, which are centrally controlled by the brain, and drive a quick and 
coordinated reaction of the body according to the environmental signals. It is also well known 
that, although the general organization of the brain is genetically programmed, experience can 
refine the connections existing between neurons, hence allowing for the essential plasticity of 
the brain [4, 5].  
 
Figure 1: Organization of the nervous system 
A) Simplified scheme of the main regions of the human brain (Biological Psychology 6e).  
B) Neuron cells contain a soma, numerous dendrites and one prolonged axone. They are 
interconnected with other neurons through thousand of synaptic connections (Mol. Biology Cell 5e). 
A
B
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Given this central, determinant function of the brain, it is not surprising that alterations 
of cerebral tissues are responsible for numerous severe pathologies in human, which are 
characterized by an important variability of symptoms. Neurodegenerative disorders refer to 
diseases affecting the nervous system, leading to a loss of neurons and to the perturbation of 
the corresponding cerebral functions. While some of these disorders, such as Parkinson’s or 
Huntington’s diseases, preferentially affect the motility of patients and their ability to perform 
coordinated movements, other alter rather their memory, thinking, behaviour and ability to 
perform everyday activities. These latter groups of pathologies, recognized as dementia, are 
the main cause of heavy dependence and institutionalization. Among them, the Alzheimer’s 
disease (AD) is the most common one, affecting more than 35 million of individuals 
worldwide, according to the Alzheimer’s Disease International organization (ADI) [6]. ADI 
further estimates that this number will double in the next twenty years to reach 115 million in 
2050. While recently a progress has been done in the identification and understanding of the 
mechanisms associated with the onset and progression of AD and associated dementia, there 
is no efficient and safe treatment yet. 
 
During my doctoral work, I focused on one group of dementia, called tauopathies, 
which are characterized by an intracellular accumulation of tau protein. I focused on 
analyzing the mechanisms underlying neuronal dysfunction in these disorders, by testing the 
toxicity of a truncated form of tau in transgenic mouse models of tauopathy. I also 
investigated whether promoting autophagy can reverse tau accumulation and alleviate the 
pathology. For these reasons, the introduction to my thesis is divided into three parts: the first 
part describes the tau protein and its functions in neurons; the second part presents the 
neurodegenerative disorders constituting the group of tauopathies and discusses hypothesized 
pathomechanisms associated with their onset and progression; the third part is dedicated to 
autophagy and its potential use as a therapeutic target for neurodegenerative disorders. In the 
following, the results obtained during my studies are presented with the corresponding 
manuscripts, which are either in preparation (Manuscript N°1) or published (Publication N°2 
and N°3). In the first manuscript, we show that truncated forms of tau exacerbate the 
propensity of tau protein to aggregate and likely contribute to an early onset of the pathology; 
in the following two publications show that induction of autophagy ameliorates tau pathology 
in mouse models of tauopathies. Finally, a general discussion on the generated data and the 
perspectives arising from them will be presented. 
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PART I 
 
Microtubule-associated tau protein: diversity, properties and functions 
 
 
The tau protein belongs to the microtubule-associated protein family (MAP) and is abundant 
in both central and peripheral nervous system neurons. In 1975, Weingarten et al. isolated a 
heat stable protein that is primordial for microtubule assembly and they called it tau due to its 
ability to induce tubule formation. In vitro, tau protein can control the polymerization of 
microtubules. Microtubules are a major constituent of axons and serve for the trafficking of 
cargoes. So far, tau protein, together with tubulin, is the only protein found to be important for 
the assembly of microtubules [7]. The role and the identity of tau were not defined in detail 
until its implication in neurodegenerative disorders such as in Alzheimer’s disease (AD) has 
been identified [8-11]. After that, many studies have been done to better understand its 
structure and principal function. 
 
1.1. Tau isoforms 
The TAU gene, located on  the chromosome 17 (locus 17q21), contains a total of 16 exons, 
the predominant form of the tau protein isoforms being produced from 11 of them [12]. 
Through alternative splicing of exons 2, 3 and 10, six isoforms of tau are generated in adult 
human brain [13]. The six isoforms differ by the presence or absence of either three (3R tau) 
or four (4R tau) microtubule-binding domains and by the number of amino terminal (N-
terminal) inserts. In parallel, the alternative splicing of exons 2 and 3 results in the absence 
(0N) or presence of one (1N) or two (2N) insert(s) of 29 amino acids in the half N-terminal 
part of the tau. Thereby, splicing of exons 2, 3 and 10 allows for six combinations 
corresponding to isoforms containing 441 amino acids (2N4R), 410 amino acids (2N3R), 412 
amino acids (1N4R), 381 amino acids (1N3R), 393 amino acids (0N4R) and, for the shortest, 
352 amino acids (0N3R) (Figure 2). During development, these six isoforms are differentially 
expressed and each of them has particular physiological roles [14]. For example, in rodents, 
only the three 4R tau isoforms are expressed in adult brain, whereas the 0N3R isoform is 
predominantly detected during development [15].  
 
 
 13 
 
 
 
 
 
 
Figure 2: Schematic representation of the human TAU gene, the TAU primary transcript and 
the six tau protein isoforms  
The human TAU gene is located on the long arm of the chromosome 17 at position 17q21 and contains 
16 exons, the exon-1 being a part of the promoter. The TAU primary transcript contains 13 exons, 
since exons 4A, 6 and 8 are not transcribed in human. Through alternative messenger RNA splicing of 
exons 2, 3 and 10, a set of six protein isoforms ranging from 352 to 441 amino acids are generated in 
adult human brain. Tau isoforms differ by the absence or the presence of one or two inserts of 29 
amino acids, encoded by the exons 2 (yellow box) and 3 (orange box), in combination with either three 
(R1, R2 and R3) or four (R1, R2, R3 and R4) repeat-regions (blue boxes) in the C-terminal region of 
the protein. The fourth microtubule-binding domain is encoded by the exon 10 (light blue box) (lower 
panel). (Adapted from Buée et al, 2000) 
Pro-Rich!
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Acidic!
region!
Repeat region!
1! 441!
1! 383!
1! 412!
1! 410!
1! 381!
1! 352!
4R2N!
4R1N!
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Human brain 
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´L. Buee et al. / Brain Research Reviews 33 (2000) 95 –130 97
Fig. 1. Schematic representation of the human tau gene, the human tau primary transcript and the six human CNS tau isoforms. The human tau gene is
located over 100kb on the long arm of chromosome 17 at position 17q21. It contains 16 exons, with exon 21 is a part of the promoter (upper panel). The
tau primary transcript contains 13 exons, since exons 4A, 6 and 8 are not transcribed in human (middle panel). Exons 21 and 14 are transcribed but not
translated. Exons 1, 4, 5, 7, 9, 11, 12, 13 are constitutive, and exons 2, 3, and 10 are alternatively spliced, giving rise to six different mRNAs, translated in
six different CNS tau isoforms (lower panel). These isoforms differ by the absence or presence of one or two 29 amino acids inserts encoded by exon 2
(yellow box) and 3 (green box) in the amino-terminal part, in combination with either three (R1, R3 and R4) or four (R1–R4) repeat-regions (black boxes)
in the carboxy-terminal part. The fourth microtubule-binding domain is encoded by exon 10 (slashed box) (lower panel). The adult tau isoforms include the
longest 441-amino acids component (2131101), the 410-amino acids component (2131102), the 412-amino acids component (2132101), the
381-amino acids component (2132102) and the 383-amino acids component (2232101). The shortest 352-amino acids isoform (2232102) is found
only in the fetal brain, and thus is referred as fetal tau isoform.
since it projects from the microtubule surface where it may [66,79,157,180,344,351]. Through these interactions, tau
interact with other cytoskeletal elements and plasma proteins may allow microtubules to interconnect with other
membrane [43,191] (Fig. 2). cytoskeletal components such as neurofilaments
In mice lacking the tau gene, an increase in microtubule- [2,257,285] and may restrict the flexibility of the micro-
associated protein 1A which may compensate for the tubules [279]. There is also evidence that tau proteins
functions of tau proteins has been observed [171]. How- interact with cytoplasmic organelles. Such interactions
ever, axonal diameter in some neurons is particularly may allow for bindi g between microtubules and mito-
affected. This may be related to the particular length of the chondria [329]. The tau N-terminal projection domain also
N-terminal domain (with or without sequences encoded by permits interactions with the neural plasma membrane
exons 2 and 3) of tau proteins in specific axons. In fact, [43]. Thus, tau may act as a mediator between micro-
projection domains of tau determine spacings between tubules and plasma membrane. More recently, this inter-
microtubule in axon and may increas axonal diameter action has been defined as involving a bi ding betwe n t e
[68]. It should be noted that in peripheral neurons which proline-rich sequence in the N-terminal part of tau proteins
often project a very long axon with large diameter, an and the SH3 domains of src-family non-receptor tyrosine
additional N-terminal tau sequence encoded by exon 4A is kinases, such as fyn [252]. Lee and colleagues have shown
present, generating a specific tau isoform called ‘big tau’ that the SH3 binding PXXP motif is located in the
[5,127]. These results strongly suggest that N-terminal sequence Thr–Pro–Pro–Lys–Ser–Pro–Ser of tau231 237
regions of tau proteins are crucial in the stabilization and proteins (according to the numbering of the longest
organization of certain types of axons. isoform). Moreover, they described the colocalization of
Tau proteins bind to spectrin and actin filaments tau and fyn just beneath the plasma membrane, and an
TAU gene!
Transcription!
TAU mRNA!
Alternative splicing!
R1! R2! R3! R4!
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1.2. Localization, structure and functions of tau 
 
Tau is a microtubule-associated protein of low molecular weight, highly expressed in both 
central and peripheral nervous system. It constitutes a major component of cytoskeletal 
structures. Primary sequence analysis demonstrates that tau consists of an N-terminal acidic 
portion followed by a proline rich region and a C-terminal tail, which is the basic part of the 
protein. Tau protein binds to the microtubules through the repeat regions R1-R4, encoded by 
exons 9-12 [16]. Each repeat region consists of stretches of eighteen, highly conserved 
residues [17]. The repeat domains are separated from each other by spacer regions of thirteen 
or fourteen residues [18-20].  
 The main function of tau is to promote tubulin polymerization, to stabilize the 
microtubules and to ensure their flexibility. Thereby tau is involved in the maintenance of 
axonal transport [7, 21-25]. Microtubules contribute to diverse cellular processes such as 
morphogenesis, cell division and intracellular trafficking [26, 27]. In cells, microtubules have 
the ability to change their length by dynamic instability [28]. The binding of tau protein to the 
microtubules is balanced by coordinated actions of kinases and phosphatases and is essential 
to maintain their integrity [29, 30]. Specific ATPase enzymes, including kinesin and dynein, 
serve as cellular motors that can transport their cargoes, such as mitochondria [31, 32], 
lysosomes [33], peroxisomes [34] as well as endocytotic and exocytotic vesicles [35], on the 
way to the cell periphery and back, towards the microtubule organizing center (MTOC) of the 
cell. Tau alters the intracellular traffic due to its tight binding to microtubules and possibly 
detaches the cargoes from kinesin, although the speed of kinesin does not seem to be 
influenced by tau protein [36] (Figure 3). 
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Figure 3:  Microtubular transport 
The presence of tau on microtubules modifies the dynamic of motor proteins such as dyneins and 
kinesins, which are using microtubules for retrograde or anterograde transport of cargoes, along the 
axon (Adapted from Jaworski et al, 2010). 
 
 
1.3. Post-translational modifications of tau 
 
Tau protein is subjected to diverse post-translational modifications and up to now it is very 
difficult to know which of them are crucial for the development of tauopathies. The 
mechanisms that lead to tau aggregation are not known but it is possible an interplay exists 
between several tau post-translational modifications that leads to tau accumulation and 
eventually the formation of neurofibrillary tangles (NFT). Here, only some of the identified 
post-translational modifications of tau will be described such as phosphorylation, 
glycosylation, ubiquitination or truncation. 
 
1.3.1. Tau phosphorylation 
Tau has been defined as a phosphoprotein by many different studies [37-39]. Most of them 
focused on the serine/threonine phosphorylation of the tau protein as well as phosphorylation 
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Figure 4: Model for Tau-mediated neurodegeneration. In normal conditions, protein Tau is regulated tightly at different levels: isoform
expression, phosphorylation, microtubule binding, turnover, all needed to ensure normal transport along microtubules in axons and
dendrites (upper panel). Increased expression of protein Tau, either genetically or pathologically in humans or experimentally in
animal models will increase the amount of protein Tau bound to microtubules, thereby competing for and blocking the binding-
sites needed for the motor proteins that carry out transport (middle panel). The resulting impairment in transport of any cargo,
from synaptic vesicles and mitochondria to proteins, will impair any transport and energy-dependent processes at the synapses, which
will extend and evolve into degenerating neuronal processes, and eventually lead to neuronal death. Defective synaptic transmission
is then expected to be an early indication or symptom. Initially, small and loose aggregates or oligomers of protein Tau collect onto
the microtubules, causing them to disintegrate or collapse. We also propose that the injured neuronal processes release proteins and
factors, purposely or accidental that contribute to the activation of microglia and astroglia. The activated inflammatory cells secrete
then factors that affect not only neurons but also other cells that constitute the unit blood-brain-barrier, provoking higher permeability,
which further negatively affects neurons [11, 30]. Interesting is the connection to increased activity of GSK3, which rescued the
axonopathy of Tau4R mice and the premature death of Tau.P301L mice by phosphorylating protein Tau and thereby detach it from
the microtubuli to restore normal transport by motor proteins (lower panel) [26, 37]. Likewise, neither cell-death nor inflammation
is provoked by AAV-Tau.255, devoid of the microtubule binding domain. The transgenic and viral models thereby underscore the
microtubule binding of protein Tau as the common mechanism of action whereby protein Tau is causing neuronal demise and eventually
neurodegeneration.
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expre sion, phosphorylation, microtubule binding, turnover, all n eded to ensure normal transport along microtubules in axons and
dendrites (upper panel). Increased expre sion of protein Tau, either genetically or pathologically in humans or experimentally in
animal models will increase the amount of protein Tau bound to microtubules, thereby competing for and blocking the binding-
sites n eded for the motor proteins that ca ry out transport (middle panel). The resulting impairment in transport of any cargo,
from synaptic vesicles and mitochondria to proteins, will impair any transport and energy-dependent proce ses at the synapses, which
will extend and evolve into degenerating neuronal proce ses, and eventually lead to neuronal death. Defective synaptic transmi sion
is then expected to be an early indication or symptom. Initially, small and loose aggregates or oligomers of protein Tau collect onto
the microtubules, causing them to disintegrate or collapse. e also propose that the injured neuronal proce ses release proteins and
factors, purposely r a cide tal that contribute to the activation of microglia and astroglia. The activated inflammatory cells secrete
then factors that affect not only neurons but also other cells that constitute the unit blood-brain-ba rier, provoking higher permeability,
which further negat vely affects neurons [11, 30]. Interesting is the connection to increased activity of GSK3, which rescued the
axonopathy of Tau4R mice and the premature death of Tau.P301L mice by phosphorylating protein Tau and thereby detach it from
the microtubuli to restore normal transport by motor proteins (lower panel) [26, 37]. Likewise, neither cell-death nor inflammation
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Figure 4: Model for Tau-mediated neurodegeneration. In normal conditions, protein Tau is regulated tightly at different levels: isoform
expression, phosphorylation, microtubule binding, turnover, all n eded to ensure normal transport along microtubules in axons and
dendrites (upper panel). Increased expression of protein Tau, either genetically or pathologically in humans or experimentally in
animal models will increase the amoun of protein Tau bound to microtubules, thereby competing for and blocking the binding-
sites n eded for the motor proteins tha carry out ranspo t (middle p nel). The resulting impairment in transport of any cargo,
from synaptic vesicles and mitochondria to proteins, will impair any transport and energy-dependent processes at the synapses, which
will extend and evolve into degenerating neuronal processes, and eventually lead to neuronal death. Defective synaptic transmission
is then expected to be an early indication or symptom. Initially, small and loose a gregates or oligomers of protein Tau collect onto
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which further negatively affects neurons [ 1, 30]. Interesting is the connection to increased activity of GSK3, which rescued the
axonopathy of Tau4R mice and the premature death of Tau.P301L mice by phosphorylating protein Tau and thereby detach it from
he micr tubuli to restore normal transport by motor proteins (lower panel) [26, 37]. Likewise, neither cell-death nor inflammation
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fro synaptic vesicles and itochondria to proteins, i l i pair any transport and energy-dependent processes at the synapses, hich
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then factors that affect not only neurons but also other ce ls that constitute the unit blood-brain-barrier, provoking higher per eability,
hich further negatively affects neurons [11, 30]. Interesting is the connection to increased activity of S 3, hich rescued the
axonopathy of Tau4 ice and the pre ature death f Tau.P301L ice by phosphorylating protein au and thereby detach it fro
the icrotubuli to restore nor al transport by otor proteins (lo er panel) [26, 37]. Like ise, neither ce l-death nor infla ation
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Figure 4: odel for Tau- ediated neurodegeneration. In nor al conditions, protein Tau is regulated tightly at different levels: isofor
expression, phosphorylation, icrotubule binding, turnover, all needed to ensure nor al transport along icrotubules in axons and
dendrites (upper panel). Increased expression of protein Tau, either genetically or pathologically in hu ans or experi entally in
ani al els will incr ase the a o nt of protein Ta bound to icrotubules, thereby co peting for and blocking the binding-
site nee for the otor proteins that carry out transport ( iddle panel). The esulting i pair ent in transport of any cargo,
fro synaptic vesicles and itochondria to proteins, ill i pair any transport and energy-dependent processes at the synapses, hich
will extend and evolve into dege er ting euronal processes, and eventually lead to neuronal death. efective synaptic trans ission
is n expected to be an early indicati n or sy t . Initially, s all a d l o aggr ga s or oligo ers of protein Tau collect onto
the icrotubules, causing the to disintegrate or collapse. e also propose that the injured n uronal processes release proteins and
factors, purposely or accidental that contribute to the activation of icroglia and astroglia. The activated infla atory cells secrete
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which fur her n gatively affect neur ns [11, 30]. Int resting is th conne tion to i creased activity of S 3, hich rescued the
axonopathy of Tau4R ice and the pre ature death of Tau.P301L ice by phosphorylating protein Tau and thereby detach it fro
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is provoked by AAV-Tau.255, devoid of the icrotubule binding do ain. The transgenic and viral odels thereby underscore the
icrotubule binding of protein Tau as the co on echanis of action hereby protein Tau is causing neuronal de ise and eventually
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on tyrosine residues. The open structure of tau allowed for an access to a large number of 
potential phosphorylation domains. Two main groups of domains have been distinguished, 
depending on whether the Ser/Thr phosphorylation site targeting by the kinase is followed by 
a proline residue or not. Proline-directed kinases include the tau protein kinase I (also called 
glycogen synthase kinase 3, GSK3), tau protein kinase II (cdk5), kinases of the MAPK (p38) 
or JNK families, as well as other stress kinases, such as cdc2. In parallel, the protein kinase A 
(PKA), protein kinase C (PKC), calmodulin (CaM) kinase II, microtubule-affinity regulating 
kinase (MARK) and casein kinase II (CKII), which modifies residues close to acidic residues 
mainly in protein region corresponding to exons 2 and 3, define the non-proline-directed 
kinases [40]. It was suggested that changes in the phosphorylation of tau play an important 
role in the regulation of tau function by modifying its affinity to microtubules. 
 In particular, there is evidence that GSK3 plays an important role in regulation of tau 
phosphorylation under physiological and pathological conditions [41]. GSK3 is ubiquitously 
expressed and found at high levels in the brain where it localizes mostly in neurons [41, 42]. 
In 2003, Cho et al. demonstrated that GSK3 phosphorylates tau on both primed (following 
prior phosphorylation of the substrate by another kinase) and unprimed sites [43]. 
Consistently, several reports both in vitro and in vivo showed that tau phosphorylation 
increased following overexpression of GSK3 [44-47]. Inversely, reduction of tau 
phosphorylation has been detected in cells treated with lithium, a well-known inhibitor of 
GSK3 [48-50]. Together, this data suggest that GSK3 might be a potential target of tau 
phosphorylation in vivo. 
 Phosphorylation state of tau is determined by equilibrium of a different set of protein 
kinases and phosphatases. Dysfunction of this balance leads to the abnormal tau 
phosphorylation seen in AD.  
 
1.3.2. Tau phosphatases 
Several phosphatases (PP) have been related to tau dephosphorylation [51-53]. However, in 
vitro studies have shown that only three phosphatases, PP1, PP2A and PP2B, predominantly 
dephosphorylate tau [54, 55]. In the brain, tau dephosphorylation seems to be mainly 
regulated by PP2A, although not all of the phosphorylation sites depend on PP2A [56-58]. In 
addition to PP2A, another protein phosphatase playing an important role in the regulation of 
tau phosphorylation in the brain is PP5. PP5 is ubiquitously expressed in mammals and the 
expression levels of PP5 are especially high in the brain. In vitro, PP5 was shown to 
dephosphorylate tau and to interact with the microtubules [59]. 
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1.3.3. Tau glycosylation 
The addition of an O-linked N-acetylglucosamine (O-GlcNac) on Ser or Thr residues in the 
proximity of Proline amino acid is O-glycosylation, which is the dynamic and abundant post-
translational modification [51]. Glycosylation is phosphorylation-dependent and aberrant 
glycosylation promotes hyperphosphorylation of tau by both increasing phosphorylation and 
by inhibiting dephosphorylation of tau [60].  
 
1.3.4. Tau ubiquitination 
Timely degradation of accumulating cytosolic proteins is crucial for the maintenance of cell 
homeostasis, particularly in non-dividing cells such as neurons. The ubiquitin-proteasome 
system (UPS) and autophagy are essential for the removal of unfolded proteins and allow an 
effective protein quality control. It has been shown that under physiological conditions tau is 
ubiquitinated and proteolytically processed by the UPS [61-64]. Both systems, UPS and 
autophagy, have recently been shown to be substantially involved in the pathogenesis of 
neurodegenerative proteinopathies, including Huntington’s disease (HD), Parkinson’s disease 
(PD) and AD [65-67]. While degradation of non-aggregated and soluble unfolded tau protein 
can be achieved by the proteasome, degradation of tau oligomers or aggregates is impossible 
due to the inaccessibility to the catalytic core of the 26S proteasome. Thus, since the UPS is in 
charge of tau degradation, its inhibition can enhance tau accumulation [62]. Despite 
ubiquitination, tau is not sufficiently degraded by the UPS and accumulates as NFT in the 
brain [65]. For this reason, dismantling of protein aggregates requires the autophagy 
machinery. In contrast to the proteasome, where ubiquitin tagged proteins are enzymatically 
degraded by the 26S proteasome, the autophagy system sequesters various forms of debris 
from proteins up to organelles by forming autophagosomes (see below, “Autophagy: an 
essential catabolic process”). 
 
1.3.5. Tau truncation 
Not all of the post-translational tau modifications illustrated above would be required for tau 
aggregation. Accumulation of tau is dependent on its propensity to switch from its 
physiological random coil to a ß-sheet structure [68]. Proteolytic tau fragmentation results in 
an altered shape of tau molecule with potentially increased aggregation propensity [69]. 
Structures like paired helical filaments (PHF) found in AD consist of pathologically folded 
tau protein (PHF-tau) [70-72]. Several studies also reported the presence of truncated forms of 
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tau in PHF structures suggesting that tau truncation may be associated with tau aggregation in 
AD brains [73-75]. Nevertheless, the time course of the emergence of cleaved tau during the 
formation of NFT remains elusive [76, 77]. Recent reports have postulated that 
hyperphosphorylation of tau appears before its cleavage and that this fragmentation occurs 
before NFT formation [78-80]. Further reports indicated that cleavage of tau by caspases is 
related to cognitive decline of AD patients [80-83]. 
 Evidence of tau cleavage by caspases was discovered in cultured cerebellar granule 
cells with the specific detection of a 17kD tau fragment during apoptosis [84]. In vitro 
experiments further revealed that tau truncated at its C-terminal domain was more toxic 
compared to the full-length form of tau, most probably due to its faster and greater 
aggregation propensity [85]. Moreover, cleavage of tau by caspase at C-terminal end, E391 
(Glu391) and D421 (Asp421) promotes its accumulation and correlates with the progression of 
AD [86, 87]. Furthermore, truncation of tau in the N-terminal region has been previously 
reported [87] and this truncation may promote tau aggregation although its pathological 
significance remains to be proven.  
The pathological role of tau fragmentation in the C-terminal region has been evaluated in 
cultured cells and transgenic animal models and multiple modifications in the organization 
and functions of membranous organelles (mitochondria and the endoplasmic reticulum) have 
been related to tau truncation [82, 84, 88-92]. Cognitive impairment associated with neuronal 
death and accumulation of misfolded truncated tau has also been reported in transgenic 
animals [93-99]. Moreover, clinicopathological analysis has been conducted for a better 
understanding of the role of tau fragmentation in the development of fibrillary structures in 
dementia and its pathological involvement in AD patients [77, 86, 100]. The evolution of AD 
correlates with the extent of tau fragmentation and precedes NFT formation [101]. Together, 
these data put emphasise on the pathophysiological importance of truncated tau in AD, which 
is of importance to identify novel diagnosis markers and to develop therapeutic tools. 
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PART II 
 
Neurodegenerative disorders and animal models 
 
The term “tauopathies” refers to the group of heterogeneous disorders clinically characterized 
by movement disturbances and the pathological accumulation of tau. 
Over the past decade, the researchers have made their effort to develop animal models in 
order to mimic particular features of tauopathies, such as behavioural, histological and 
biochemical aspects. These models are useful to understand the pathomechanisms of 
tauopathies and to test potential therapeutic strategies. 
 
 
2.1. Alzheimer’s disease 
 
Alzheimer’s disease (AD) is a heterogeneous disorder in terms of clinical presentation and 
neuropathology. Its diagnosis is difficult due to the absence of specific disease markers and 
the overlap of clinical and pathological symptoms with those observed in non-demented 
elderly individuals and in patients affected by other types of dementia. In 1901, the german 
psychiatrist Alois Alzheimer (1864-1915) first met a patient named Mrs. Auguste D. at the 
Frankfurt Asylum (Figure 4). This 51 year-old woman suffered from a loss of short-term 
memory, among other cognitive symptoms that puzzled Dr. Alzheimer [102]. Five years later, 
the patient died and Dr. Alzheimer obtained her brain and medical records that were sent to 
him from Munich, where he was working with Dr. Emil Kraeplin. By staining sections of her 
brain, Dr. Alzheimer was, for the first time, able to identify and describe senile plaques and 
neurofibrillary tangles [103-105].  
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1.2.1. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of
people worldwide. The history of AD started in 1901 when the German psychiatrist Alois
Alzheimer (1864-1915) (Figure 3) began to be involved in the observation of a 51-year-
old female patient, Auguste D (Figure 3) 
[155]
. Her first symptoms included changes in
personality with strong feelings of jealousy toward her husband. Over one year, this
patient developed a serious impairment in new memory formation that was followed by
hallucinations, paranoid ideas, speech difficulties and behavioural problems 
[155]
. After
her death in 1906, Alzheimer published a clinicopathological description of her illness
[156-158]
. By the use of a silver staining method described by Max Bielschowsky (1869-
1940), he found abundant senile plaques and neurofibrillary tangles (NFT) in the cerebral
cortex 
[159]
. Blocq and Marinesco, however, had described these plaques already
previously in an epileptic patient but Alzheimer was the first to discover the tangle
pathology 
[160]
 (Figure 3).
Figure 3. Alois Alzheimer and Auguste D.
Alois Alzheimer (1864-1912) (left image) and his first patient, Auguste D., in whom he
described the typical lesions of the disease now bearing his name. On the right the
original drawing by Alois Alzheimer showing the neurofibrillary lesions present in this
patient’s brain is depicted.
 
 
igure 4: Alois Alzheimer and Auguste D 
Alois Alzheimer (1864-1912) (left image) and his first patient (middle image), Auguste D., in whom 
he described the typical lesions due to the disease, now bearing his name. On the right, the original 
dr wi g by Alois Alzhe m r shows the neurofibrillary tangles  present in the brain of this patient.  
 
 
The main pathological hallmarks of AD are i) the senile plaques composed of ß-amyloids 
(Aß), and ii) the neurofibrillary tangles (NFT) consisting of paired filaments of aggregated tau 
protein. The neuronal and dendritic loss in the perithinal and entorhinal cortex, the 
hippocampus and the cerebral cortex [106] as well as the synaptic damage [107-109] are also 
typical for this disease. 
 
 
2.1.1 Senile plaques 
In Alzheimer’s original report senile plaques have been described as “miliary foci” (Figure 5) 
[103], which correspond to spherical lesions of 10-200 µm in diameter, today recognized as 
composed extracellular Aß deposit and cellular elements. The Bielschowsky silver technique 
has been used to identify and classify senile plaques. This method of staining is still in use 
nowadays [110]. It should be noted that before Alzheimer’s report, Blocq and Marinesco had 
already described senile plaques in an elderly epileptic patient [111]. 
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Figure 5: Extracellular deposition of Aß 
Left panel: Bielschowsky silver impregnation is the technique used by Alzheimer in his original 
description of Auguste D. showing “miliary foci”(arrows) [112]. These typical foci were known to 
occur in association with  “dementia senilis” before Alzheimer’s description. Middle and right panel: 
Immunohistochemical staining of Aß showing the two main types of extracellular deposits 
encountered in AD: senile plaque with its compact amyloid core (middle, arrow) and Aß deposition in 
vessel walls (CAA; right) (Adapted from Castellani et al., 2008). 
 
 
There have been several pathological mechanisms postulated responsible for the generation of 
senile plaques. The main constituents of senile plaques are the extracellular deposits of 
aggregated Aß. These deposits are surrounded by dystrophic neurites, activated microglial 
cells and reactive astrocytes [113, 114]. In addition, Aß deposits are also present in the walls 
of cerebral [115, 116] and leptomeningeal blood vessels, now called cerebral amyloid 
angiopathy (CAA) [117, 118] (Figure 4). 
 
 The Aß peptide [119-121] is a 4 kDa protein fragment of 39-43 amino acids which 
results from the proteolysis of the amyloid precursor protein (APP) [122-125]. APP is a 
transmembrane glycoprotein, which can be proteolytically cleaved by the membrane-
associated α-, β- and γ-secretases. The α-secretase cleaves APP within its Aß domain and 
produces soluble α-APP. This process is non-amyloidogenic, as the cleavage prevents the 
formation of Aß. In contrast to α-secretase cleavage, proteolysis may happen in the 
amyloidogenic endosomal-lysosomal pathway, triggered by ß-secretase and followed by γ-
secretase, which together generate the highly fibrillogenic Aß peptide. Only one protein, 
BACE1, has been described so far to be required for ß-secretase activity, whereas γ-secretase 
and cotton-wool. The neuritic plaque (Fig 3) in particular has been touted
to be the most pathogenically relevant, and often highlighted as the plaque
type of significance in the major consensus criteria for the diagnosis of
AD at autopsy, although it is interesting that according to Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD) criteria (the most
commonly employed plaque-based criteria),18 standard brai regions are
assessed via the Bielschowsky silver technique, which is a nonspecific
impregnation that reacts to all plaque types. The other major hallmark, the
NFT, is occasionally given descriptors, such as “globose,” and “pret-
angles,” although NFT are not semiquantitated in the standard criteria, but
rather assigned significance based on location within the brain (see
below).19 Because of more detailed characterization of the AD brain
using phospho-tau antibodies, other closely related lesions include neu-
ropil threads (thread like accumulations of phospho-tau within neuropil of
gray matter and also white matter) and dystrophic neurites (terminal
neuritic swellings) that occur within (and properly define) neuritic
plaques.
FIG 1. Cored “miliary focus” is demonstrated in this Bielshowsky silver impregnation, the
technique that Alzheimer used in his original description of Auguste D.1 Such foci were
known to occur in association with “dementia senilis” before Alzheimer’s description.5
488 DM, September 2010
!
cause CAA. These include A!PP (sporadic CAA, CAA related to AD and
Down syndrome, hereditary cerebral hemorrhage with amyloidosis—
Dutch type), cystatin C (hereditary cerebral hemorrhage with amyloid-
osis—Icelandic type), transthyretin (meningovascular amyloidosis), gel-
solin (familial amyloidosis, Finnish type), prion protein (Gerstmann-
Straussler-Scheinker disease with Y145 stop mutation), ABri precursor
protein (familial British dementia), and Adan precursor protein (familial
Danish dementia). All bu A! are associate only rarely with CAA, while
CAA due to A! deposits is rather common in elderly individuals, being
the most common “cause” of nonhypertensive intracerebral hemorrhage
in this age group. In light of the fact that vascular deposition of A!, with
or without AD, comprises the overwhelming majority of CAA cases, the
issue of the relationship between CAA and AD naturally arises. Some
arguments favoring the view that CAA plays a major role in the cognitive
decline in AD are as follows: (i) the frequency and severity of CAA is
increased in AD; (ii) amyloid angiopathy produces ischemia and hemor-
rhage that could then cause cognitive dysfunction; (iii) even when mild,
CAA alters vascular physiology such that end-organ consequences are not
FIG 11. Immunohistochemical stain for A! in an individual who died of complications of lobar
intracerebral hemorrhage. The patient was living independently with no evidence of cognitive
dysfunction before death.
506 DM, September 2010
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1.2.1.1. Neuropathological hallmarks
The plaques and tangles that were observed in the brain of Alzheimer’s original patient
are still the two undisputed histopathological hallmarks of AD. Neuropathologically, they
are accompanied by variable neuronal losses in the entorhinal cortex, hippocampus, and
cerebral cortex 
[161]
; synaptic damage 
[162-164]
; loss of cholinergic innervation 
[165]
; and
signs of inflammation 
[166]
.
Aβ deposits and APP processing
The senile plaques are composed of extracellular deposits of aggregated amyloid-β
protein (Aβ), surrounded by dystrophic neurites, activated microglial cells and reactive
astrocytes 
[167, 168]
. Aβ deposits are also encountered in diffuse plaques that present a
more amorphous profile and lack Aβ fibrils [169, 170] and in the walls of cerebral and
leptomeningeal blood vessels, also called cerebral amyloid angiopathy (CAA) 
[171, 172]
(Figure 4).
Figure 4. Extracellular deposition of Aβ
Immunohistochemistry for Aβ s owing the main types of extracellular deposits
encountered in AD. Senile plaque with amyloid core (left), diffuse plaque (middle) and
Aβ deposition in vessel wall  (cerebral amyloid angiopathy; ight).
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activity depends on the presence of a large heterotypic complex composed of presenilin, 
nicastrin, APH-1 and PEN-2 proteins [126, 127].     
  
 
  
 
 
Figure 6: Schematic representation of APP processing by α-, ß-, γ-secretases  
Cleavage by α-secretase (left panel) generates the large and soluble APPsα and the transmembrane C-
terminal fragment (CTFα). Cleavage by ß-secretase (right panel) results in the production of soluble 
APPsß and production of C-terminal fragment (CTFß). Both CTFα and CTFß serve as substrates for γ-
secretase, which gives, yields a 3 kDa peptide called p3 from cleavage of CTFα and Aß production 
from cleavage of CTFß. (Adapted from Kahle et al., 2003). 
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The idea that the neurodegeneration in AD may be caused by the deposition of Aß peptide in 
plaques (the “amyloid cascade” hypothesis) has been first suggested in 1991 [128]. According 
to this hypothesis, the pathogenesis of AD is driven by the aggregation of Aß fibrils in the 
brain. The progression of the disease, including the formation of neurofibrillary lesions, 
microglia activation, synaptic dysfunction and neuronal loss, would then be an outcome of an 
imbalance between Aß production and clearance [129]. However, in elderly subjects 
presenting intact cognitive functions it is possible to find abundant cortical Aß aggregation 
[130, 131]. Several studies support a modification of the amyloid cascade hypothesis and 
suggest that Aß assembly into neurotoxic oligomers, and not into amyloid plaques, is the 
major toxic effector in AD pathogenesis [132-135]. Most probably fibrillar amyloid plaques 
serve as a container for the amyloid oligomers or constitute a pool of sequestered soluble and 
precipitated Aß. They would, therefore, have a protective rule or simply constitute the end 
stage of the Aß cascade [136]. 
 
 
2.1.2. Neurofibrillary lesions 
Another hallmark of AD pathology is the intracellular accumulation of hyperphosphorylated 
tau proteins in NFT and the neuropil threads (NT) or dystrophic neurite associated with senile 
plaques (Figure 7). It has been suggested that Aß toxicity is tau dependent, even though the 
mechanism remains uncertain. Indeed, it has been shown that knocking out tau alleviates 
cognitive impairment without affecting Aß levels in an APP mouse model of AD [137]. Tau 
is normally localized in axon and has been shown to be mislocalized in dendrites and soma of 
neurons in AD. Tau in dendrites would interact with kinase protein and lead to Aß toxicity 
[138]. On the other hand, recent reports have shown that injection of Aß fibrils in P301L 
transgenic mice model increases the formation of NFT. In this study the authors demonstrated 
that the injection exaggerates hyperphosphorylation of tau and NFT formation [139].  
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Figure 7: Intracellular lesions made of aggregated tau protein 
Gallyas silver staining shows neurofibrillary tangles in the cortex of subjected with AD.  
 
 
2.2. Other tauopathies 
 
The central event leading to the formation of NFT and neuronal loss in AD is not exactly 
known. In AD, Aß peptides may play a central role in the formation of NFT [128]. However, 
as mentioned before, a number of neurodegenerative diseases known as tauopathies share the 
feature of tau inclusion in neurons and glial cells but in the absence of Aß pathology. Only the 
most frequent of them will be shortly described here. 
   
2.2.1. Progressive supranuclear palsy 
Progressive supranuclear palsy (PSP) is also known as Steele-Richardson-Olszewski 
syndrome. This neurodegenerative disorder is characterized by supranuclear vertical gaze 
palsy and motor impairment including axial rigidity and dystonia [140]. Neuropathologically, 
neuronal loss, gliosis and NFT formation are the characteristic symptoms of PSP. Since NFT 
appears first in the basal ganglia (mainly the globus pallidus and the subthalamic nucleus), 
brainstem and cerebellum [140]. PSP thus constitutes a “subcortical dementia” [141, 142]. 
Typical tau aggregates appear in different brain area as round or globose-type NFT and as NT 
[143, 144] as well as in astrocytes (tufted astrocytes) and oligodendrocytes (coiled bodies) 
[145] (Figure 8). 
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2.2.2. Corticobasal degeneration 
Corticobasal degeneration (CBD) is an adult-onset, sporadic, slowly progressive 
neurodegenerative disorder. Clinically CBD is characterized by an extrapyramidal motor 
syndrome and cognitive dysfunction associated with aphasia and apraxia. In contrast to 
Parkinson’s disease, this disorder is poorly responsive to dopaminergic drugs. [146-148]. In 
CBD, the dysfunction of the neurons is observed in many components of the basal ganglia 
including the substantia nigra. Thus, a treatment with dopamine agonist, unlike in Parkinson’s 
disease, meets no intact effector cells in the striatum. Neuropathological observation of the 
brain reveals a frontoparietal, often asymmetrical atrophy together with neuronal and glial 
abnormalities including “astrocytic plaques” [149] (Figure 8). 
 
2.2.3. Pick’s disease 
Pick’s disease (PiD) is a rare, neurodegenerative disorder with a progressive clinical course 
characterized by frontal and temporal lobes symptoms with behavioural abnormalities, mood 
changing and impairment of language [150]. The specific pathological feature is an atrophy of 
the frontal and temporal lobes associated with severe neuronal loss, gliosis and argyrophilic. 
Even though Gallyas staining is negative, tau containing intraneuronal inclusions known as 
Pick bodies has been detected in both cortical and subcortical areas [151, 152], granule cells 
of the dentate gyrus and pyramidal neurons of the hippocampus [153, 154] (Figure 8). 
  
2.2.4. Argyrophilic grain disease 
Argyrophilic grain disease (AgD) is a common, sporadic dementia affecting elderly 
individuals, with a prevalence of 5% [155, 156]. AgD is characterized by an abundance of 
argyrophilic tau immunoreactive grains in the enthorinal cortex, hippocampus (CA1, 
subiculum) and amygdala [157, 158] often together with NFT typical of AD. The 
pathogenesis of AgD and the mechanisms leading to the accumulation of these grains remain 
unknown. The clinical symptoms of the pathology comprises a cognitive decline, dementia 
[156, 159] as well as behavioural changes like mood and emotional imbalance [155]. Besides, 
it has been shown that there is an occasional memory loss in AgD, making it difficult to 
distinguish from AD in some cases (Figure 8). 
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Figure 8: Different types of tau pathology in tauopathies 
Upper panel, left: classical neurofibrillary tangles in AD revealed by immunohistochemistry with 
phosphorylation-dependent anti-tau antibody (arrow). Middle: Tau immunohistochemistry shows a 
globose tangle (arrow). Right: Tufted astrocytes in PSP revealed by Gallyas silver staining (arrow) 
(Adapted from M. Neumann et al., 2009). Lower panel, left: Tau immunohistochemistry shows 
astrocytic plaques in CBD (arrows) (Adapted from M. Neumann et al., 2009), (middle) pick bodies 
(spherical intraneuronal inclusions, arrows) using phospho-tau immunohistochemistry in Pick’s 
disease. Right: Argyrophilic grain in the neuropil (arrowhead) and abnormal accumulation of 
hyperphosphorylated in hippocampal pyramidal cells in a case of argyrophilic grain disease (arrow). 
 
 
2.2.5. Frontotemporal dementia and parkinsonism linked to chromosome 17 
In 1994, a familial form of frontotemporal dementia with parkinsonism was linked to the 
locus 17q21.2 [160]. Mutations in the TAU genes were shown to be responsible for these 
pathological conditions which were gathered under the term of Fronto-Temporal Dementia 
and Parkinsonism linked to chromosome 17: FTDP-17 [161]. The neuropathological 
hallmarks of FTDP-17 are: neuronal loss, astrocytic gliosis and filamentous accumulation of 
hyperphosphorylated tau. The clinical features of this disease include personality changes, 
motor disturbances and cognitive decline, which leads to severe dementia. Depending on the 
mutation affecting the TAU gene, and the fact whether it is located in the coding or non-
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Figure 2. Pathological features in FTLD-tau. (a) Severe atrophy of the frontal and temporal lobes and (b) Pick
bodies in the temporal cortex of a patientwithPickdisease. (c) Tufted astrocyte and (d) a globose tangle in acase
with progressive supranuclear palsy. (e) Astrocytic plaque as a hallmark lesion of corticobasal degeneration. (f)
Abundant argyrophilic grains in the hippocampus of a patient with argyrophilic grain disease. (g) Neurofibrillary
tanglesandneuropil threads in the frontalcortexofacasewith frontal variantAlzheimerdisease.Arrowindicatesa
neuritic plaque. (h) Tau pathology in sector CA2 of the hippocampus in hippocampal sclerosis dementia. (i)
Neuronal and glial tau pathology in the frontal cortex of a patient with an intron 10 þ3 splice-site mutation in
the tau gene. b, d, e, f, h, tau immunohisto hemistry; c, g, i, Gallyas-Braak silver stain. Scale bars: 50 mm.
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Argyrophilic grain disease
 
273
the hippocampus, the entorhinal/transentorhinal cortex
and the amygdaloid nucleus. In sector CA1, one might
find up to 80% of pyramidal cells exhibiting diffuse AT8
staining of their cell bodies and dendrites. Because this
constitutes a highly characteristic finding for AgD it is
considered as one of the core lesions yet not essential for
routine diagnosis (Table 1). In AgD almost all of the neu-
ronal types prone to accumulate hyperphosphorylated tau
protein belong to the class of projection neurons and
include constituents of he tr nsentorhinal and entorhinal
 
Fig. 2
 
(A) Abundant AT8-immunoreactive argyrophilic grains in hippocampal sector CA1 next to some pretangle neurons. (B)
AT8-immunostained pretangle neuron in the entorhinal cortex of an argyrophilic grain disease case (A 
 
¥
 
380; B 
 
¥
 
460).
 
Table 1
 
Argyrophilic grain disease (AgD): neuropathological and biochemical features
 
†
 
1. Core lesions of AgD
1.1. Essential for diagnosis
– Argyrophilic grains (Gallyas-positive, Tau-positive)
1.2. Consistent features but not essential for diagnosis
– Coiled bodies (Gallyas-positive, Tau-positive)
– Abundant non-argyrophilic (Gallyas-negative), tau-positive limbic projection neurons (‘pretangle’ neurons).
1.3. Biochemical tau profile of AgD:
– Tau doublet at 64 and 69 kDa. Pathological tau aggregates mainly made of four-repeat tau isoforms
2. AgD associated lesions – frequent findings but not essential for diagnosis
– Ballooned neurons (Gallyas-negative. Tau- and 
 
a
 
B-crystallin-positive. Present in amygdala and layers V and VI of basal 
temporal neocortical areas)
– Non-argyrophilic (Gallyas-negative), tau-positive astrocytes (present in amygdala and entorhinal and transentorhinal cortices)
– Associated lesions of the Alzheimer-type
– Neurofibrillary lesions (Braak stages I-III; frequent finding)
– Senile plaques (few, mainly diffuse type; two thirds of cases)
3. AgD associated lesions – atypical findings
– Superficial laminar spongiosis (layers II-III of basal temporal neocortical areas)
– Cortical and subcortical gliosis (entorhinal and transentorhinal cortices, posterior parahippocampal gyrus)
 
†
 
Adapted from Tolnay 
 
et al.
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coding region, tau aggregates can be constituted predominantly of 3R, 4R or a combination of 
3R and 4R tau isoforms.  
 
 
2.3. Development of experimental mouse models of tau pathology 
 
Different transgenic mouse models of AD and other tauopathies have been generated over the 
last fifteen years. Several mouse models have been engineered and selected examples will be 
presented in the following part. 
 
 Transgenic mice with mutations present in familial forms of tauopathies develop a 
similar pathology as seen in human patients. The missense mutations substituting the proline 
301 for a leucine (P301L) or serine (P301S) were discovered in FTDP-17 [162, 163]. These 
mutations affect TAU exon 10, which encodes the highly conserved microtubule-binding 
domain, and thereby only alter the 4R tau isoform. Transgenic mice expressing human 4R tau 
with FTDP-17 mutation P301L under the control of the mouse prion promoter  (JPNL3 line) 
develop progressive motor and behavioural impairments [164]. Aggregated tau and NFT 
formations are found in the cortex, the hippocampus and the basal ganglia of these mice. 
JPNL3 mice show a sever phenotype at 6.5 months in hemizygous and 4.5 months in 
homozygous animals, even though the expression of the transgene is low. A similar model 
created in 2002 expresses the human TAU gene carrying the P301S mutation under control of 
the Thy 1.2 promoter [165]. In humans, this mutation causes an early onset form of FTDP-17. 
P301S mice develop a progressive motor deficit, which is related to the abundance of tau 
filaments inclusions in the brainstem and the spinal cord. These filaments contain 
hyperphosphorylated tau protein. While in FTDP-17 patients nerve and glial cells are affected 
[166], in P301S model the accumulation of tau is restricted to nerve cells which is due to the 
selective neuronal expression of the tau transgene by the Thy 1.2 promoter. These two murine 
models carrying mutation in the TAU gene (P301L and P301S) highlight the role of tau in 
neurodegenerative diseases and are currently being used for the development of possible 
therapeutic strategies against tauopathies. 
 Other mouse models have further established that an imbalance between the 3R/4R 
isoforms can be responsible for the development of tauopathies [18, 51, 167-169]. 
Notwithstanding, transgenic mice expressing the shortest 3R tau isoform under the HMG-
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CoA reductase promoter [170] or under the Prnp promoter [171] recapitulate key features of 
tauopathy.  
 As mentioned before, tau can be cleaved by caspases at Asp421. This fragmentation 
affects the conformation of the protein, which accumulates rapidly [74, 75], co-localizes with 
tangles and associates with degenerating neurons [93, 95, 96]. Interestingly, rTg(tauP301L) 
4510 mice showed a quick activation of the caspases, followed by the development of NFT in 
neurons. After tangle formation, caspase activity was suppressed in NFT-containing neurons 
without neuronal death. The authors established the hypothesis that the formation of NFT is 
not responsible per se or prerequisite for tau induced neurodegeneration or neuronal death. 
Furthermore, they demonstrated that NFT formation occurs after caspase activation [96]. In 
addition to cleavage at Asp421, tau can also be truncated at Glu391 at later stages in the 
progression of tau pathology. Recent studies showed that in rat models expressing fragmented 
human tau (3R or 4R), NF are widely accumulated in the brainstem and cortex [172, 173]. 
Moreover, these rat models developed muscle weakness and wasting, which might have 
caused their death. These studies highlight the major role of truncated tau in the development 
of pathologic condition by increasing the propensity for tau accumulation.  
 
 The main of our actual work is to understand the impact of fragmented tau on the 
pathogenesis of tauopathies. To this end, we have studied the toxicity of truncated tau in a 
novel inducible transgenic mouse in the presence of human full-length tau. In parallel, we 
have investigated whether increased autophagy can prevent tau aggregation in mouse models.  
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PART III 
 
Autophagy: an essential catabolic process 
 
Most neurodegenerative diseases share a similar pathogenesis with the occurrence of 
abnormal protein inclusions in the nervous system, containing specific misfolded proteins. 
Such human diseases, also called “proteinopathies”, include Alzheimer’s disease (AD), 
Parkinson’s disease (PD), or Huntington’s disease (HD). In these disorders, abnormal protein 
accumulation alters essential cellular functions and leads to neurological impairment and 
neuronal loss [174-177]. 
 
 
3.1. Mechanisms of the autophagy process 
 
Autophagy (i.e. “self-eating” in greek) is a catabolic pathway conserved among eukaryotes, 
which allows cells to rapidly eliminate large, unwanted structures such as abnormal protein 
aggregates, damaged organelles and invading pathogens [178]. Three different types of 
autophagy can deliver cytoplasmic components into the lumen of lysosomes for degradation: 
macroautophagy, microautophagy and chaperone-mediated autophagy (Figure 9). 
Macroautophagy is considered to be the major type of autophagy occurring in cells and it has 
been more extensively studied than microautophagy and chaperone-mediated autophagy. 
Therefore, in the following part, the term “autophagy” will refer to macroautophagy for 
simplification.  
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Figure 9: Different types of autophagy 
During macroautophagy, a portion of cytoplasm, including organelles, is engulfed by a double-
membrane vesicle, called autophagosome. Autolysosomes are formed by the fusion of the outer 
membrane of the autophagosome with lysosomes and allow the degradation of the sequestrated 
material. During microautophagy, small pieces of cytoplasm are directly engulfed by inward 
invagination of lysosomal or late endosomal membrane. During chaperone-mediated autophagy, 
specific substrate proteins containing a KFERQ-like pentapeptide sequence are first recognized by 
cytosolic Hsc70 and co-chaperones. After binding with lysosomal Lamp-2A, the complex substrate-
Hsc70-co-chaperones are translocated into the lysosomal lumen (Adapted from N. Mizushima et al., 
2011). 
MACROAUTOPHAGY! MICROAUTOPHAGY! CHAPERONE-MEDIATED 
AUTOPAGHY!
Lysosome/late endosome  !
Invagination!
Lysosome!
Autophagosome!
Isolation!
membrane!
Autolysosome!
Substrate! Hsc70 &!co-chaperones!
Lamp 2A!
Lysosome!
Degradation products!
Protein synthesis, energy production, gluconeogenesis, etc…!
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At basal levels, autophagy can be considered as a housekeeping mechanism involved in the 
constitutive elimination of protein aggregates and other macromolecules inaccessible to the 
ubiquitin-proteasome pathway. Autophagy is dependent on the up-regulation of multiple 
autophagy-related genes (ATG) [179]. Autophagy starts with the formation of an isolating 
membrane, a crescent-shaped double membrane, which originates from the smooth ER or 
from another, not yet defined, subcellular location [180]. The isolating membrane completely 
surrounds cargoes targeted for degradation (Figure 10). 
 
 
 
 
Figure10: The autophagy process 
Autophagy occurs at low basal levels and can be activated by multiple stimuli such starvation or 
mTOR inhibition. It involves the sequestration of cytoplasmic material by an isolating membrane 
(derived from a crescent structure also termed a phagophore) to form a double-membrane vacuole, the 
autophagosome. Mature autophagosomes fuse with lysosomes containing lysosomal hydrolase to form 
autolysosomes, then degrading cargo and enabling components to be recycled.  
Initiation!
Phagophore!
Lysosome!
Maturation!
LC3I!
LC3II!
Conjugation!
Stimuli: Starvation, growth factor deprivation, ER stress, …!
Atg12-
Atg5-
Atg16!
Atg8!
LC3I!
Atg7!
mTOR! Rapamycin!
Induction!
Expansion!
Degradation!
Autophagosome! Autolysosome!
Defective or damaged organelles!
Excessive or defective proteins!
Pathogens!
Lysosomal hydrolase!
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The formation of the autophagosomes and the progression of the autophagy processing 
require two ubiquitin-like conjugation reactions: i) the formation of a Atg12–Atg5–Atg16 
complex and ii) the conjugation of Atg7 (also known as microtubule-associated protein 1 light 
chain 3 protein or LC3) to phosphatidylethanolamine [181]. LC3 is commonly used as a 
biochemical marker for autophagy, since it is specifically lipidated and associated to 
autophagosomes during autophagy induction [182, 183]. Induction of autophagy by 
rapamycin (also known as sirolimus (Rapamune; Pfizer)) and CCI-779 is related to inhibition 
of TOR complex in yeast [184] and mTORC1 (mammalian target of rapamycin complex 1), a 
well-known, major inhibitor of autophagy, in mammals [185]. It should be noted, however, 
that some amino acid signalling can suppress autophagy in an mTOR-independent manner 
[186, 187]. Moreover, small molecule enhancers of the cytostatic effects of rapamycin (called 
SMERs) have been identified as inducers of autophagy independently of mTOR [188].  
 
3.2. Autophagy in neurodegenerative disease 
 
The accumulation of abnormally aggregated or mutant proteins plays a crucial role in 
neurodegenerative diseases [189]. On the other side, a dysfunction of autophagy, including 
accumulation of autophagosomes, has been reported in neuronal pathologies such as in 
Parkinson’s, Huntington’s and Alzheimer’s diseases [190-192]. Induction of autophagy in 
these disorders can be interpreted in two ways. On one hand, increased activity of the 
autophagy machinery may be a primary element of the pathogenesis and could contribute to 
neurodegeneration e.g by the generation of toxic protein fragments or other yet unspecified 
mechanisms [193, 194]. On the other hand, autophagy induction may constitute an adaptative, 
protective response to activate the degradation of aggregate-prone proteins. Accordingly, 
impaired autophagy leads to the accumulation of neurotoxic proteins that later on become 
responsible for neuron death. In this light, modulation of the autophagic flux constitutes a 
potential therapeutic strategy to treat or ameliorate neurodegenerative disorders. 
 
 
 3.2.1. Parkinson’s disease and the autophagy process 
Parkinson’s disease (PD) is a common neurodegenerative disorder of yet unknown origin. 
Clinical symptoms include resting tremor, slowness of movement, rigidity and postural 
instability. The symptoms are primarly attributed to a dramatic loss of dopamine containing 
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neurons in the substantia nigra pars compacta, leading to dopamine depletion in the striatum 
[195]. Histopathologically, PD is characterized by the presence of ubiquitinlated α-synuclein 
in cytoplasmic inclusions called Lewy bodies; however the origin and significance of Lewy 
bodies remain unclear. Cell models for PD revealed that the clearance of mutant forms of α-
synuclein is highly dependends on autophagy [196, 197]. Hence, autophagy inhibitors, such 
as 3-methyladenine and bafilomycin A1, delay their degradation whereas autophagy inducers, 
including rapamycin, enhance their elimination [196, 197]. In a recent study, rapamycin was 
found to have beneficial effects in both in vivo and in vitro models of PD and to protect 
dopaminergic neuron cells from death [198]. In another study, the neuroprotective action of 
rapamycin in PD was related to an increase of autophagic degradation steps, the promotion of 
the autophagosome-lysosome fusion, and thereby to an enhanced clearance of the 
autophagosomes [199]. It remains difficult to rule out the contribution of the various other 
molecular pathways affected by rapamycin, however it is likely that the positive effects of 
rapamycin on PD are mainly mediated by an increase in the autophagy flux.  
 
 
3.2.2. Huntington’s disease and the autophagy process 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
characterized by progressive motor dysfunction, dementia and emotional disturbances [200]. 
HD is caused by an autosomal, dominant (CAG) triplet repeat expansion mutation in the HTT 
gene, encoding the ubiquitously expressed protein huntingtin (Htt). Mutated Htt (mtHtt) 
accumulates inside neurons and forms toxic oligomeric species and aggregates, which 
probably lead to cell death [200]. No effective treatment has been developed so far for the 
disease. Nonetheless, it has been demonstrated that rapamycin attenuates the neuronal toxicity 
of mtHtt fragment, both in vitro and in animal models of HD. In particular, efficiency of 
rapamycin has been proven using the powerful genetic model of Drosophila melanogaster 
visual system [185]. When these flies are fed with food containing rapamycin from the larval 
stage into adulthood, they present reduced degeneration of rhabdomere sensors of the visual 
neurons compared to untreated flies [185]. Rhabdomere degeneration and the associated cell 
death were also attenuated by genetic induction of autophagy [201]. The effects of rapamycin 
treatment were also tested and analyzed in a mouse model for HD expressing a mtHtt 
fragment in brain [185]. These mice display a drastic phenotype, reminiscent of that observed 
in human, including dyskinesia, tremors, weight loss and premature death [185]. Treatment 
with rapamycin reduced mTORC1 activity, attenuated protein aggregation and finally, 
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ameliorated the behaviour phenotype [185]. Taken together, most results indicate that 
pharmacological induction of autophagy by rapamycin or other comparable substances may 
constitute potential therapeutic strategies for HD by favouring the removal of mtHtt. 
 
 
3.2.3. Alzheimer’s disease and autophagy dysfunction 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is 
characterized by memory loss and various cognitive dysfunctions. In AD brains, the two 
major pathological hallmarks are the extracellular deposition of amyloid plaques and the 
intracellular aggregation of tau [202]. In AD, massive accumulation of autophagosomes along 
dystrophic and degenerating neurites is caused by impaired maturation of the autophagosomes 
and their altered retrograde transport to the neuronal cell body [203]. Indeed, autophagosomes 
and endosomes actively form in synapses and along neuritic processes while lysosomes are 
concentrated in neuronal soma. Hence, autophagic degradation in neurons necessitate an 
efficient trafficking of autophagosomes along microtubules [66]. 
 Several studies have reported a beneficial effect of autophagy induction in AD models.  
First of all, treatment with rapamycin was shown to decrease toxicity of mutated tau in 
transgenic flies [204, 205]. Induction of autophagy by using viral vector-mediated expression 
of beclin 1, also known as autophagy-related protein 6 (Atg6), reduced intracellular and 
extracellular ß-amyloid deposition in APP transgenic mice [206]. Similarly, enhancement of 
lysosomal activity in the transgenic mouse model of AD, (TgCRND8 line), decreased 
intraneuronal and extracellular Aß levels, and inhibited the progression of deficits of learning 
and memory in these animals [207]. Inversely, inhibition of autophagy increased Aß induced 
toxicity in neuron cell cultures [208]. Caccamo et al. using an AD mouse model found that 
mTORC1 inhibition with rapamycin improved cognitive deficits and alleviated tau pathology 
by enhancing autophagy [209]. Lastly, in two different genetic mouse models for AD, the 
PDAPP mice also known as hAPP (J20 line), which accumulate soluble and aggregated Aß, 
and the 3xTgAD mice expressing APPSwe/P301L/mutant PS1M146V, rapamycin restrained their 
cognitive deficits and attenuated amyloid and tau pathology by enhancing autophagy [209, 
210].  
 It should be noted that imbalanced activity of mTORC1, which plays an important role 
in sensing nutrient and energy in cells, correlates with autophagy impairment in AD [203]. 
The mTORC1 pathway is more activated in the presence of Aß peptides accumulation whilst 
Aß levels are reduced with a decrease in signalling. Moreover, in AD brain, activity of 
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mTORC1 and levels of its downstream targets such as eukaryotic initiation factor 4E binding 
protein 1 (4EBP1), correlate with tau protein accumulation [211].  
 The importance of autophagy deficits in AD is not fully understood. It is well known 
that aging is an important risk factor for the development of AD and many other 
neurodegenerative diseases. Notably, rapamycin treatment in animals has been shown to 
prolonge lifespan in several recent studies, and to limit the development of age-related 
dysfunctions in several tissues, likely by promoting autophagy (see below, “Role of 
rapamycin in aging”). Hence, promoting autophagy in age-related neurodegenerative 
disorders constitutes a promising therapeutical strategy [212, 213]. 
 
 
3.3. The mTORC1 pathway and tau protein 
 
mTOR is a 289kDa serine/threonine protein kinase that belongs to the phosphoinositide 3-
kinase (PI3K)-related kinase family and serves as a main regulator of cell metabolism, 
growth, proliferation and survival [214-217]. Two main types of multi-protein complexes 
form with mTOR: the mTOR complex 1 (mTORC1) characterized by the raptor protein and 
the mTOR complex 2 (mTORC2) including the rictor protein [218]. mTORC1 positively 
regulates cell growth and proliferation by modulating anabolic processes such as protein 
synthesis and by blocking catabolic processes like autophagy. mTORC1 is recruited to and 
activated on lysosomal membranes in the presence of amino acids, and thereby can promote 
translation and inhibit autophagy [209, 219, 220]. 
 Beyond its relation to tauopathy through the inhibition of autophagy (see above, 
“Autophagy in neurodegenerative disease”), mTORC1 pathway seems to play a role in 
neurodegenerative disorders by regulating tau translation, modulating its phosphorylation and 
thereby, the formation of PHF and NFT [221]. Moreover, tau phosphorylation has been 
shown to be regulated by the balance between PP2A and GSK3, which can be modulated 
through the PI3K/mTORC1 signalling [222]. All together, these data suggest that the 
mTORC1 pathway may be a potential, effective therapeutic target for tau-related pathological 
conditions. 
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3.3.1. Role of rapamycin in aging  
Increased age is a risk factor shared by many neurodegenerative diseases, although the direct 
molecular link between ageing and neurodegeneration is still unknown. As mentioned before, 
several studies established that rapamycin extends life span in different species, including 
yeast [223], fruitflies [224] and mice [212]. Some of the reports also demonstrated that 
rapamycin exerts a beneficial effect on age-related neurodegeneration. According to these 
results, mTORC1 constitute a key player and a target for lifespan extension [225]. Anti-aging 
effects obtained by pharmacological or genetic inhibition of mTORC1 mainly rely on the 
induction of autophagy. However, it has also been suggested that lifespan extension promoted 
by rapamycin may be related to the reduction in protein synthesis in D. melanogaster [224]. 
Indeed, upregulation of S6K activity or genetic ablation of the translational suppressor 4E-BP 
abolished rapamycin mediated lifespan extension [224]. Furthermore, other reports proposed 
that increased lifespan in yeast are achieved due to the reduction in age-related genome 
instability [223]. In particular, ribosomal DNA (rDNA) recombination, associated with the 
formation of toxic repetitive extrachromosomal rDNA circles, can be repressed by the 
induction of sirtuin deacetylases, which belong to a family of key regulators of cell survival 
[226]. Interestingly, both caloric restriction and mTORC1 inhibition were shown to promote 
the activity of sirtuin enzymes. 
 Hence, the same molecular mechanisms may underlie the function of rapamycin on 
longevity and its neuroprotective effects in different models of neurodegeneration. This may 
shed light on the potential molecular link, still not yet identified, existing between aging and 
neurodegenerative disorders. 
 
3.3.2. Rapamycin as a therapeutical approach 
Rapamycin is an established Food and Drug Administration (FDA) approved drug. First 
identified as an antifungal and antibiotic drug, it is now recognized as a major 
immunosuppressor, and used to prevent transplant rejection [227, 228]. By inhibiting 
mTORC1, rapamycin may also limit tumor growth, in particular in the tuberous sclerosis 
complex (TSC) disease, and restrain cancers. Given the positive effect of the molecule on 
longetivity [212], one can suppose that rapamycin may also be used to fight against 
neurodegenerative disease such as AD [213, 229]. 
 Preclinical tests also showed that rapamycin improves learning and restrains memory 
deficits, by promoting neuronal survival and plasticity and by reducing Aß and tau pathology 
[209, 210, 230]. Moreover, the accumulation of aggregated protein can be moderated through 
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the induction of autophagy, which can be in turn promoted by mTORC1 inhibition [231]. 
Together, these findings highlight that rapamycin or other analogue treatment targeting 
mTORC1 may constitute a basis for the development of treatment strategies that would 
improve proteinopathies such as AD.  
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 Tau fragmentation exacerbates the toxicity of tau protein and participates 
in the onset of neuronal dysfunction 
 
 
Publication N°2: 
 
Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau 
Transgenic Mice 
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Stimulation of autophagy reduces neurodegeneration in a mouse model of 
human tauopathy 
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Rationale and Aims of the thesis 
 
 
1- Previous results 
Before the beginning of this thesis, in autumn 2009, the impact of truncated forms of tau had 
been shown to favour tau aggregation [85], and tau fragmentation by proteases had been 
identified in vitro, in brain from AD patients, as well as in transgenic mouse models for AD 
[75, 86, 95]. In parallel, other groups had already suggested that induction of autophagy by 
rapamycin has a beneficial effect on age-related tissue dysfunction and on lifespan in various 
species, including yeast, fruitflies and mice [212, 223, 224]. Furthermore, in 2004, Ravikumar 
et al. also demonstrated in a pioneer study that mTORC1 inhibition and thereby autophagy 
induction is sufficient to limit the toxicity of polyglutamine expansions and to improve the 
associated HD-related phenotype of their fly model [185]. 
 
2- Specific questions 
These prior reports opened interesting avenues regarding the mechanisms at play in the 
pathogenesis of tauopathies and potential therapeutical strategies [185]. To get further insight 
on the importance of tau fragmentation on the pathogenesis, we generated new transgenic 
mouse models, expressing a truncated form of tau (noted ∆tau) in basal conditions (TAU62 
mice) or concomitantly with the expression of full length forms of tau (P301SxTAU62 noted 
P62, ALZ17xTAU62). With this project, we wanted i) to test whether ∆tau expression in vivo 
is sufficient to provoke characteristic tauopathy associated changes in mice, ii) to determine if 
∆tau modifies the toxicity of full length forms of tau protein and promotes the formation of 
tau aggregates, iii) to identify which forms (soluble/insoluble aggregates, oligomers, tangles, 
filaments) of tau are predominantly responsible for tau induced neuronal dysfunctions and iv) 
to further elucidate the cellular events at play in the onset and progression of tauopathies. The 
use of an inducible promoter in TAU62 mice furthermore allowed us to analyze the evolution 
of ∆tau initiated pathology in the corresponding mice also when the expression of ∆tau was 
stopped. 
  
 In parallel, as aging constitutes the most important risk factor for AD, and since 
autophagy impairment is thought to be involved in the onset of proteinopathies, it was of 
major interest to investigate the impact of autophagy inducers on the progression of 
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tauopathies. To shed light on this open question, we decided to study whether autophagy 
stimulation would promote tau clearance in a transgenic mouse model for tauopathy. To this 
end, P301S mutant tau mice, which were previously generated and characterized i.e. by Allen 
et al. [165], were treated with the autophagy-inducing agent rapamycin and the consequences 
on their phenotype were analyzed. The principal aim of the project was to determine whether 
mTORC1-dependent restoration of the autophagy process would reduce the accumulation of 
insoluble tau protein in the brain and spinal cord, and thereby ameliorate the associated 
neuron dysfunctions. In a comparable study, conducted in collaboration with the group of Dr. 
Michel Goedert (Cambridge, UK), P301S mice were treated with another well-known inducer 
of autophagy, trehalose, whose effect has been shown to be independent from mTORC1.  
 
3- Publications arising from this work 
This thesis is written in a manuscript-based format: the following part contains one 
manuscript in preparation and two published papers.  
 
 In the Manuscript N°1 (“Tau fragmentation exacerbates the toxicity of tau protein 
and participates in the onset of neuronal dysfunction” - Sefika Ozcelik, Graham Fraser, Zhiva 
Skachokova, Dorothee Abramowski, Alphonse Probst, Ludwig Kappos, Stefan Frank, 
Matthias Staufenbiel, Michel Goedert, Markus Tolnay, David T. Winkler - in preparation), we 
demonstrate that ∆tau fragment exerts a drastic toxic effect when co-expressed with full-
length tau in vivo, and causes a severe but reversible motor phenotype associated with 
extensive neuronal changes in double transgenic mice. Notwithstanding, these ∆tau-related 
defects were associated with the formation of toxic oligomers, in the absence of insoluble tau 
aggregates or tangles. Hence, this supports the hypothesis that tau fragmentation constitutes a 
central, determining event in the onset of tauopathies, and the prevention of tau cleavage may 
therefore be considered as a promising therapeutic strategy for these disorders. 
 
In the Publication N°2 (“Rapamycin Attenuates the Progression of Tau Pathology in 
P301S Tau Transgenic Mice” - Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, 
Breu K, Clavaguera F, Sinnreich M, Kappos L, Goedert M, Tolnay M, Winkler DT. PLoS 
One. 2013 May 7;8(5):e62459.), we establish that rapamycin treatment significantly delayed 
the progression of tau pathology and the associated histopathological and biochemical 
changes in P301S mice. Comparable effects are described in the Publication N°3 
(“Stimulation of autophagy reduces neurodegeneration in a mouse model of human 
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tauopathy” - Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Brain. 
2012 Jul;135(Pt 7):2169-77) by using trehalose treatment, another inducer of autophagy. 
Together, these data encourage the development of drugs promoting the induction of 
autophagy for patients suffering from tauopathies, although side effects of such therapeutics 
should be carefully considered and examined. 
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Abstract 
Hyperphosphorylation and aggregation of tau protein constitute the main pathological 
hallmark of tauopathies, including Alzheimer’s disease (AD). Proteolytically derived, 
aggregation prone peptides e.g. amlyoid-β or cleaved Huntingtin substantially contribute to 
the pathogenesis of neurodegenerative proteinopathies. In this light, the role of tau 
fragmentation in the course of tauopathies is being debated. We here study the effects of tau 
truncation in vivo, by developing a novel inducible transgenic mouse model, called TAU62 
mice, expressing the human Δtau151-421 fragment. These mice show a slowly progressive 
motor phenotype and histopathological signs of axonal damage. To mimic the human 
situation, where tau fragmentation occurs in presence of full-length tau, we co-express Δtau 
with human full-length wild-type 2N4R or mutant 0N4R tau, by breeding TAU62 mice with 
ALZ17 and P301S mice, respectively. In those double transgenic mice, Δtau co-aggregates 
and co-accumulates with full-length tau and forms potentially toxic oligomers. This is 
associated with a severe axonopathy and a rapidly progressive, drastic motor impairment in 
P301SxTAU62 (abbreviated P62 mice) mice. Strikingly, these changes occur in absence of 
tau tangles and are widely reversible when Δtau expression is switched-off. Fragment-induced 
tau toxicity is less pronounced in ALZ17xTAU62 mice, although a subset of these mice also 
develops severe paralysis at about one month of age. In contrast, co-expression of the 0N4R 
(P301S mice) and 0N3R full-length isoforms (ALZ31 mice) does not result in any rapid 
motor disturbances. In conclusion, we demonstrate that Δtau exacerbates the toxicity of full-
length forms of tau and favours the development of tauopathy typical changes, such as 
disruption of the Golgi network and microtubule dysfunction. Hence, our work underlines the 
importance of tau fragmentation in the context of the early pathogenesis of AD.  
 
 
 
 3 
Introduction 
 
Tau pathology is the hallmark of the most prevalent forms of dementia including Alzheimer’s 
disease (AD), frontotemporal dementia (FTD) and less frequent disorders like corticobasal 
degeneration (CBD), progressive supranuclear palsy (PSP) and the amyotrophic lateral 
sclerosis/parkinsonism-dementia (ALS/PD) complex of Guam. Tau promotes microtubule 
(MT) growth, stabilizes MTs and limits their dynamics, thereby contributing to the 
maintenance of axonal growth, transport and polarity [1, 2]. Protein fragmentation has been 
implicated in the pathogenesis of many neurodegenerative disorders. Protein aggregates in 
neurodegenerative proteinopathies often consist either of fragments derived from longer 
precursor proteins, like amyloid-β (Aβ) in AD or amyloid-Bri (ABri) in Familial British 
Dementia (FBD) [3], or they comprise full-length proteins and cleaved fragments in parallel, 
e.g. for α-synuclein in Parkinson’s disease (PD) [4, 5] or in TDP-43 related disorders [6, 7]. 
Aberrant protein cleavage also plays a prominent and early role in the pathogenesis of triplet 
expansion disorders including Huntington’s disease (HD) [8], spinocerebellar-ataxia-3 
(SCA3, Machado–Joseph disease) [9], and SCA7 [10]. 
Fragmentation of tau has been identified in patients suffering from AD, CBD, and PSP 
[11], in vitro [12], as well as in tau transgenic mouse models [13]. In AD, tau fragmentation 
occurs relatively early during the disease course and precedes tau tangle formation [14-20]. 
Tau fragments of various lengths involving different N- and C-terminal cleavage sites have 
been identified [15, 21, 22]. Caspase 3, caspase 6, and calpains are the main enzymes 
involved in tau cleavage, with the Asp421 being the most prominent caspase cleavage site 
[17, 23, for review see 24, 25]. However, it remains unclear whether tau truncation is part of 
the pathomechanism leading to the onset and progression of the disease, and what are the 
consequences of tau fragment expression on neuron homeostasis. 
We here studied the impact of a short, wild-type Δtau fragment in vivo, using a novel 
inducible Δtau transgenic mouse model. These TAU62 mice overexpress a human, 3 repeat 
domains (3R) containing Δtau151-421 fragment that spans from the two proline rich regions to 
the main C-terminal caspase cleavage site [2]. Δtau expression induces a slowly progressive 
axonopathy associated with a mild to moderate motor phenotype. Δtau, but not full-length 
wild-type 0N3R (ALZ31 mice) tau, drastically exacerbates the axonopathy and motor 
phenotype of mutant P301S full-length tau transgenic mice, resulting in early and severe 
palsy in absence of tau tangle formation. Importantly, Δtau-induced paralysis and the 
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associated changes in P62 mice are fully reversible when Δtau expression is halted. These 
findings reveal the extensive toxic potential of tau fragments by their vicious interaction with 
full-length tau in vivo and strengthen the view that tau cleavage may substantially contribute 
to the pathogenesis of tauopathies. The reversibility of even severe tau fragment induced 
changes gives hope that early inhibition of tau fragmentation might constitute a novel 
beneficial therapeutic approach.    
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Materials and Methods 
 
Transgenic mice  
Inducible Δtau expressing TAU62 transgenic mice have been generated by co-injection of two 
Thy 1.2 minigene based constructs into C57BL/6J oocytes. The Thy1.2-tTS construct was 
obtained by replacing exon 2 of the murine Thy 1.2 promoter by a tetracycline controlled 
transcriptional silencer element (tTS). The Thy1.2-TRE-Δtau construct contained a 
tetracycline responsive element (TRE) upstream of human wild-type Δtau cDNA encoding 
amino acids 151 to 421 of a 3-repeat domain spanning human wild-type tau fragment (0N3R 
tau151-421). A total of 6 positive transgenic founder TAU62 mice (C57BL/6J-TgN(tTS-Thy1-
Δtau151-421) were identified and the inducible expression of human Δtau was assessed by 
western blot and immunohistochemistry. Lines 62-2 and 62-48 exhibited comparable and 
robust Δtau expression without leakage upon doxycycline withdrawal. All quantitative 
experiments were performed with mice of the TAU62-48 line, abbreviated TAU62 mice 
(C57BL/6J-TgN(tTS-Thy1-Tau)62). TAU62-2 mice were used in order to rule out an 
insertion side effect causing the drastic motor phenotype observed in P301SxTAU62-48 
double transgenic mice. 
Generation of P301S mutant 0N4R tau transgenic mice (C57BL/6J-TgN(Thy1-hTauP301S)) 
[26] and ALZ17 wild-type 2N4R tau transgenic mice (C57BL/6J-TgN(Thy1-hTau)) [27] has 
been described previously. 
For the generation of ALZ31 wild-type human 0N3R tau transgenic mice (C57BL/6J-
TgN(Thy1-ALZ)31), 0N3R human cDNA was cloned into a standard neuron-specific Thy 1.2 
promoter element [28] and injected into C57BL/6J oocytes.  
P301SxTAU62 (called P62), ALZ17xTAU62 and P301SxALZ31 double transgenic mice 
have been obtained by crossing the respective single transgenic tau mouse lines. We will note 
P62on the mice receiving doxycycline, and P62on-off mice after the treatment was stopped. All 
double transgenic mice were heterozygous for the transgenes of interest. Chow containing 
500mg/kg doxycycline was provided ad libitum to induce Δtau expression. All animal 
experiments were approved by the local Ethics and Animal Care and Use Committees. 
 
Histology and immunohistochemistry 
Mice were deeply anaesthetized with sodium pentobarbital (100mg/kg) and transcardially 
perfused with cold phosphate-buffered saline (PBS). Brains were removed and one half of the 
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brain was immersion fixed in 4% paraformaldehyde and embedded in paraffin. Sagittal serial 
sections of 4-20µm thickness were cut with a microtome throughout the hemisphere [29]. 
Hematoxylin and eosin (H&E), Holmes-Luxol (HL), Thioflavin S were done according to 
standard protocols [30]. Fibrillary tau tangle pathology was assessed by Gallyas silver 
staining. Antibodies used for immunohistochemistry: Tau-C3 (anti caspase-cleaved tau at 
Asp421, Santa Cruz Biotechnology, Texas), PHF1 (anti phospho-tauSer396/404, gift from Peter 
Davies, Albert Einstein College, NY), MC1 (conformation specific tau, gift from Peter 
Davies, Albert Einstein College, NY), AT100 (anti phospho-tauSer212/Thr214, Pierce, Rockford, 
IL), AT8 (phospho-tauSer202/Thr205, Pierce, Rockford, IL), anti-MG160 (gift from Nicholas 
Gonatas, Pathology and Laboratory Medecine, PA), anti-synaptophysin (Milipore 
Corporation, MA), anti-VAMP2/Synaptobrevin 2 (Synaptic System, Germany), anti-Cox 
subunit 1a (Abcam plc, UK), 2f11 (anti-neurofilament-light-chain protein , DakoCytomation, 
DK), NF200 (anti-neurofilament heavy-chain, [27])  and anti-GFAP (Clone Ab1, Thermo 
Scientific Freemont, CA). 
 
Sarkosyl extraction and Western blot analysis  
Following PBS perfusion, one half of the mouse brain was dissected into forebrain and brain 
stem and immediately frozen in liquid nitrogen. Sarkosyl extraction was performed as 
described previously [13]. Briefly, the brain tissue was homogenized in 3X volume (w/v) of 
800mM NaCl, 10% sucrose, 10mM tris HCl pH 7.4, 1mM EGTA by using Ultraturrax T8 
(IKA labortechnik) and then sonicated (Bandelin Sonopuls) at 90% power, 10% cycle and 10 
pulses. Then the samples were centrifuged at 80 000g for 15 min by using ultracentrifuge 
(Beckman Coulter, OptimaTM L-70K Ultracentrifuge) by using SW55Ti rotor (Beckman 
Coulter). The supernatant was collected to use for the analysis of soluble tau and the 
remaining pellets are homogenized in A68 buffer (w/v). Samples were centrifuges at 5 000 
rpm for 20 min and 1% of sarkosyl (N-laurylsarcosine, Sigma) added for 1h30 at 37 °C in 
thermoshaker under shaking. Samples were then centrifuged at 80 000g for 30 min and the 
pellet is resuspended in 150µl/g of tissue 50mM Tris HCl pH 7.4, considered as sarkosyl 
insoluble tau.  Antibodies used for Western blotting are for detection of tau cleaved at Asp421 
(Tau-C3 from Santa Cruz Biotechnology (Texas)), of human tau (HT7 antibody human tau, 
Pierce Biotechnology (Rockford, IL)) and of the human 3R isoform of tau (RD3 antibody 
from Milipore Corporation (Billerica, MA)). 
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Behavioural assessment 
Phenotypic characterisation included the observation of motor behaviour including gait ataxia 
and tremor and testing of hind limb reflexes at ages of 12, 18 months old for TAU62 mice and 
11 days up to 2 months old for P62. Quantitative motor testing was performed on a Rotarod® 
and a grid test. For Rotarod® testing, the mice were trained on 2 consecutive days on the 
accelerating Rotarod®. The day after, the mice were tested in 3 consecutive daily sessions 
over 3 days. The accelerating Rotarod was started at 4 rpm, increasing its speed over 2 
minutes to a maximum speed. The time the mice were able to keep walking on the 
accelerating rod was noted. For the grid testing, mice were placed on a vertical mesh grid and 
the latency to fall of the grid was measured. Non-paralyzed mice attached to the grid climb 
towards the upper end of the grid and explore the whole grid, while paralyzed mice fall of the 
grid within the observation period of 180 seconds.  
 
Statistical analysis 
Statistical analysis was performed using IBM® SPSS® Statistics Version 19 for t-tests and 
ANOVA (see Supplementary Methods for details). P-values adjusted for multiple 
comparisons by the Holm-Bonferroni method are reported and outlined in all figures as 
follows: *=p<0.05, **=p<0.01, ***p=<0.001. The mean and SD are indicated in all figures. 
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Results 
 
Δtau expression caused progressive motor phenotype associated with pretangle tau 
pathology 
To test the toxicity of tau fragment on neuron cells in vivo and determine the role of tau 
truncation in the onset of tauopathies, we generated a novel transgenic mouse model  (TAU62 
mice), which overexpresses the human wild-type tau151-421 fragment (Δtau) under the control 
of a transcriptional silencer element (tTS)-regulated Thy-1-promoter (Fig 1A). In TAU62 
mice, this new, inducible, neuron-specific Thy-1.2 promoter element drives robust expression 
of Δtau when doxycycline is provided, while Δtau generation ceases completely when 
doxycycline is withdrawn (Fig 1B). Δtau expression was detected by immunohistochemistry 
with C3 antibody, throughout the nervous system including cortex, hippocampus and the 
brain stem region (Fig 1C). Continuous doxycycline administration maintained stable Δtau 
levels in heterozygous TAU62 mice up to high ages  (data not shown).  
 At age of 3-6 months, a slowly progressive, initially mild motor phenotype became 
visible in TAU62 mice. Δtau-induced motor impairment started with mild tremor and gait 
ataxia (data not shown). At higher ages, a mild hind limb paralysis evolved and TAU62 mice 
showed an abnormal limb flexion (Fig S1A), comparable to earlier observations made in very 
aged transgenic mice expressing the human, full-length, wild-type tau [27]. Rotarod 
performance of TAU62 mice was still not significantly worsened by their paralysis at 18 
months of age (data not shown). However, aged TAU62 mice failed to adhere to a vertical 
metal grid (grid test), while aged control mice were able to walk and climb on the grid for 180 
seconds (Fig S1B). 
 The phenotype of 18-months-old TAU62 mice was associated with cerebral pretangle 
tau pathology. Widespread tau hyperphosphorylation at the AT8 epitope (phospho-
TauSer202/Thr205) with somato-dendritic redistribution of tau was most pronounced in the 
forebrain and the brain stem region, while being less dominant in the hippocampus (Fig 1D). 
While some brain stem neurons were positive with PHF1 antibody, detecting phospho-
TauSer396/404, in aged TAU62 mice (Fig 1E, upper), neither Gallyas stained tau tangles (data 
not shown) or tau hyperphosphorylated at late epitopes e.g. AT100 (phospho-TauSer212/Thr214 - 
Fig 1E, left half) and MC1 (conformation specific tau, data not shown). It should be lastly 
noted that Δtau was also robustly expressed in spinal cord neurons (Fig 1F), where again 
pretangle tau pathology evolved with AT8 positive tau accumulation predominantly in motor 
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neurons (Fig 1F). Occasional axonal spheroids could be seen by Holmes Luxol staining (Fig 
1F, right panel).  
 
Δtau exacerbates the toxicity of P301S full-length form of tau in vivo and leads to severe 
neurologic phenotype 
In man, tau fragmentation occurs in the presence of human full-length tau. In this light, we 
next co-expressed Δtau with human full-length tau in vivo by crossing P301S (0N4R) tau 
transgenic mice [26] with TAU62 mice, the resulting mice being called P62. Homozygous 
P301S mice developed a progressive motor phenotype with relevant hind limb palsy at age of 
5 months and immobilizing limb paralysis at ages of 6-7 months (Fig 2A, upper, left half) as 
previously described [26]. Heterozygous P301S mice remained ambulatory up to more than 
18 months of age (data not shown). 
Co-expression of P301S full-length tau and Δtau resulted in an unexpectedly early and 
severe motor impairment in the P62on double transgenic mice. P62on mice showed mild gait 
ataxia at 9 days of age and reached complete hind limb palsy at about 3 weeks of age (Fig 2A, 
right half). Strikingly, this severe palsy was completely reversible when Δtau expression was 
stopped at age of 3 weeks (Fig 2A, down, left half). After stopping Δtau expression, the 
majority (5/9) of P62on-off mice rapidly recovered from their severe hind limb palsy, and their 
gait became normal within 2-3 weeks (Fig S2B). Moreover, upon Δtau switch-off, the small 
and low weight P62 mice steadily regained body weight (data not shown). The two P62on-off 
mice, which did not show signs of rapid recovery, were sacrificed for the reason of animal 
welfare (Fig S2B).  
In order to rule out that an insertion site effect of the transgene underlies the observed 
phenotype in P62on mice, P301S mice were also crossed with the TAU62-2 line, what resulted 
in comparable phenotypic and histopathological findings (data not shown). Importantly, 
P301SxALZ31 mice, obtained by crossing P301S mice with 0N3R tau-expressing transgenic 
animals (ALZ31), did not develop a relevant motor phenotype up to adulthood, although high 
levels of the full-length 3R tau were detected in the mice (Fig S4). These results demonstrate 
that the drastic, reversible phenotype of P62 mice is induced by Δtau expression and caused 
by the specific toxicity conferred by tau fragment. 
 
 10 
Δtau-derived phenotype is related to the formation of toxic oligomers, but not of tangles 
and insoluble aggregates 
In P62 mice, the levels of Δtau fragment were significantly increased compared to 
heterozygous TAU62 single transgenic mice (Fig 2B and 2C). In parallel, levels of total tau 
exceeded even those measured in homozygous P301S mice of the same age, indicating an 
accumulation of both full-length tau and Δtau in P62 mice (Fig 2B and 2C). Western blots run 
under non-reducing conditions revealed an accumulation of higher molecular weight-tau 
forms, compatible with small oligomers with human tau HT7 antibody (Fig 2D). Antibody 
targeting 3R tau (RD3) confirmed the inclusion of 3R isoforms e.g. the Δtau fragment in the 
higher molecular aggregates (Fig 2D). By contrast, at the time point when P62 mice reached 
severe hind limb palsy, only mild AT8 hyperphosphorylation was observed in cortical, 
hippocampal and brain stem neurons. This hyperphosphorylation was widely reversible, when 
Δtau expression was switched-off (Fig 2E). No phosphorylation at so-called late epitopes e.g. 
PHF1 and AT100 was detectable (Fig 2F). Gallyas silver staining as well as Thioflavin S 
staining remained negative in all mice (Fig 2G). Correspondingly, no sarcosyl-insoluble tau 
aggregates formed in paralyzed P62 mice (data not shown). Together these results indicate 
that Δtau toxicity is related to the formation of oligomers but not to the presence of tangles or 
insoluble aggregates.  
Interestingly, expression of the wild-type 2N4R tau with Δtau, by breeding TAU62 
mice with ALZ17 animals [27], resulted in severe paralysis only in a subset of these double 
transgenic mice at age of about 1 month. In paralyzed ALZ17xTAU62 mice, comparably to 
P62 mice, pretangle tau pathology was present without signs of Gallyas positive structures 
(data not shown). Although a milder toxicity of Δtau is observed in the presence of the full-
length, wild-type form of tau, this observation further confirms that the pathology is arising 
independently from tangle and aggregate formation. 
 
Δtau-induced neuronal dysfunction is associated with reversible disruption of the Golgi 
network, deregulation of synaptic proteins and mitochondrial mislocation 
Although only mild tau hyperphosphorylation was noted in the hippocampus of P62on mice, 
detailed analysis revealed a disruption of the Golgi network as shown in CA1 pyramidal cells: 
the Golgi apparatus, stained with antibodies directed against MG160 protein, became 
fragmented and swollen compared to controls (Fig 3). When Δtau expression was halted, the 
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Golgi structure normalized (Fig 3). Compatible with a disturbed protein sorting, 
synaptophysin, a protein associated with presynaptic vesicles, was dislocated and 
accumulated within the soma of the pyramidal cells in P62on mice, which was restored in 
P62on-off (Fig 3). There were furthermore signs of missorting of the vesicular protein VAMP2 
that was extensively lost from CA1 dendrites when Δtau was expressed (Fig 3). Interestingly, 
mitochondria also reversibly agglomerated within the soma of the pyramidal cells as well as 
in patchy axonal clusters with cox antibody (Fig 3). These results indicate that Δtau toxicity is 
related to altered Golgi and mitochondria dynamics and/or localization, which likely modify 
the synaptic functioning. 
 
Δtau expression in P301S mice causes severe axonal damage of spinal cord neurons 
Δtau was widely expressed in the spinal cord of P62on mice (Fig 4A) and associated with 
reversible tau hyperphosphorylation at the AT8 epitope (Fig 4B). Again, no AT100, MC1 or 
Gallyas positive structures were observed (data not shown). In parallel with the massive 
motor impairment, spinal cord neurons exhibited signs of severe dysfunction with 
pathological swelling, beginning chromatolysis, as shown with Holmes Luxol staining (Fig 
4C). Axonal damage with extensive accumulation of neurofilaments stained with 2f11 and 
NF200 antibodies were also observed and sometimes formed axonal spheroids (Fig 4D-E). 
These changes as well as the accompanying astrogliosis (Fig 4F) recovered with motor 
improvement in P62on-off mice. Electron microscopy further confirmed that axonal spheroids 
comprised massed neurofilaments and multiple small, congested mitochondria (Fig 4G).  
 
P301SxTAU62on transgenic mice develop a drastic but reversible neuro- and myopathy 
The changes at the spinal cord level were accompanied by substantial axonal neuropathy in 
paralyzed P62on mice. As observed with Holmes Luxol, Masson Trichrome, which stains 
myelinated axons, and p-Phenyldiamine staining, which reacts with collagen, the sciatic 
nerves exhibited pathological vacuolization of nerve fibres, collapses of myelin sheets and 
loss of fibres (Fig 5A). Upon recovery, no more vacuolization was noted in P62on-off mice, the 
myelin debris were removed and intact fibres of apparently smaller diameters were seen (Fig 
5A).  
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The rapidly progressive hind limb palsy in P62on mice was associated with severe 
muscle wasting (Fig S3). Compared to controls, Hematoxylin and Eosin staining revealed 
marked muscle fibre atrophy (Fig 5B). Both types I and II fibres were severely affected, as 
shown by the ATPase coloration (Fig 5B). Atrophic and angulated fibre profiles were also 
noted, which was compatible with an atrophy related to both neuropathy and disuse. In 
parallel to the motor improvement of P62on-off mice, the muscles macroscopically widely 
recovered (Fig S3) and they histologically comprised hypertrophic muscle fibres, 
predominantly of type II, with centralized nuclei consistent with a regenerative step involved 
in the restoration of the fibres (Fig 5B).  
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Figure 1: Tau fragmentation is sufficient to induce pretangle pathology 
(A) In TAU62 mice, neuronal ΔTau expression is driven by a novel inducible Thy1.2 
promoter element that includes a tetracycline responsive element (TRE).  
(B) Western blot analysis with C3 antibody directed against ∆tau (cleaved at Asp421) shows 
that the robust ΔTau generation is fully halted when doxycycline (Dox) treatment is 
withdrawn (-).  
(C-F) Tau protein immunoreactivity in brains and spinal cords from TAU62 mice. C3 
antibody reveals ΔTau expression in the cortex (Ctx), the hippocampus (Hipp), the brain stem 
(BS) from 12 month-old TAU62 mice (C) and spinal cord (SPC) from 18 month-old mutant 
mice (F). AT8 antibody recognizing phospho-tauSer202/Thr205 was used to stain the cerebral Ctx, 
Hipp and BS (D) and SPC (F) from 18 month-old mice. In D, higher magnification shows 
somato-dendritic redistribution of hyperphosphorylated tau in BS. (E) PHF-1 and AT100 
antibodies directed against phospho-tauSer212/Thr214 protein were used to stain the brainstem 
(BS) from 18 month-old of TAU62 mice. Aged tangle bearing P301S homozygous mouse 5 
month-old are used as positive control. In (F) Holmes Luxol (HL) staining shows axonal 
spheroid formation in SPC from 18 month-old of TAU62 mice. Scale bar in C equals 200µm 
in Ctx and BS, 400µm in Hipp; Scale bar in D equals 100µm in Ctx, BS (left panel), and 
50µm in BS (right panel), 100µm in Hipp; Scale bar in E equals 100µm in BS (PHF-1), 
100µm in BS (TAU62 and P301S; AT100); Scale bar in F (HL) equals 100µm in SPC (C3), 
and 50µm (C3 and AT8). 
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Figure 2: Co-expression of P301S full-length tau with ΔTau provokes severe neuronal 
dysfunction, in the absence of tangles and insoluble aggregates  
(A) Global appearance of the transgenic mice generated 5 month-old P301S homozygous 
mice develop progressive gait disturbances. P62on double transgenic mice, heterozygous for 
both transgenes, show after 9 days progressive gait ataxia and reach severe hind limb palsy 
resulting in dragging their hind limbs at age of 3 weeks. The severe motor phenotype of 2 
month-old P62on-off is almost fully reversible when ∆Tau expression is stopped. 
(B) Immunoblot analysis of tau protein in brains from TAU62, P62on and P301S mice show 
accumulation of ΔTau and total tau with anti-tau antibody HT7 targeting the human tau form.  
(C) ΔTau expression quantified by Western blot is 6 times higher in P62on mice compared to 
heterozygous TAU62 mice and total tau levels in P62on animals exceed the levels measured in 
homozygous P301S mice.  
(D) Western blot under non-reducing conditions show tau isoforms with higher molecular 
weight in young paralyzed P62on mice, using HT7 antibody specific for human tau. Similar 
oligomers-like tau forms are detected in aged homozygous P301S mice. Immunoblot does not 
reveal oligomers in young single transgenic TAU62 mice, heterozygous P301S mice and in 
P62on-off mice. In P62on mice, the high molecular tau forms also contain 3R tau isoforms 
detected with RD3 antibody.  
(E) Staining of the brainstem region of 3 week-old P62 mice with anti-tau antibody AT8. The 
phosphorylation-dependent anti-tau antibody AT8 shows accumulation of 
hyperphosphorylated tau, which is almost fully reversible when ∆Tau expression is stopped 
(P62on-off mice) even though P301S tau expression is maintained.  
(F) Immunohistochemistry with PHF-1 and AT100 antibodies shows no accumulation of the 
phosphorylated tau forms (at Ser396/404 and phospho-tauSer212/Thr214, respectively) in the 
brainstem of 3 week-old P62on mice.  
(G) Gallyas-Braak silver and Thioflavine S stainings reveal the absence of tangle formation in 
3 week-old P62on mice, while strong positive signal is detected in 5 month-old P301S 
homozygous mice. Scale bar in E equals 100µm in F and G and scale bar for Thioflavin S 
equals 50µm.! 
 
 
  
 17 
  
B6! P62on! P62on-off!
VA
M
P2
!
Co
x!
S
yn
ap
to
ph
ys
in
 
M
G
16
0 
 18 
Figure 3: Expression of P301S full-length tau with ΔTau leads to Golgi disruption and 
mitochondria mislocation 
Immunohistochemistry using Golgi-specific MG160 antibody reveals fragmented and 
enlarged Golgi structures in CA1 (cornu ammonis 1) pyramidal layer in 3 week-old P62on 
mice, while normal organization is observed in 2 month-old P62on-off mice. C57/Bl6 (B6) mice 
are used as control. In parallel, the abnormal accumulation of synaptic protein synaptophysin 
(arrows) within the soma of CA1 pyramidal cells of P62on mice is also reversed in P62on-off 
mice. The vesicular protein VAMP2 is widely lost in CA1 dendrites in P62on mice (arrow) but 
restored after stopping ΔTau expression (arrow). Lastly, perisomatic clustering of 
mitochondria, detected by immunofluorescence staining for cox protein (arrowhead), in CA1 
pyramidal neurons of paralyzed P62on mice is not observed anymore in P62on-off mice. Scale 
bar equals 100µm in MG160, Synaptophysin and 100µm in VAMP2. 
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Figure 4: ΔTau expression in spinal cord causes severe axonal damage  
(A, B) ΔTau, detected by immunohistochemistry with C3 antibody, is widely expressed in the 
spinal cord (A) and associated with moderate hyperphosphorylation at the AT8 epitope in 3 
week-old P62on mice (B). Upon cessation of ΔTau generation in 2-month-old P62on-off mice, 
no more ΔTau (A) nor AT8 hyperphosphorlyated tau (B) are detectable. Scale bar equals 
100µm. 
(C) Holmes Luxol (HL) staining is used to reveal axonal spheroids (arrow), chromatolysis 
and ballooned neurons (arrowhead) in spinal cord of 3 week-old P62on mice. Scale bar equals 
100µm.  
(D, E) Immunohistochemistry with 2f11 antibody recognizes the 200kDa and 68kDa 
neurofilament proteins (D, left) and NF200 antibody directed against NFH (high-molecular 
weight neurofilament subunit; 200kD) (E, left) reveals the accumulation of neurofilaments in 
neurons of P62on mice. Axonal spheroids containing neurofilaments are observed in P62on 
(arrow) and widely disappear in P62on-off mice in parallel with the normalization of the 
neurofilament distribution (D, E, right). Scale bar equals 50µm in D and 20µm in E. 
(F) Immunohistochemistry directed against the glial GFAP shows reversible astrogliosis, 
which parallels with the neuronal dysfunction in P62 mice. Scale bar equals 50µm. 
(G) Electron microscopy of the nerve cells in spinal cord from mice of P62on line. Higher 
magnification of axonal spheroids shows accumulated poorly oriented neurofilaments 
intermingled with multiple small, mitochondria (i). Sparse microtubular profiles in a 
myelinated axon of the spinal cord (ii, arrows) and abundant neurofilaments (iii, arrows) in a 
3 week-old P62on mice. 
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Figure 5: Paralyzed P301SxTAU62on mice exhibit extensive signs of peripheral 
neuropathy 
(A) Holmes Luxol (HL) and Masson Trichrome stainings of the sciatic nerve of 3 week-old 
P62on mice show vacuolar degeneration of nerve fibres (arrows) and digestion chambers along 
nerve fibres indicative of Wallerian degeneration (arrows), respectively. 
Paraphenylenediamine staining (p-Phenyldiamine) further reveals collapsed myelin sheets and 
signs of fibre loss (arrows). When ΔTau expression was stopped (P62on-off mice), the nerve 
largely recovered but contained much larger amounts of small myelinated fibres. Scale bar 
equals 20µm.  
(B) The severe palsy of P62on mice at 3 weeks of age is associated with marked neurogenic 
muscle atrophy in gastrocnemius muscles. HE and ATPase pH4.2 stainings show that both 
fibres are atrophic. Small angular shaped muscle fibres are organized into large groups 
(arrow), consistent with disuse and neurogenic muscle atrophy. After stopping ΔTau 
expression (P62on-off mice), some muscle fibres become hypertrophic and display internalized 
nuclei (arrowheads), whereas others remain as atrophic (grouped) fibres with mostly 
angulated fibre profiles. Scale bar equals 50µm. 
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Supplementary figures 
 
 
Figure S1: Neurologic phenotype in mice of the TAU62 line 
Tail suspension test with normal spreading of the hind limbs in 18 month aged B6 mice and 
pathological retraction of the hind limbs in aged TAU62 mice (A). TAU62 mice show a 
slowly progressive motor palsy and the time they walk on a vertical grid is reduced at higher 
ages (B).  
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Figure S2: ∆Tau expression in P62 mice impairs motor function 
Expression of ΔTau is detected in the brainstem (BS) of 3 week-old P62on and 2 month-old 
P62on-off mice by immunohistochemistry with C3 antibody (A). The majority (5/9) of formerly 
severely paralyzed P62 mice become able to climb successfully on a vertical grid 1-2 weeks 
after the stop of ΔTau expression (B), even though P301S tau expression is maintained (Grid-
Test: course of recovery of paralyzed P62 mice; P301S heterozygous controls (n=8)). Scale 
bar equals 100µm in A. 
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Figure S2: ∆Tau expression in P62 mice impairs motor function!
!
Expression of ΔTau is detected in the brainstem of 3-week-old P62on and 2-months-old P62on-off mice by 
immunohistochemistry with C3 antibody (A). The majority (5/9) of formerly severely paralyzed P62 
mice become able to climb successfully on a vertical grid 1-2 weeks after the stop of ΔTau expression 
(B), even though P301S tau expression is maintained (Grid-Test: course of recovery of paralyzed P62 
mice; P301S heterozygous controls (n=8)). Scale bar equals 100µm in A.!
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Figure S3: Macroscopic picture of muscles in P62 mice 
Severe muscle atrophy is observed in paralyzed, 3 week-old P62on mice (left half panel) 
compared to heterozygous P301S heterozygous mouse (P301S het). From top: gastrocnemius 
and soleus, tibialis anterior and extensor digitorum longus. Within 4 weeks upon stop of ΔTau 
expression, the hind limb musculature widely recovers (right half panel) and becomes 
macroscopically comparable to control muscles (P301S het). 
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Figure S3: Macroscopic picture of muscles in P62 mice!
!
Severe muscle atrophy is observed in paralyzed, 3-week-old P62on mice (left half panel) compared to 
heterozygous P301S heterozygous mouse (P301S he ). From top: gastrocnemius and soleus, tibialis 
anterior and extensor digitorum longus. Within 4 weeks upon stop of ΔTau expression P62on-off, the 
hind limb musculature widely recovers (right half panel) and becomes macrosc pically comparable to 
control muscles (P301S het).!
!
GC/Sol!
P30
1S 
het
!
P30
1S 
het
!
TA!
EDL!
 26 
 
 
Figure S4: Co-expression of full-length 0N4R and 0N3R tau with ∆Tau 
A 3 week-old P62on mouse fails to spread its hind limbs when suspended by the tail (A), 
contrasting with a 3 week-old P301SxALZ31. (B) Immunoblot analysis of tau protein in brain 
from P62on, ALZ31 and P301SxALZ31 mice show the expression of tau using anti-tau 
antibody HT7 targeting the human tau form. 
 
 
 
 
 
 
 
 
 
 
Figure S4: o-expression of full-length 0 4  and 0 3  tau ith ∆ au"
"
A 3-week-old P62on mouse fails to spread its hind limbs when suspended by the tail (A). This contrasts 
with  a  3-week-old  P301SxALZ31  mouse  spreads  its  hind  limbs  when  suspended  by  the  tail.  (B) 
Immunoblot analysis of tau protein in brain from mice of P62on, ALZ31 and P301SxALZ31 tau lines 
shows the expression of tau in P301SxALZ31 with anti-tau antibody RD3 targeting the human 3R tau 
form.!
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Discussion 
 
Protein fragments play a major role in neurodegenerative disorders and the relevance of 
proteolysis in the pathogenesis of tauopathies is increasingly being recognized. Here, we 
establish for the first time that tau truncation exacerbates the toxicity of full-length forms of 
tau promoting the onset of pretangle pathology with severe neuronal dysfunction. 
To study the effects of a tau fragment in vivo, we firstly established a novel inducible 
TAU62 transgenic mouse line that overexpresses a human wild-type Δtau151-421 fragment in a 
neuron-specific manner. Sheer Δtau151-421 expression in TAU62 mice causes a mild, rather 
slowly progressive motor phenotype associated with pretangle stage histological features 
including tau hyperphosphorylation and axono-dendritical redistribution of tau, similar as that 
observed in the full-length wild-type ALZ17 transgenic mouse model [27]. In contrast to 
reports on overexpression of tau fragments in rats [31, 32], but similarly to findings in mice 
expressing a C-terminally cleaved 1N4R tau1-391 fragment [33], TAU62 mice stay devoid of 
tau tangle formation up to high ages of 26 months and do not accumulate relevant amounts of 
sarkosyl insoluble tau. In absence of full-length human tau, the toxicity of Δtau151-421 in 
TAU62 mice does not exceed the effects of full-length 3R tau reported previously in mice 
[34].  
In order to mimic the situation of human tauopathies, where tau fragments are co-occurring 
with full-length human tau, we next crossed full-length human tau expressing P301S mice 
with TAU62 mice. While our homozygous P301S mice start to develop a visible motor 
phenotype with trembling and mild hind limb palsy at ages of 4-6 months, heterozygous 
P301S mice can reach more than 15 months of age without limiting paralysis. Unexpectedly, 
a much more drastic phenotype evolves in P62 double transgenic mice, although 
heterozygous for each transgene, which reach almost complete hind limb palsy at 3 weeks of 
age. Δtau thus exponentiates the toxicity of full-length tau and both tau forms co-accumulate 
in the brain and spinal cord of the mice. This results in extensive neuronal dysfunction and 
neuropathological findings typically found in human tauopathies and tauopathy models such 
as Golgi network disruption and mitochondria mislocation and axonal transport deficits. 
Eventually, co-expression of full-length 0N3R tau with P301S full-length tau does not result 
in any severe phenotype up to the age of 3 months in ALZ31xP301S mice, which underscores 
the importance of the fragment for the induced toxicity.  
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Biochemical analysis reveals increased levels of Δtau and total tau in P62 mice 
compared to the respective levels in TAU62 or even in homozygous P301S mice.  This points 
towards a direct interaction of Δtau with human full-length tau, which results in stabilization 
of both tau variants. This in vivo interaction of two amyloidogenic proteins is comparable to 
findings reported earlier in amyloid-β (Aβ) overexpressing mice, where intraneuronal co-
expression of Aβ42 with Aβ40 resulted in the stabilization and accumulation of Aβ40 [35]. 
Interestingly, tau isoforms of higher molecular weight were detected in the brain of P62 mice, 
which was compatible with small oligomeric tau forms. In contrast, there was no sign, using 
biochemical and histochemical analyses, of overt tau aggregation into sarcosyl insoluble 
forms or tangle formation in paralyzed P62 mice. The absence of tangles, even when the mice 
reached severe palsy, is thereby in line with the hypothesis that tangles are not the main toxic 
agents in tauopathies [36-39]. Inversely, the sheer accumulation of Δtau induced toxic or 
dysfunctional oligomeric tau species seems to be sufficient to provoke severe neuronal 
dysfunction. This confirms the recently recognized importance of sarcosyl-soluble but 
oligomeric tau species for the pathogenesis of tauopathies [40-42]. Formation of tau dimers 
and subsequent oligomerization has been observed early in the cascade of AD pathology [43, 
44]. Although late tangled tau aggregates correlate with disease progression in man, cognitive 
deficits and neuronal dysfunction precede and exceed tau tangle pathology in man and 
transgenic models, including P301S mice [36, 45, 46]. In tangle bearing mouse models e.g. 
rTG4510 mice, the toxicity of tau oligomers has been shown to correlate better with neuronal 
dysfunction than the extent of tau tangles [47]. The absence of extensive tau 
hyperphosphorylation in parallel to the observed severe neuronal dysfunction is compatible 
with the hypothesis that tau hyperphosphorylation is a secondary reactive measure of the cell 
in order to cope the accumulation of excessive tau, rather than being a primary pathogenic 
event. This would be comparable to the situation of TDP-43 associated disorders, where 
fragmentation of TDP-43 protein has been shown to precede its phosphorylation and 
aggregation into insoluble forms [48].  
Δtau induced tau accumulation results in extensive neuronal dysfunction and 
histopathological changes of tauopathy typical character in P62 mice. A part of the lower 
motor neurons degeneration is indicated by the partly neurogenic muscular atrophy present in 
these mice. Furthermore, multiple axonal spheroids, filled with small jammed mitochondria, 
and accumulated neurofilaments similar to findings in human AD [49] are consistent with 
transport deficits in spinal cord axons. Notwithstanding, even in the hippocampus, where only 
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very limited tau hyperphosphorylation is noted, we observed dislocated and clustered 
mitochondria in CA1 pyramidal neurons, similar to findings in AD brain tissue [50]. 
Interestingly, comparable perinuclear mitochondrial clumping has also been found in rTg4510 
tau transgenic mice where it was shown to correlate primarily with the presence of soluble tau 
species but not with tau tangles [50]. Most prominently, we find dispersed and swollen Golgi 
networks associated with somatic accumulation of synaptophysin pointing towards congested 
Golgi pathways, comparable to previously reported findings in JLNP3 mice [51]. This 
fragmentation of the Golgi apparatus, the central sorting machinery for all newly generated 
proteins destined for fast axonal transport [52], is comparable with findings in AD patients 
[53, 54]. Disruption of Golgi traffic has been observed in various neurodegenerative disorders 
and it may be directly linked to a dysfunction of microtubular structure, on which the Golgi 
assembly is dependent [55, 56].  
These pathological changes observed in paralyzed P62 mice point towards a 
widespread cellular transport disruption. Axonal transport deficits have been reported in a 
broad spectrum of neurodegenerative diseases and the term dysferopathies has been proposed 
to summarize these disorders [57]. In agreement with the hypothesis that tauopathies are 
associated with a disrupted microtubule network, recent studies in transgenic mouse models 
reported behavioral and histopathological improvements of P301S transgenic mice following 
the administration of microtubule stabilizing drugs e.g. Epothilone D [58-60] or Paclitaxel 
[61]. The consequences of microtubule disruption, Golgi network alteration and obstruction 
of axonal transport are far reaching and may result in the depletion of synaptic protein pools, 
energy depletion by a lack of mitochondria at distal site and eventually cause overt neuronal 
dysfunction and even degeneration as seen in our P62 mice.  
Importantly, we here showed that most of these events are widely reversible when the 
generation of dysfunctional tau is halted. Although P301S tau expression is ongoing, 
cessation of Δtau expression is sufficient to decrease the levels of toxic tau forms below a 
threshold that allows neurons in P62on-off mice to cope with P301S tau and even to recover 
functionally. This firstly outlines the importance of Δtau for the maintenance of tau toxicity in 
this model. Secondly, it proofs the reversibility of the toxicity of soluble oligomeric tau forms 
in a more drastic way than previously shown in inducible tau transgenic mice and in the 
absence of overt tau tangle aggregates [38, 62]. It remains however yet unclear, how soluble 
toxic tau species cause the disruption of axonal transport. Even total absence of tau in mice 
affects only subtypes of neurons and causes a reduction in microtubules, but does not lead to a 
severe phenotype [63, 64]. This implies that toxic di- or oligomeric tau species might exert a 
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toxic gain of function by interfering dysfunctionally with MT assembly, e.g. with end-binding 
proteins [65], and cause “catastrophe” events with MT breakdowns [66]. This hypothesis 
might explain the rapid recovery noted in our P62 model. Consistently, when co-expressing 
less aggregation prone 0N4R wild-type human full-length tau with Δtau, only a subset of such 
ALZ17xTAU62 mice develop severe motor impairments; this would be compatible with the 
existence of a threshold level of dysfunctional oligomeric tau, which cannot be coped by the 
cellular degradation pathways.  
Most neurodegenerative disorders share the important role of small aggregation prone 
protein fragments in their pathogenesis. Cleaved proteins are substantially involved in 
Alzheimer’s disease (Aβ), Huntington’s disease (Huntingtin) [67], Parkinson’s disease (PD) 
[4, 5], TDP-43 related disorders [48], Familial British Dementia (FBD) [3], Familial Danish 
Dementia (FDD) [68], and triplet repeat disorders e.g. SCA3 [9] or SCA7 [10]. While in a 
subset of hereditary variants of these diseases the causes of increased or altered cleavage have 
been identified, e.g. for presenilin mutations in AD or the frame shift mutations in FBD, the 
causes for the accumulation of the cleaved products has yet remained elusive in most of the 
sporadic forms of these disorders. Here, we established that tau truncation harbours the 
potential to provoke the aggregation of tau isoforms with drastic dysfunctional consequences. 
The initiation of tau fragmentation in human tauopathies has yet remained unclear. Tau is 
mainly cleaved by caspases and calpain. Caspase activation has been shown to precede tangle 
formation in transgenic mice and to potentially persist for a long time without direct induction 
of cell death [19]. Aberrant caspase cleavage within the lysosomal system has been shown to 
induce toxic oligomer formation in vitro, and disturbed lysosomal function increase tau 
cleavage and toxicity in a Drosophila model [69, 70]. Moreover, tau fragmentation is being 
observed widely and early in the pathogenesis of human tauopathies [11, 14-20, 71].  
In light of our in vivo findings, reduction of tau cleavage may constitute a promising 
therapeutic target, which might be comparably effective as secretase inhibition in the case of 
APP. Our novel, severely affected P62 tauopathy model constitute an ideal tool to test such 
therapeutical strategies or to screen potential drugs addressing other pathomechanistic targets, 
e.g. increasing tau clearance by immunotherapy or autophagy activation. 
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Abstract
Altered autophagy contributes to the pathogenesis of Alzheimer’s disease and other tauopathies, for which curative
treatment options are still lacking. We have recently shown that trehalose reduces tau pathology in a tauopathy mouse
model by stimulation of autophagy. Here, we studied the effect of the autophagy inducing drug rapamycin on the
progression of tau pathology in P301S mutant tau transgenic mice. Rapamycin treatment resulted in a significant reduction
in cortical tau tangles, less tau hyperphosphorylation, and lowered levels of insoluble tau in the forebrain. The favourable
effect of rapamycin on tau pathology was paralleled by a qualitative reduction in astrogliosis. These effects were visible with
early preventive or late treatment. We further noted an accumulation of the autophagy associated proteins p62 and LC3 in
aged tangle bearing P301S mice that was lowered upon rapamycin treatment. Thus, rapamycin treatment defers the
progression of tau pathology in a tauopathy animal model and autophagy stimulation may constitute a therapeutic
approach for patients suffering from tauopathies.
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Introduction
Alzheimer’s disease (AD) and fronto-temporal dementia with
tau inclusions (FTD-T) are the most frequent types of dementia
[1]. They are characterized by intraneuronal accumulation,
hyperphosphorylation and aggregation of tau protein. Despite of
intense research efforts, causative treatments are still lacking [2]
and the pathogenesis of sporadic AD and FTD-T has yet
remained only partly understood. Autophagy dysfunction however
is known to contribute to the evolution of different neurodegen-
erative proteinopathies including tauopathies [3,4,5,6].
We have recently reported beneficial effects of autophagy
activation by trehalose on tau pathology in vivo [7], and others
have shown similar effects in vitro [8]. Autophagy can be
pharmacologically stimulated by the FDA approved drug rapa-
mycin that inhibits the mammalian target of rapamycin complex 1
(mTORC1) and thereby facilitates the formation of autophago-
somes. First studies investigating the use of rapamycin for the cure
of neurodegenerative disorders in transgenic mouse models
reported reduced neuronal protein aggregation following rapa-
mycin administration in a murine model of Huntington’s disease
[9], a triple transgenic model of Alzheimer’s disease [10,11], and
recently in a model of spinocerebellar ataxia type 3 [12].
We here studied the effect of rapamycin on tau pathology in a
pure tauopathy mouse model. We find a significant reduction of
cortical tau tangle pathology in P301S mice after long- and short-
term rapamycin treatment. Furthermore, astrogliosis was reduced
and accumulation of the autophagy associated proteins p62 and
LC3 in aged tangle bearing P301S mice was lowered. The FDA-
approved drug rapamycin might thus be evaluated as a
therapeutic approach for tauopathies, in particular for patients
suffering from hereditary tauopathies.
Materials and Methods
Transgenic Mice
A total of 49 homozygous P301S tau transgenic and non-
transgenic control mice ranging from 3 weeks to 5.5 months of age
were included in the present study. Generation of P301S
transgenic mice overexpressing the shortest human four-repeat
tau isoform (0N4R) under the control of a neuron-specific Thy-1.2
promoter element has been described previously [13]. This study
was carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
Swiss Federal Veterinary Office. The protocol was approved by
the Committee on the Ethics of Animal Experiments of the
University of Basel and the Federal Veterinary Office of the
Kanton Basel-Stadt (Permit Number: 2364).
Rapamycin Treatment
In brief, P301S mice were treated twice weekly intraperitoneally
with 15 mg rapamycin per kg body weight or vehicle from the age
of 3 weeks to 5.5 months of age (group 5-months treatment, 5MT;
n=6 rapamycin; n= 5 vehicle), and from 3 months to 4.5 months
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of age (6-weeks treatment, 6WT; 6/6). For a detailed study outline
including further control groups see Fig. S1.
Rapamycin powder (LC Laboratories, Woburn, MA) was
dissolved at 20 mg/ml in ethanol and stored at 270uC. Before
each administration, rapamycin was diluted in 5%Tween 80, 5%
polyethylene glycol monolaurate (Sigma-Aldrich, Saint Louis,
MO) [14,15]. Vehicle contained comparable amounts of ethanol,
Tween 80, and polyethylene glycol monolaurate as the rapamycin
solution. Levels of rapamycin were measured by HPLC in blood
and perfused brain tissue as published previously [16].
Histology and Immunohistochemistry
Mice were deeply anaesthetized with sodium pentobarbital
(100 mg/kg body weight) and transcardially perfused with cold
phosphate-buffered saline (PBS). Brains were removed and one
half of the brain was immersion fixed in 4% paraformaldehyde
and embedded in paraffin. Sagittal serial sections of 20 mm
thickness were cut with a microtome throughout the hemisphere
[17]. Fibrillary tau tangle pathology was assessed by Gallyas silver
staining. Immunohistochemistry on paraffin fixed sections was
done according to previously published protocols [18] using the
avidin–biotin–peroxidase complex method and VECTOR No-
vaRED kits (Vector Laboratories, Burlingame, CA) as chromogen.
Samples of rapamycin and vehicle treated mice were processed
pairwise in parallel. AT8 (ptau Ser202/Thr205, Pierce, Rockford,
IL), AT100 (ptau Ser212/Thr214, Pierce, Rockford, IL), and
GFAP (Clone Ab1; Thermo Scientific Freemont, CA) antibodies
were used. Cortical GFAP staining was assessed qualitatively by
three independent raters (S.O., K.B., D.W.). Blinded sets
comprising every fifth 20 mm section of 5MT mice were rated
from – to +++ and mean scores of the three raters were obtained
(see also Fig. S2).
Stereology
Quantification of tau tangles was performed on Gallyas silver
stained sections using the Optical Fractionator [19]. In the 5MT
group, cortex, hippocampus and brain stem were taken into
account for stereological analysis, while in the 6WT group the
quantification was limited to the cortex. AT8 positive cortical cells
were quantified in both groups. In brief, every 5th section of
20 mm thickness throughout the left hemisphere was assessed using
a Zeiss Axioplan microscope and StereoInvestigator software
(Version 9.14; MicroBrightField, Williston, VT).
Sarkosyl Extraction and Western Blot Analysis
Following PBS perfusion, one half of the mouse brain was
dissected into forebrain and brain stem and immediately frozen in
liquid nitrogen. Sarkosyl extraction was performed as described
previously [20]. The brain tissue was homogenized in 0.5 ml of
800 mM NaCl, 10% sucrose, 10 mM tris HCl pH 7.4, 1 mM
EGTA using a Kinetica polytron. Samples were centrifuged at
5000 rpm for 15 min. The supernatant was collected and sarkosyl
added to 1% for 1 hour, shaking. Samples were then centrifuged at
80,000 rpm for 30 min and the pellet resuspended in 150 ml/g of
tissue 10 mM Tris HCl pH 7.4. Antibodies used for Western
blotting are listed in detail including the targeted epitopes in
Methods S1. In brief, we used for detection of tau: BR134 [21];
RD3 from Millipore Corporation (Billerica, MA); T49 [22,23], a
kind gift of Prof. Virginia Lee, CNDR, University of Pennsylvania
School of Medicine, Philadelphia, PA; AT8 and AT100 from
Pierce Biotechnology (Rockford, IL). For evaluation of mTORC1
signalling and autophagy were used: anti-S6 Ribosomal Protein
(#2217), anti-Phospho-S6 Ribosomal Protein Ser235/236
(#2211), anti-LC3B (#2775), from Cell Signaling Technology
(Danvers, MA); anti-Phospho-S6 Ribosomal anti-p62 (GP62-C)
from Progen Biotechnik (Heidelberg, Germany).
Statistical Analysis
Statistical analysis was performed using IBMH SPSSH Statistics
Version 19. Biochemical data of tau Western blots was subjected
to unpaired T-tests and T-tests adjusted for unequal variances
(Welch-Test), yielding both similar results. Holm-Bonferroni
corrections were applied. Biochemical data of p62 and LC3-levels
was analyzed by ANOVA. Stereological samples of vehicle and
rapamycin treated mice were stained in parallel. Accordingly, the
pairwise reduction of Gallyas or AT8 positive counts was analysed
using one-sample T-tests per brain region. Significant p-values
adjusted for multiple comparisons by the Holm-Bonferroni
method are reported and outlined in all figures as follows:
* = p,0.05, ** = p,0.01, ***p=,0.001. The mean and SD are
indicated in all figures.
Results
Aged vehicle treated P301S tau transgenic mice developed
extensive tau pathology, spreading throughout the central nervous
system including the forebrain, comparable with previous reports
[13] (Fig. 1A). Preventive long-term rapamycin administration
initiated at 3 weeks of age resulted in a marked reduction of
cortical tau tangles at age of 5.5 months (Fig. 1B). While in vehicle
treated mice, abundant Gallyas stain positive tangle pathology was
seen throughout the cortex, pronounced in rostral motor cortex,
only few isolated tangles formed in the cortex of rapamycin treated
5MT P301S mice (Fig. 1C). In parallel, cortical tau phosphory-
lation at the early hyperphosphorylated AT8 epitope and the late
AT100 epitope was diminished by rapamycin treatment (1D, E).
With the evolution of tau tangle pathology, P301S mice develop
progressive astrogliosis [24]. In parallel to the marked reduction in
cortical tangle load, we noted a qualitative alleviation of cortical
astrogliosis in long-term rapamycin treated mice (Fig. 1F, Fig. S2).
While in the hippocampus of vehicle treated 5MT P301S mice,
only sparse tangles and limited tau hyperphosphorylation were
seen, there was a markedly advanced tangle formation affecting
the brain stem region. Only a mild qualitative reduction of the
sparse hippocampal and the extensive brain stem tau pathology
became visible following rapamycin administration (Fig. 1G, H).
We further studied whether a favourable effect on tau pathology
progression could also be attained when treatment was started
only after the onset of tau hyperphosphorylation in P301S mice. A
short 6 weeks treatment with rapamycin was initiated at 3 months
of age (6WT group) and again resulted in a notable reduction of
cortical tau hyperphosphorylation and tangles (Fig. 1I).
Quantitative stereological analysis confirmed a significant
reduction in cortical tangles by 86% comparing long-term
rapamycin treated mice to vehicle treated mice (5MT group,
n = 5, Gallyas positive tangle count reduced to 13.7%618.8%,
p,0.001) (Fig. 2). Cortical tau hyperphosphorylation, assessed by
neuronal AT8 positivity, was reduced to 29.5628.9% (p= 0.02) in
long-term rapamycin treated mice (5MT). While a trend towards a
reduction of tau tangles was noted in the hippocampus (p = 0.05),
the lowering of the marked tangle pathology observed in the brain
stem region did not reach statistical significance (Fig. 2).
The short 6 weeks treatment started at 3 months of age
significantly reduced cortical tangles (6WT group, n = 6, tangle
count reduced to 38.9%625.7%, p= 0.004) and lowered tau
hyperphosphorylation at the AT8 epitope (reduction to
45.5632.7%; p= 0.04; Fig. 2).
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In parallel to the observed attenuation in cortical tau tangle
pathology in the stereological assessment, biochemical analysis
revealed a significant reduction of sarkosyl insoluble tau in the
forebrain of long- and short-term treated P301S mice (5MT:
rapamycin group: percentage of vehicle treated mice:
56.7617.5%, p= 0.03, Fig. 3A; 6WT: 28.0636.2%, p= 0.004,
Fig. 3B). Tau hyperphosphorylated at AT8 and AT100 was
significantly lowered upon 6 weeks of rapamycin treatment as
measured by Western blotting (6WT: rapamycin group: percent-
age of vehicle treated mice: AT8:11.2642.3%, p= 0.004;
AT100:4.1617.9%, p= 0.04, Fig. 3C). In contrast, no decrease
of forebrain soluble tau levels was noted in these aged mice, and
no acute suppression of soluble tau protein generation occurred
after rapamycin administration in pretangle P301S mice (Fig.
S3A). Endogenous murine tau furthermore remained unchanged
after acute and chronic rapamycin administration in P301S mice
as assessed by the mouse tau specific antibody T49 [22] (Fig. S3B).
High levels of rapamycin were measured in the brain
following its intraperitoneal administration, in confirmation that
rapamycin penetrates the blood-brain barrier (Fig. S4A).
Rapamycin induced inhibition of the mTORC1 pathway in
the brain of treated mice resulted in significantly reduced
phosphorylation of ribosomal S6 protein (S6) (5MT, Fig. 4A).
S6 suppression by rapamycin was comparable in the forebrain
and the brain stem (Fig. S4B).
In line with the activation of autophagy by rapamycin, a
significant increase in LC3II by 229% was found in rapamycin
treated P301S mice (6WT, p= 0.02, Fig. 4B). High levels of the
autophagy associated proteins p62 and LC3 in a set of vehicle
treated old tangle bearing P301S mice furthermore pointed
towards a disturbed autophagy flux in our tauopathy model. This
accumulation of p62 and LC3 was prevented by rapamycin
treatment (Fig 4C).
Figure 1. The extensive cortical tau tangle pathology present in 5.5 months old vehicle (veh) treated P301S mice (A) was widely
attenuated in long-term rapamycin (rapa) treated mice (B). The lowering in tangle formation was most pronounced in the motor cortex (C:
left vehicle treated/right rapamycin) and associated with reduced pathological tau hyperphosphorylation at the AT8 and AT100 epitopes (D, E). In
parallel, cortical astrogliosis was diminished following rapamycin treatment (F). While there was a trend towards a reduction of the sparse tangles in
the hippocampus, the advanced tau pathology in the brain stem however was not significantly ameliorated by rapamycin (G, H). Short-term
treatment at 3 months of age for 6 weeks again resulted in a marked reduction of cortical tangles (I) (A–H: 5MT group; I: 6WT. A–C, G–I: Gallyas silver
stain; D: AT8 IHC; E: AT100 IHC; F: GFAP IHC. Bar in A equals 300 mm in A and B, 150 mm in C, G and I, 75 mm in D–F, 600 mm in H).
doi:10.1371/journal.pone.0062459.g001
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Discussion
We report a significant alleviation of cortical tau pathology in a
murine tauopathy model following long- and short-term admin-
istration of the autophagy inducing drug rapamycin. Alzheimer’s
disease (AD) and other tauopathies including fronto-temporal
dementia with tau pathology (FTD-T) constitute the most
prevalent forms of neurodegenerative disorders [1]. Despite a
broad range of concepts, only few tau targeting approaches such as
tau directed immunotherapy [25,26] and administration of lithium
chloride [27], sodium selenate [28] or methylene blue [29] have
been effective in vivo.
Disturbed autophagy is known to be involved in the pathogen-
esis of AD [4,30]. We have recently shown that trehalose alleviates
tau pathology by autophagy stimulation in vivo [7]. A beneficial
effect of autophagy induction on amyloid-b and associated tau
pathology has furthermore been found in a triple transgenic mouse
model of AD [10,11].
We here studied the effect of the FDA approved drug
rapamycin on tau pathology in absence of amyloid-b pathology,
using the P301S mutant tau transgenic mouse model. Vehicle
treated P301S mice develop extensive tau pathology with tau
redistribution towards the cell body and dendrites, early tau
hyperphosphorylation at 4–6 weeks of age, and subsequently, at
ages of 3 months, progressive aggregation of tau into tangles. We
show that long-term rapamycin treatment reduces cortical tau
tangle burden by more than 80% and levels of sarkosyl insoluble
tau in the forebrain by 70%. In parallel to the attenuation of tau
pathology, we note reduced astrogliosis following rapamycin
administration. Rapamycin is also able to alleviate tau tangle
pathology when a short-term treatment is started after tau
hyperphosphorylation has already been initiated. These findings
extend previous observations in rodent models on beneficial effects
of rapamycin for cerebral proteinopathies e.g. polyglutamine
disorders [9,12] and the amyloid-b cascade [10] to tauopathies.
Comparably to trehalose treatment [7], rapamycin does not
fully prevent the formation of tau pathology in P301S mice.
Particularly in the brain stem, the persisting tangle formation
might be caused by the extensive basal tau pathology present in
this brain region in P301S mice that could overrun the benefical
effect of autophagy induction in this brain area [13]. Rapamycin
treatment thus seems to be subjected to a ceiling effect that does
not allow coping with a very high tau load. As a limitation of our
present study, the rapidly progressive brain stem pathology
Figure 2. After long-term rapamycin treatment (n=6), unbi-
ased stereology confirmed a significant reduction of cortical
tau tangles to only 14% of the amount of tangles seen in
vehicle treated (n=5) P301S mice (vehicle=100%). The number
of AT8 stained cells containing hyperphosphorylated tau was reduced
to 30% in aged rapamycin treated mice compared to controls (100%)
(5MT group). A significant attenuation of Gallyas-stained (to 39% of
controls) and AT8-positive cells (to 46% of controls) was also achieved
by late short-term rapamycin treatment (6WT, n= 6/6). The reduction of
tangles in the hippocampus (to 33% of controls) and the brain stem (to
72% of controls) did not reach the level of significance adjusted for
multiple testing. Pairwise reduction of Gallyas or AT8 positive counts
was analysed using one-sample T-tests per brain region. Significant p-
values, adjusted for the multiple comparisons of all 6 tested groups by
the Holm-Bonferroni method, are outlined as follows: *p,0.05,
**p,0.01, and ***p,0.001.
doi:10.1371/journal.pone.0062459.g002
Figure 3. Levels of sarkosyl extracted insoluble tau were significantly reduced in the forebrain of P301S mice after 5 months of
long-term rapamycin treatment (R, n=6) when compared to vehicle treated mice (V, n=5) (A, 5MT group; Western blot using
BR134 antibody). A comparable lowering of insoluble tau was obtained by late short-term rapamycin administration over 6 weeks (B; 6WT group,
n = 6/6). In parallel, the accumulation of tau hyperphosphorylated at the AT8 and AT100 epitopes was significantly lowered (C; 6WT group, n = 6/6).
Quantification of tau Western blots was subjected to unpaired T-tests and T-tests adjusted for unequal variances (Welch-Test), yielding both similar
results. *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0062459.g003
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furthermore precludes the observation of a significant clinical
improvement in the P301S model. Detailed analysis of behav-
ioural and functional parameters including the characterization of
early effects on tau metabolism following rapamycin treatment
should therefore be addressed in future studies.
Prevention from protein aggregation by rapamycin in different
models of neurodegenerative disorders has mainly been attributed
to its autophagy inducing property [5,10]. Here we show that
intraperitoneally administrated rapamycin penetrates the blood-
brain-barrier in mice. It reaches effective levels in the brain to
inhibit mTOR and stimulate autophagy. Our analysis of
autophagic flux is limited by the ex vivo nature of our specimen
and the long-term treatment effects. However, in vehicle treated,
tangle bearing P301S mice, we observe an accumulation of LC3
protein and the autophagy substrate protein p62, similar to reports
on findings in human tauopathy patients’ brains [31]. Lowered
levels of p62 and LC3 in our rapamycin treated P301S mice thus
may point towards a restoration of the autophagic flux,
comparable to a recent observation in APP transgenic, amyloid-
ß depositing CRND8 mice [32]. Besides autophagy stimulation,
rapamycin can attenuate tauopathy progression also by its
immunosuppressive properties. The later mechanism may underlie
the observed reduction in astrogliosis, as tau associated gliosis has
earlier been reported to be responsive to immunosuppression [33].
Rapamycin has furthermore been shown to modulate tau
phosphorylation in vitro during neuronal development [34,35]. A
favorable effect on tau phosphorylation may therefore contribute
to the attenuation of tau pathology in our model. It has
furthermore been reported that rapamycin can inhibit protein
synthesis [36]. We however see no reduction in endogenous mouse
tau nor in transgenic human tau following short-term rapamycin
administration, precluding that the observed favourable effects on
tau pathology evolution are primarily based on a reduced
generation of tau in our model.
Rapamycin is an established FDA-approved drug. Its use as an
mTOR inhibitor for the treatment of tuberous sclerosis has
recently been translated from transgenic mouse models to man
[37]. The beneficial effects of rapamycin on the progression of tau
pathology in our murine model may encourage the development
of autophagy inducing agents for patients suffering from
tauopathies.
Supporting Information
Figure S1 Scheme of the study indicating the treatment
schedules of the different groups of rapamycin (R) or vehicle (V)
treated P301S mutant tau transgenic mice and non-transgenic
C57BL/6J mice. P301S mice were treated twice weekly
intraperitoneally with 15 mg rapamycin per kg body weight or
vehicle from 3 weeks to 5.5 months of age (group 5-months
treatment, 5MT; n= 6 rapamycin; n= 5 vehicle), and from 3
months to 4.5 months of age (6-weeks treatment, 6WT; 6/6).
Additional P301S mice were treated at age of 3 months for 1.5
weeks in order to analyze the immediate effects on soluble tau
levels (1.5-weeks-treatment, 1.5WT; 5/5). Furthermore, non-
transgenic C57BL/6J mice were treated accordingly at the age
of 3 months for 1.5 weeks (B6-1.5WT; 2/2). A total of 8 adult
C57BL/6J mice (4 rapamycin, 4 vehicle) have been used to
measure the levels of rapamycin in blood and brain (B6 sir; 4/4). A
total of 4 additional rapamycin treated mice died during the
experiments and could therefore not be included for data
collection.
(PDF)
Figure S2 For the qualitative assessment of astrogliosis in long-
term rapamycin treated mice, blinded sets comprising every 5th
Figure 4. Consistent with cerebral mTOR inhibition, phosphorylation of S6 (S6P) was significantly reduced following rapamycin
administration (A, 5MT group, n=4/4). Compatible with an induced autophagy pathway, LC3II levels were increased upon rapamycin treatment
(B, 6WT group, n = 6/6). High levels of the autophagy associated proteins p62 and LC3 were measured in aged vehicle treated P301S transgenic mice
(C; 5MT Vehicle, n = 4). This accumulation of p62 and LC3 was prevented by long-term rapamycin administration, pointing towards a restored
autophagic flux (C; 5MT Rapa, n = 4). Forebrain tissue was used and data was analyzed by ANOVA. *p,0.05, **p,0.01, and ***p,0.001.
doi:10.1371/journal.pone.0062459.g004
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20 mm section of 5MT mice were rated from – (A), + (B), ++ (C) to
+++ (D) by three independent raters (S.O., K.B., D.W.). The
median rating of the GFAP stainings of all sections was listed per
brain region and mouse for a qualitative comparison of the 5
vehicle treated to the 6 rapamycin treated mice (E).
(TIF)
Figure S3 Forebrain levels of soluble tau protein remained
unchanged after both, 5 months or 6 weeks of rapamycin
treatment (A; 5 MT, p= 0.35; 6 WT, p= 0.18). We also analyzed
the immediate effects of a short rapamycin treatment of 1.5 weeks
duration on forebrain tau levels in pretangle P301S mice. There
again was no reduction of soluble tau by rapamycin treatment (A;
1.5 WT, p= 0.53). Furthermore, unchanged levels of mouse tau
following rapamycin administration indicate that there is no
suppression of endogenous tau synthesis by rapamycin in our
model (D; T49 antibody (kindly provided by Prof. V. Lee); 1.5
WT, p= 0.20; 6 WT, p= 0.86).
(TIF)
Figure S4 Intraperitoneal rapamycin administration resulted in
high cerebral rapamycin levels as measured by HPLC. Similar
levels were achieved in the forebrain and the brain stem (A; B6 1.5
WT; FB= forebrain, BS: brain stem, BL: blood). Consistent with
cerebral mTOR inhibition, Western blotting of forebrain tissue
showed significantly reduced phosphorylation of S6 following
rapamycin administration (see Fig. 4A). Suppression of the
phosphorylation of S6 (S6P) was comparable in brain stem and
forebrain tissue, compatible with a similar effect of rapamycin on
mTOR in both brain regions.
(TIF)
Methods S1
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Scheme!of!the!study!indicating!the!treatment!schedules!of!the!different!groups!of!rapamycin!(R)!or!vehicle!(V)!
treated!P301S!mutant!tau!transgenic!mice!and!non>transgenic!C57BL/6J!mice.!!
P301S!mice!were!treated!twice!weekly! intraperitoneally!with!15mg!rapamycin!per!kg!body!weight!or!vehicle!
from!3!weeks!to!5.5!months!of!age!(group!5>months!treatment,!5MT;!n=6!rapamycin;!n=5!vehicle),!and!from!3!
months!to!4.5!months!of!age!(6>weeks!treatment,!6WT;!6/6).!Additional!P301S!mice!were!treated!at!age!of!3!
months! for!1.5!weeks! in!order! to!analyze! the! immediate!effects!on! soluble! tau! levels! (1.5>weeks>treatment,!
1.5WT;!5/5).!Furthermore,!non>transgenic!C57BL/6J!mice!were!treated!accordingly!at!the!age!of!3!months!for!
1.5! weeks! (B6>1.5WT;! 2/2).! A! total! of! 8! adult! C57BL/6J! mice! (4! rapamycin,! 4! vehicle)! have! been! used! to!
measure!the!levels!of!rapamycin!in!blood!and!brain!(B6!sir;!4/4).!A!total!of!4!additional!rapamycin!treated!mice!
died!during!the!experiments!and!could!therefore!not!be!included!for!data!collection.!!
!
! 2!
Supplementary,Figure,S2,,,
!
!
For! the! qualitative! assessment! of! astrogliosis! in! long>term! rapamycin! treated! mice,! blinded! set! comprising!
every!5th!20µm!section!of!5MT!mice!were!rated!from!–!(A),!+!(B),!++!(C)!to!+++!(D)!by!three!independent!raters!
(S.O.,!K.B.,!D.W.).!The!median!rating!of!the!GFAP!stainings!of!all!sections!was!listed!per!brain!region!and!mouse!
for!a!qualitative!comparison!of!the!5!vehicle!treated!to!the!6!rapamycin!treated!mice!(E).!!
,
,
Supplementary,Figure,S3,
,
,
!
Forebrain! levels! of! soluble! tau! protein! remained! unchanged! after! both,! 5!months! or! 6!weeks! of! rapamycin!
treatment! (A;! 5MT,! p=0.35;! 6WT,! p=0.18).! We! also! analyzed! the! immediate! effects! of! a! short! rapamycin!
treatment!of!1.5!weeks!duration!on!forebrain!tau!levels!in!pretangle!P301S!mice.!There!again!was!no!reduction!
of! soluble! tau! by! rapamycin! treatment! (A;! 1.5WT,! p=0.53).! Furthermore,! unchanged! levels! of! mouse! tau!
following! rapamycin! administration! indicate! that! there! is! no! suppression! of! endogenous! tau! synthesis! by!
rapamycin!in!our!model!(D;!T49!antibody!(kindly!provided!by!Prof.!V.!Lee);!1.5WT,!p=0.20;!6WT,!p=0.86).!!
! 3!
Supplementary,Figure,S4,
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,
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Intraperitoneal! rapamycin! administration! resulted! in! high! cerebral! rapamycin! levels! as! measured! by! HPLC.!
Similar!levels!were!achieved!in!the!forebrain!and!the!brain!stem!(A;!B6!1.5WT;!FB=!forebrain,!BS:!brain!stem,!
BL:!blood).!Consistent!with!cerebral!mTOR!inhibition,!Western!blotting!of!forebrain!tissue!showed!significantly!
reduced! phosphorylation! of! S6! following! rapamycin! administration! (see! Fig! 2C).! Suppression! of! the!
phosphorylation! of! S6! (S6P)! was! comparable! in! brain! stem! and! forebrain! tissue,! compatible! with! a! similar!
effect!of!rapamycin!on!mTOR!in!both!brain!regions.!
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Supplementary,Methods!
!
Rapamycin)quantification)in)brain)tissue)and)blood)by)HPLC)
In! order! to!measure! brain! levels! of! rapamycin,! a! total! of! 8! C57BL/6J!mice!were! treated! for! 1.5!weeks!with!
rapamycin! or! vehicle! (4/4).! The! mice! then! were! deeply! anesthetized,! blood! was! collected! in! EDTA! tubes!
following!cardiac!puncture,!and!the!mice!were!perfused!with!NaCl!before!removing!and!immediately!freezing!
their! brains.! The! forebrain! halves! were! homogenized! and! subjected! to! HPLC! measurement! of! rapamycin!
according!to!a!previously!published!protocol![1].!Brain!halves!and!blood!samples!of!vehicle!treated!mice!were!
used!to!calibrate!the!HPLC!system.!!
!
Antibodies)used)for)Western)blotting)
For!Western!blotting,!the!following!antibodies!were!used:!!
i) for!detection!of!tau:!BR134!detecting!the!C!terminus!of!human!and!murine!tau!independently!of!
its!phosphorylation![2],!RD3!targeting!aa209>220!of!human!tau!and!recognizing!3>repeat!human!
and!murine!tau!isoforms!from!Millipore!Corporation!(Billerica,!MA),!T49![3,4]!specific!for!mouse!
tau! (kind! gift! of! Prof.! Virginia! Lee,! CNDR,! University! of! Pennsylvania! School! of! Medicine,!
Philadelphia,! PA),! AT8! against! the! phosphorylated! Ser202! tau! residue! from! Endogen! (Woburn,!
MA),! and! AT100! against! tau! phosphorylated! at! Ser212! and! Thr214! from! Pierce! Biotechnology!
(Rockford,!IL),!
ii) for! evaluation! of! mTORC1! signalling! and! autophagy:! anti>S6! Ribosomal! Protein! (#2217),! anti>
Phospho>S6! Ribosomal! Protein! Ser235/236! (#2211),! anti>LC3B! (#2775),! from! Cell! Signaling!
Technology!(Danvers,!MA),!anti>Phospho>S6!Ribosomal!anti>p62!(GP62>C)!from!Progen!Biotechnik!
(Heidelberg,!Germany),!!
iii) as! loading!controls:! anti>GAPDH! ((#32233)! from!Santa!Cruz!Biotechnology! (Santa!Cruz,!CA),! and!
anti>beta>Actin!(#A5316)!from!Sigma>Aldrich!(Saint!Louis,!MO).!
!
Statistics)
Statistical!analysis!was!performed!using!IBM®!SPSS®!Statistics!Version!19.!Biochemical!data!of!tau!Western!blots!
was!subjected!to!unpaired!T>tests!and!T>tests!adjusted!for!unequal!variances!(Welch>Test),!yielding!both!similar!
results.! Holm>Bonferroni! corrections!were! applied.! Biochemical! data! of! p62! and! LC3>levels!was! analyzed! by!
ANOVA.!Stereological!samples!of!vehicle!and!rapamycin!treated!mice!were!stained!in!parallel.!Accordingly,!the!
pairwise!reduction!of!Gallyas!or!AT8!positive!counts!was!analysed!using!one>sample!T>tests!per!brain!region.!
Significant! p>values! adjusted! for! multiple! comparisons! by! the! Holm>Bonferroni! method! are! reported! and!
outlined! in! all! figures! as! follows:! *=p<0.05,! **=p<0.01,! ***p=<0.001.! The! mean! and! SD! is! indicated! in! all!
figures.!!!!
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The accumulation of insoluble proteins is a pathological hallmark of several neurodegenerative disorders. Tauopathies are
caused by the dysfunction and aggregation of tau protein and an impairment of cellular protein degradation pathways may
contribute to their pathogenesis. Thus, a deficiency in autophagy can cause neurodegeneration, while activation of autophagy is
protective against some proteinopathies. Little is known about the role of autophagy in animal models of human tauopathy.
In the present report, we assessed the effects of autophagy stimulation by trehalose in a transgenic mouse model of tauopathy,
the human mutant P301S tau mouse, using biochemical and immunohistochemical analyses. Neuronal survival was evaluated
by stereology. Autophagy was activated in the brain, where the number of neurons containing tau inclusions was significantly
reduced, as was the amount of insoluble tau protein. This reduction in tau aggregates was associated with improved neuronal
survival in the cerebral cortex and the brainstem. We also observed a decrease of p62 protein, suggesting that it may contribute
to the removal of tau inclusions. Trehalose failed to activate autophagy in the spinal cord, where it had no impact on the level of
sarkosyl-insoluble tau. Accordingly, trehalose had no effect on the motor impairment of human mutant P301S tau transgenic
mice. Our findings provide direct evidence in favour of the degradation of tau aggregates by autophagy. Activation of autophagy
may be worth investigating in the context of therapies for human tauopathies.
Keywords: autophagy; neurodegenerative disorders; neuroprotection; protein aggregation; tau
Abbreviation: LC3 = microtubule-associated protein light chain 3
Introduction
Most neurodegenerative diseases are characterized by the accu-
mulation of misfolded proteins. Thus, !-synuclein aggregates
in Parkinson’s disease and other synucleinopathies, TDP-43 (TAR
DNA-binding protein 43) in TDP-43 proteinopathies, huntingtin in
Huntington’s disease and both b-amyloid and tau in Alzheimer’s
disease (Goedert et al., 2010). Filaments made of hyperpho-
sphorylated tau protein are a good predictor of the cognitive
state in Alzheimer’s disease, because a negative correlation has
been described between the number of neurofibrillary tangles,
and the Mini-Mental score (Giannakopoulos et al., 2003).
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Tau deposits also constitute the defining pathological hallmark of
several other diseases, including progressive supranuclear palsy,
corticobasal degeneration, Pick’s disease and frontotemporal de-
mentia and parkinsonism linked to chromosome 17 (Goedert and
Jakes, 2005; Goedert and Spillantini, 2011). Since filament
assembly is a concentration-dependent process, a reduction in
the production and/or increased clearance of tau are potential
targets.
In eukaryotic cells, there are two major systems responsible for
the degradation of cytoplasmic proteins: the ubiquitin–proteasome
system and the autophagy–lysosome pathway (Goldberg, 2003).
The accumulation of ubiquitinated tau in intracellular filamentous
inclusions suggests a possible impairment of tau degradation by
the ubiquitin–proteasome system and/or the autophagy–lysosome
pathway. Indeed, inactivation of the ubiquitin–proteasome system
or the autophagy–lysosome pathway has been reported to lead to
neurodegeneration associated with the presence of ubiquitinated
aggregates (Hara et al., 2006; Komatsu et al., 2006; Bedford
et al., 2008; Riley et al., 2010). Particularly, ubiquitin–proteasome
system or autophagy–lysosome pathway inhibition induces the
accumulation of tau (Blard et al., 2006; Ramesh Babu et al.,
2008; Liu et al., 2009; Lee et al., 2010). Moreover, accumulation
of autophagic vacuoles has been observed in Alzheimer’s disease
brain and in a mouse model of tauopathy (Lin et al., 2003; Nixon
et al., 2005), suggesting a possible disturbance of lysosomal
proteolysis in tauopathy. Macroautophagy (hereafter referred to
as autophagy) is the major form of autophagy. Although it is
known that the suppression of autophagy causes neurodegenera-
tion (Hara et al., 2006), relatively little is known about the role of
autophagy in animal models of human tauopathy. In the triple
transgenic mouse model of Alzheimer’s disease and in a mouse
model expressing human mutant tau on a null background for the
E3 ubiquitin ligase parkin, stimulation of autophagy promoted the
degradation of insoluble tau (Caccamo et al., 2011; Majumder
et al., 2011; Rodriguez-Navarro et al., 2011). However, these
studies did not allow one to determine whether the effects of
autophagy stimulation were due to a direct interaction between
the autophagic machinery and tau or whether they were indirect.
To date, there has been no report of the effect of increased
autophagy in a mouse model of human tauopathy. We therefore
administered trehalose, a mammalian target of rapamycin
(mTOR)-independent activator of autophagy (Noda and Ohsumi,
1998; Sarkar et al., 2007a), to mice transgenic for human mutant
P301S tau.
Materials and methods
Antibodies
We used phosphorylation-independent anti-tau antibodies BR133
and BR134 which recognize both murine and human tau isoforms.
Phosphorylation-dependent anti-tau antibodies AT8 and AT100
(Innogenetics) were also used. AT8 recognizes tau protein phosphory-
lated at S202 and T205 (Goedert et al., 1995), whereas AT100
detects tau phosphorylated at T212, S214 and T217 (Yoshida and
Goedert, 2006). Autophagy was assessed using an antibody against
microtubule-associated protein light chain 3 (LC3) (Novus Biologicals).
We also used an antibody against p62/SQSTM1 (Santa Cruz
Biotechnology). To normalize protein levels, an anti-GAPDH
(Millipore, Ltd.) antibody was used.
Animals and treatment
Homozygous human P301S tau transgenic mice (Allen et al., 2002)
and age-matched wild-type C57BL/6 mice were used (n = 6 per
group for western blot analysis; n = 3 per group for immunohisto-
chemistry and stereology experiments). From weaning onwards, the
animals were treated with 2% trehalose or 2% sucrose, which were
used as the control. A separate group received normal drinking
water (no treatment). The water solutions were changed twice
weekly. Animals were checked daily and the quantity of water
drunk and the animals’ weights were assessed twice a week.
P301S tau transgenic mice develop motor deficits at !3–4 months
of age, as shown using Rotarod (Scattoni et al., 2010). We routinely
evaluated these deficits by visual inspection, as they form in a
stereotypical manner consisting of an unstable gait followed by gen-
eral stiffness and hindlimb paralysis. Furthermore, at 3–4 months of
age, the human P301S tau mice are unable to extend their hind-
limbs when lifted by the tail (Allen et al., 2002). In this study, we
assessed the motor deficits by visual inspection and used the time
when all the animals had developed hindleg stiffness and were
unable to extend their hindlimbs when suspended by the tail as
the endpoint (20 weeks of age).
Tissue extraction
To extract sarkosyl-insoluble proteins from brain and spinal cord,
frozen tissues were weighed and homogenized in cold extraction
buffer [10 mM Tris–HCl, pH 7.4, 800mM NaCl, 1mM EGTA, 0.1M
phenylmethylsulphonyl fluoride, 10% sucrose and one tablet of
complete protease inhibitor cocktail (Roche)]. The homogenates
were spun at 6000g for 20min and the supernatants incubated with
1% sarkosyl for 1 h at room temperature. After a 1 h centrifugation at
80 000 g, the supernatants were discarded and the pellets resuspended
in 50mM Tris–HCl, pH 7.4 (300 ml/g tissue). For investigation of
soluble tau, brains and spinal cords were homogenized in 25mM
Tris–HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1mM
phenylmethylsulphonyl fluoride and one tablet of complete protease
inhibitor cocktail. Samples were centrifuged at 80 000 g for 15min.
The resulting supernatant constituted the soluble fraction. The samples
were analysed by SDS-PAGE.
Immunoblot analysis
After SDS-PAGE, the gels were blotted for 1 h at room temperature
onto polyvinylidene difluoride membranes (Millipore). The membranes
were blocked for 1 h at room temperature in 0.1M phosphate buffer,
pH 7.4, 0.2% Tween 20 and 5% milk, followed by an overnight
incubation with the primary antibody in blocking buffer. Membranes
were then washed in 0.1M phosphate buffer, pH 7.4, 0.2% Tween 20
and incubated for 1 h at room temperature with peroxidase-
conjugated secondary antibody (Pierce) in blocking solution. After
washing, the blots were developed using enhanced chemiluminescence
(Amersham Biosciences).
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Quantification of proteins
Band intensities were quantified (ChemidocTM XRS and Quantity One!
software, Bio-Rad) and the amounts of soluble proteins normalized
with respect to GAPDH. Insoluble tau was normalized relative to the
tissue weight. Data were expressed as means ! SEM. Statistical
analysis was performed using a one-way ANOVA test followed by
Tukey’s post hoc comparisons (Prism, GraphPad Software, Inc.).
Immunohistochemistry
Mice were perfused transcardially with 4% paraformaldehyde in 0.1M
phosphate buffer, pH 7.4. Brains and spinal cords were dissected and
post-fixed overnight at 4"C, followed by cryoprotection in PBS con-
taining 30% sucrose for at least 24 h. Serial sagittal brain sections
(30 mm) were cut on a Leica SM2400 microtome (Leica
Microsystems) and stored at 4"C in PBS containing 0.1% sodium
azide. For fluorescence labelling, sections were permeabilized for
5min with cold PBS containing 0.5% Triton X-100 and washed
three times with PBS, 0.1% Triton X-100 (PBST). After 2 h blocking
at room temperature with PBST containing 3% bovine serum albumin,
sections were incubated with the primary antibodies in blocking solu-
tion for 24 h at 4"C. This was followed by three washes and a 2 h
incubation at room temperature with Alexa Fluor! 488 (Molecular
Probes) or Cy5 (Abcam) secondary antibodies in blocking solution.
After washing and DAPI (4,6-diamidino-2-phenylindole) staining, the
sections were mounted using Vectashield mounting medium (Vector
Laboratories). They were analysed using a Leica DMRB fluorescence
microscope (Leica) or a Radiance 2100 confocal microscope (Bio-Rad).
Images were taken using a Sharp 2000 laser (Zeiss Bio-Rad) and were
typically 512 # 512 pixels. Staining for neuronal nuclei (NeuN;
Chemicon) (Mullen et al., 1992; Wolf et al., 1996; Lind et al.,
2005) and tau phosphorylated at the AT100 epitope were carried
out in brains of wild-type and transgenic mice using immunoperoxi-
dase (Vectastain ABC kit, Vector Laboratories). Endogenous peroxidase
was quenched for 15min with 3% H2O2 in distilled water. After
washing, sections were blocked for 1 h with normal horse serum in
PBST and incubated overnight with the anti-NeuN antibody (1:500) in
blocking solution at 4"C. After three rinses with PBST, sections were
incubated with a biotin-conjugated anti-mouse antibody for 2 h at
room temperature. Next, the avidin–biotin-conjugated complex was
applied for a further 2 h. Finally, the antigen was visualized using
the Vector! VIP substrate kit (Vector Laboratories). Sections were
mounted on SuperFrost! glass slides (VWR international) and dehy-
drated using a series of ascending ethanol solutions (70, 95 and
100%) and xylene.
Stereology
The Stereo Investigator 9 (MBF Bioscience) was used to quantify the
number of NeuN-positive cells. Sections through the brain were
sampled in a systematic random manner using 1:12 series for quanti-
fication of NeuN-positive and AT100-positive neurons. The thickness
of each section was determined using the Stereo Investigator 9 soft-
ware. For a given section, the outline of the region of interest was
traced under a #10 objective and the enclosed area calculated by the
software. Sections within the highlighted area were then sampled at
random and cells counted under the #40 objective to determine the
total number of immunoreactive cells. Statistical analyses were
performed using a one-way ANOVA test followed by Tukey’s
post hoc comparisons (Prism, GraphPad Software, Inc.).
Results
Animal health
Water consumption of the three groups (no treatment,
sucrose-treated and trehalose-treated) was similar. Sucrose and
trehalose had no impact on the animals’ weights or coat aspects,
suggesting that the health of the mice was similar among the
three groups. The human P301S tau mice were sacrificed at
20 weeks of age, when they developed an unstable gait and
motor abnormalities, which is typical of homozygous transgenic
mice (Allen et al., 2002). The development of motor deficits
was not significantly different between treated and non-treated
human P301S tau transgenic mice. Thus, untreated mice
developed the first motor deficits at 19 ! 0.19 weeks of age,
which was not significantly different from the ages at which
they appeared in sucrose-treated (18.8 ! 0.31 weeks) and
trehalose-treated (19.25 ! 0.23 weeks) mice (Supplementary
Fig. 1).
Effects of trehalose on autophagy
activation
To investigate autophagy activation, we measured the conversion
of LC3-I into LC3-II, a marker of autophagic vacuole formation
(Kabeya et al., 2000; Mizushima et al., 2004; Tanida et al., 2004).
We observed the conversion of 17.5 ! 2.3% LC3-I into LC3-II in
the brains of trehalose-treated mice, while no detectable LC3-I
conversion was seen in untreated or sucrose-treated mice
(Fig. 1A). Unexpectedly, trehalose had no effect on LC3-I conver-
sion in the spinal cord (Fig. 1B). We therefore focused our study
on the brain. Immunohistochemistry of brain sections from mice
transgenic for human mutant P301S tau showed the presence
of LC3 puncta in trehalose-treated mice (Fig. 1E). The punctate
distribution of LC3 was absent from control groups (Fig. 1C and
D). In trehalose-treated transgenic mice, AT100-positive tau
aggregates were also immunoreactive for LC3, indicating the
co-localization of autophagic vacuoles and tau aggregates
(arrows, Fig. 1F–H).
Effects of trehalose on tau pathology
and neuronal survival
Total soluble tau and soluble tau phosphorylated at the AT8 epi-
tope were not affected by trehalose treatment (Supplementary
Fig. 2). In contrast, quantification of sarkosyl-insoluble tau in the
brain indicated that trehalose decreased the amount of insoluble
tau compared with untreated controls ($53%, P5 0.01) or to
controls treated with sucrose ($46%, P50.05) (Fig. 2A).
Trehalose treatment had no effect on the amount of sarkosyl-
insoluble tau in the spinal cord (Fig. 2B). Immunofluorescence
staining for anti-tau antibody AT100 showed a drastic reduction
in the number of positive cells in layers I–III of the cerebral cortex
($66.5% compared with untreated animals, P5 0.01; $80.1%
compared with sucrose-treated mice, P50.001) (Fig. 2C–F)
and in the brainstem, particularly the pontine nucleus
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(!75% compared with untreated animals, P5 0.001; !58.6%
compared with sucrose-treated mice, P50.01) (Fig. 2G–J).
Nerve cell numbers were counted in layers I–III of the cerebral
cortex and in the pontine nucleus. The number of neurons in
layers I–III was higher in trehalose-treated P301S tau mice than
in animals that received either no treatment ( + 55.5%, P5 0.05)
or were treated with sucrose ( + 59.6%, P50.05) (Fig. 3A).
The number of neurons in trehalose-treated mice and in untreated
wild-type animals was not significantly different (Fig. 3A). In
the pontine nucleus, the number of neurons increased in
trehalose-treated animals compared with untreated ( + 79.2%,
P5 0.01) and sucrose-treated controls ( + 61.6%, P5 0.05)
(Fig. 3B). The number of NeuN-positive cells in the pontine
nucleus was similar in trehalose-treated P301S tau mice and in
wild-type controls (Fig. 3B).
Effects of trehalose on p62/SQSTM1
Immunohistochemistry revealed the co-localization of p62/
SQSTM1 and AT100-positive tau aggregates in P301S tau
transgenic mice (Fig. 4D–F), while no co-staining was observed
in wild-type controls (Fig. 4A–C). We assessed the levels of
p62/SQSTM1 in the brains of wild-type and transgenic P301S
tau mice subjected to the different treatments. We observed
a reduction in p62/SQSTM1 levels in mice treated with trehalose
compared with mice that received either no treatment (!52.1%,
P50.05) or sucrose (!46.7%, P50.05) (Fig. 4G). No significant
difference was detected between wild-type controls and P301S
tau transgenic mice (Fig. 4G).
Discussion
The assembly of normally soluble proteins into amyloid-like fibrils
is a pathological hallmark of several neurodegenerative disorders,
with tauopathies being the most common (Goedert et al., 2010).
Herein, we report on the effects of stimulation of autophagy on
tau inclusions and nerve cell survival in a mouse line transgenic for
human mutant P301S tau. Trehalose activated autophagy in the
brain, as shown by the increased formation of LC3-II, and reduced
Figure 1 Conversion of LC3-I into LC3-II was assessed by western blotting in the spinal cord (A) and the brain (B) of mice transgenic for
human P301S tau. LC3-II staining was only present in brain where autophagic vacuoles were observed in trehalose-treated mice (arrow in
E). Autophagic vacuoles were not present in the brains of non-treated (C) or sucrose-treated (D) mice. (F–H) Confocal analysis indicated
that AT100-positive tau inclusions (F) were also immunoreactive for LC3-II (G), suggesting the presence of tau inclusions in autophagic
vacuoles in trehalose-treated transgenic mice (H). NT = no treatment; Su = sucrose-treated; Tr = trehalose-treated. Scale bar = 20mm.
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the level of sarkosyl-insoluble tau. However, it did not stimulate
autophagy in the spinal cord and consequently had no effect on
the level of insoluble tau. The mechanism of action of trehalose is
not completely understood, but it is believed to activate autop-
hagy in an mTOR-independent manner (Sarkar et al., 2007a).
These findings suggest that autophagic pathways may differ
between brain and spinal cord. The absence of a detectable
effect of trehalose in the spinal cord probably accounted for the
persistence of a pathological motor phenotype in treated P301S
tau transgenic mice. We cannot exclude that a detailed behav-
ioural assessment could have revealed subtle differences between
treated and non-treated mice. However, the motor deficit charac-
teristic of the human P301S tau transgenic mice probably results
from the degeneration of spinal cord motor neurons, consequent
to the development of a toxic filamentous tau pathology (Allen
et al., 2002; Delobel et al., 2008), and possibly the sequestration
of proteins important for motor behaviour. As tau pathology in
the spinal cord was unchanged after trehalose administration,
an improvement in motor function was unlikely. The reasons
underlying our inability to activate autophagy in the spinal cord
remain to be determined. They could be related to a less efficient
delivery of trehalose to the spinal cord, although it has been
shown that the blood–spinal cord barrier is more permeable to
tracers and cytokines than the blood–brain barrier (Prockop
et al., 1995; Pan et al., 1997). We hope that future experiments
will allow us to overcome this limitation.
Figure 2 Sarkosyl-insoluble tau was decreased in the brain of trehalose-treated mice compared with non-treated or sucrose-treated
animals (A), while trehalose treatment had no effect on sarkosyl-insoluble tau in the spinal cord (B). In trehalose-treated mice, the number
of nerve cells with AT100-positive inclusions was drastically reduced in layers I–III of the cerebral cortex (C–F) and in the pontine nucleus
of the brainstem (G–J). NT = no treatment; Su = sucrose-treated; Tr = trehalose-treated. *P50.05, **P50.01 and ***P5 0.001.
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In the brains of trehalose-treated mice, we observed a decrease
in sarkosyl-insoluble tau and the number of nerve cells with tau
inclusions. Besides its ability to activate autophagy, trehalose has
also been reported to act as a protective chaperone in a murine
model of Huntington’s disease (Tanaka et al., 2004). However,
the reduction in tau inclusions in our mouse line was probably
due to the degradation of tau aggregates by trehalose-induced
autophagy. Indeed, we observed a decrease in tau inclusions
only in regions where autophagy was activated. Moreover, we
showed co-localization between autophagic vacuoles and tau
inclusions, suggesting that tau aggregates were engulfed by
autophagosomes before degradation. Sucrose, a chemical
chaperone, which has been shown to reduce the conversion of
the cellular prion protein to its protease-resistant form
(DebBurman et al., 1997), failed to reduce tau aggregates in the
human mutant P301S tau transgenic mice, confirming that the
effect of trehalose on tau aggregates was mediated through an
increase in autophagy.
Altogether, our results indicate that the in vivo stimulation of
autophagy reduced the amount of tau aggregates and improved
nerve cell survival. A role for autophagy in the clearance of protein
aggregates has been suggested for a number of proteins, including
b-amyloid, !-synuclein, ataxin-3, prion protein and huntingtin
(Webb et al., 2003; Sarkar et al., 2007b; Pickford et al., 2008;
Figure 3 Nerve cell numbers were assessed using stereology. Trehalose treatment increased the number of neurons in layers I–III of the
cerebral cortex (A) and in the pontine nucleus of the brainstem (B). *P50.05 and **P50.01.
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Heiseke et al., 2009; Casarejos et al., 2011; Majumder et al.,
2011; Riedel et al., 2011; Spilman et al., 2011). Activation of
autophagy has also shown protective effects in mouse and fly
models of tauopathy (Berger et al., 2006; Caccamo et al., 2011;
Majumder et al., 2011; Rodriguez-Navarro et al., 2011).
However, in mice, tau was not the only engineered protein. In
one study, the mice overexpressed human mutant tau and carried
a deletion of the gene encoding parkin (Rodriguez-Navarro et al.,
2011), a potential mediator of autophagy (Olzmann et al., 2007;
Chin et al., 2011). Therefore, not surprisingly, restoration of
autophagic activity decreased the number of tau aggregates and
improved cell survival. In separate studies, autophagy was acti-
vated in triple transgenic mice exhibiting tau and b-amyloid
pathologies (Caccamo et al., 2011; Majumder et al., 2011). It is
well established that b-amyloid can promote tau pathology in
some brain regions (Go¨tz et al., 2001; Lewis et al., 2001;
Oddo et al., 2003, 2004). However, direct evidence for the
relevance of autophagy in modulating tau pathology was missing.
We now show that the activation of autophagy markedly reduced
the number of tau aggregates and nerve cell loss in a mouse
model of human tauopathy.
We also investigated p62/SQSTM1 expression in wild-type and
P301S tau transgenic mice. p62/SQSTM1 is a protein that acts as
a receptor for selective autophagy, mainly because of its ability to
bind both ubiquitin and LC3 (Pankiv et al., 2007; Lamark et al.,
2009). It has previously been implicated in the degradation of
protein inclusions (Bjorkoy et al., 2006; Watanabe and Tanaka,
2011) and has been found in tau inclusions in human
Figure 4 Immunohistochemistry for p62/SQSTM1 (A and D) and assembled tau (AT100; B and E) showed co-localization in P301S tau
transgenic mice (F) but not in wild-type animals (C). Scale bar = 20 mm. (G) Western blot of p62/SQSTM1 levels in the brains of wild-type
controls and mice transgenic for human mutant P301S tau that received either no treatment or were given sucrose or trehalose. The
amount of p62/SQSTM1 signal is shown normalized with respect to GAPDH. *P50.05 and **P50.01.
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neurodegenerative diseases (Kuusisto et al., 2001, 2002; Zatloukal
et al., 2002). We now show co-localization of p62/SQSTM1 with
tau inclusions in P301S tau transgenic mice, consistent with the
human pathology. In addition, we observed a decrease in
p62/SQSTM1 levels in trehalose-treated mice, suggesting that
p62/SQSTM1 may be an adaptor molecule for tau inclusions
before their degradation by autophagy. Although the majority of
tau filaments in P301S tau transgenic are not ubiquitinated
(Allen et al., 2002), p62/SQSTM1 may nonetheless be involved,
as it has been shown to play a role in the autophagic degradation
of non-ubiquitinated protein aggregates (Watanabe and Tanaka,
2011). The levels of p62/SQSTM1 were similar between P301S
tau transgenic mice and wild-type controls, indicating that
p62/SQSTM1 synthesis and basal autophagy were not affected
in the transgenic mice. In conclusion, we show that activation of
autophagy in mice transgenic for human mutant P301S tau
decreased the number of tau inclusions and increased nerve cell
survival in cerebral cortex and brainstem.
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In 2011, about 107’500 people living in Switzerland were suffering of dementia including 
Alzheimer’s disease (AD) [6]. Unfortunately, this number will increase to approximately 
200’000 by 2030 and 300’000 by 2050, according to the Swiss Alzheimer Association [6]. 
Nowadays, there is no curative treatment available for AD or other tauopathies, as 
pharmacological therapies are limited to symptomatic approaches. Although numerous 
research projects are currently trying to unravel the pathomechanisms leading to dementia, the 
exact molecular and cellular events associated to their onset and progression are still only 
partly understood. While the attention had been focused for a long time on the amyloid-ß 
peptide, tau is now recognized as an equal key element of the pathogenesis and progression of 
AD. 
During my thesis, the development of novel mouse models allowed to better 
understand the pathomechanisms at play in tauopathies. These studies established that tau 
fragmentation, which likely happens at the pretangle stage and aggravates the propensity of 
tau protein to aggregate, might constitute a major, early event in neuronal dysfunction. This 
toxicity and the associated alterations of the nervous system were reversed when the 
expression of the tau fragment was halted, hence shedding light on new, promising 
therapeutic strategies to counter the progression of the disease. As described for other 
neurodegenerative pathologies, pharmacological treatments promoting the induction of 
autophagy also showed their efficiency to improve tauopathies in transgenic mouse models. 
These data open novel avenues regarding the pathogenesis and potential therapeutic 
approaches for dementia, but also underline important questions that remain to be answered in 
follow up studies.  
 
From mouse models to the identification of the early molecular mechanisms involved in 
the onset and progression of tauopathies  
 
What is toxic in tau protein? What do we learn from a novel mouse model for tauopathies? 
One of the hallmarks of AD is the presence of extracellular accumulation of amyloid-ß (Aß) 
peptide, a cleavage product of the APP protein, which constitutes the major component of the 
amyloid fibrils forming senile plaques. Aß activates multiple deleterious events leading to 
altered neuronal homeostasis, such as mitochondria dysfunction, increased oxidative stress 
and hyperphosphorylation of tau protein [232, 233]. The hypothesis of the “amyloid cascade” 
as the central, determining event of AD pathogenesis was originaly based on in vitro and in 
vivo studies showing the toxicity of Aß peptide, on findings in trisomie 21 patients and then 
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supported by the discovery of genetic mutations in the APP, PS1 and PS2 genes in familial 
AD [129]. Recent reports further indicate that this amyloid cascade would be triggered by the 
oligomeric and fibrillary forms of Aß, which constitute the most toxic forms of the peptide 
[234].  
The exact role of tau protein in the onset and progression of AD is still unknown. Its 
involvement in neuronal dysfunction is underlined by its accumulation, in the absence of 
extracellular Aß deposition, in the brain of patients suffering from neurodegenerative diseases 
other than AD [235]. Furthermore, diverse mutations in the MAPT gene, encoding tau protein, 
were associated with FTDP-17 [163, 236, 237]. Reproduction of these mutations lead to the 
generation of different transgenic animal models, which mimic various aspects of tauopathies, 
including age-related accumulation of filamentous tau, neuron loss and axonal transport 
defects [238]. 
In tauopathies, tau accumulates in different forms associated with post-translational 
modifications such as phosphorylation, glycosylation, ubiquitination as well as truncation. 
Tau aggregation and its abnormally high phosphorylation had been widely recognized as the 
toxic elements involved in neuron dysfunction. Recent reports furthermore suggested that tau 
truncation, a characteristic feature observed in human, sporadic AD, would constitute an 
upstream event in the proteolytic cascade occurring in the disease and would precede tau 
tangles formation [239-242]. In vitro studies further established that fragmentation of tau 
favours its polymerization compared to the full-length forms of the protein, hence paving the 
way for new mechanisms implicated in the onset of neurodegenerative diseases [85, 100].  
 
During my thesis, I analyzed a novel inducible, transgenic mouse model to study the 
impact of a short, wild-type ∆tau fragment in vivo. TAU62 mice express the 3R repeat 
domain-containing ∆tau151-421 fragment and developed a mild to moderate motor deficiency 
with a slowly progressive axonopathy. This phenotype was similar to that observed in aged 
transgenic ALZ17 mice expressing the human, full-length tau (2N4R) [243]. Interestingly, tau 
fragment expression in TAU62 mice was sufficient to cause a pretangle tau pathology, 
characterized by tau hyperphosphorylation in cerebral and spinal cord neurons, its cellular 
redistribution and impaired neuron function, in the absence of tangles formation and insoluble 
tau accumulation. Similarly, McMillan group generated a mouse model expressing 1N4R tau 
fragment cleaved at E391 in the C-terminal insert, which did not develop tau tangles [99]. 
Notwithstanding, this contrasts with previous reports linking the overexpression of tau 
fragments in rats with the development of neurofibrillary degeneration [172, 173]. Based on 
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the mild phenotype of our TAU62 mice, we concluded that in the absence of the full-length 
human form of tau, ∆tau151-421 has only minor toxic effects similar to that of full-length forms 
of wild-type tau. 
 
What are the early events in the molecular cascade leading to tauophathies? What is the 
propensity of different forms of tau to aggregate? 
Previous studies have suggested that tau mutant fragments are highly toxic, which was 
related to their important propensity to aggregate [244, 245]. Indeed, truncation increases the 
ability of tau to form filaments in both in vivo and in vitro models. Caspase-3 induces 
cleavage of tau at D421 and the truncated (∆tau) form was shown to exacerbate the toxicity of 
mutant full-length tau [89]. In order to mimic better the pathological situation of AD where 
truncated and full-length forms are co-existing, we next co-expressed the wild type ∆tau151-421  
fragment with the full-length, mutant (P301S) human form of tau, by breeding TAU62 mice 
with the P301S transgenic mice.  Missense mutations in the MAPT gene had been shown to 
cause FTDP-17 disease, which is characterized by neuronal loss, astrocystic gliosis, 
filamentous accumulation of hyperphosphorylation of tau, as well as motor and cognitive 
impairment [161]. Accordingly, P301S transgenic mice display motor deficit and 
accumulation of tau filaments in brainstem and spinal cord [165]. Importantly, our double 
transgenic P62on mice developed an unexpected early, severe motor impairment. Complete 
hind limb palsy was observed as soon as at 3 weeks of age and this severe phenotype was 
associated with neuronal dysfunctions, such as mild tau hyperphosphorylation, intraneuronal 
accumulation of neurofilaments, formation of axonal spheroids and reactive gliosis. 
Notwithstanding, breeding of TAU62 mice with the ALZ17 animals expressing the wild type, 
full-length tau (2N4R) lead to a less pronounced neurodegenerative phenotype, although some 
of these mice develop a severe paralysis around 1 month of age. The main between 2N4R tau 
isoform and the mutant P301S form of tau (0N4R), resides in their aggregation propensity. 
Further investigations remain to be done to understand and confirm these observations and to 
characterize the influence of the aggregation propensity of the co-expressed full-length tau 
form. It should be noted that cross-breeding of P301S animals with ALZ31 mice expressing 
the wild-type, human full-length 0N3R form of tau, did not lead to the same aggravation of 
the motor phenotype.  
Hence, our data reveal that ∆tau, when associated with full-length forms of tau, 
strikingly exacerbates the toxicity of tau protein and its propensity to cause neuron 
dysfunction. By contrast, these tau forms alone (i.e. full-length or truncated) exert a less 
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detrimental effect on neuronal homeostasis. In both mouse models with co-expression of ∆tau 
and a full-length form of the protein, we observed severe neuronal impairment while tangle 
formation and insoluble forms of tau were not detected. Similarly, drosophila models for 
tauopathies displayed severe neuron degeneration, associated with behavioural phenotypes, 
without developing any tau filaments [240, 241, 246-248]. Our results confirmed these 
previous reports suggesting that tau tangles formation constitutes a secondary event in the 
pathology and that tangles are not the decisive toxic agent in tauopathies.  
 
Is abnormal oligomerization of the full-length and truncated forms of tau involved in the onset 
of the pathology? 
Tau oligomers can contain hyperphosphorylated and non-phosphorylated tau proteins and can 
form both soluble and insoluble products. They have been identified in AD and FTDP-17 
brains [239, 249, 250] and are considered to intermediate events between soluble tau 
monomers and insoluble tau filaments. According to these observations, tau oligomers might 
play a crucial role in the onset and progression of tauopathies. Notably, previous studies 
revealed that tau oligomers have a toxic effect on axonal transport [251-253]. Moreover, tau 
oligomerization may be promoted by other oligomers such as Aß oligomers in AD or alpha-
synuclein in PD and FTDP-17 [252, 254] and co-localization between tau oligomers and Aß 
has been observed in synaptosomal fractions of brain from AD patients [254].  
 P62 mice constitute an ideal tool to identify, which forms of tau are present in the 
pre-tangle stage and associated with the severe form of the phenotype. Our preliminary data 
suggest that tau-containing complexes of higher molecular weight (55-250kDa) are present in 
the brain of these mice, which likely correspond to soluble oligomers [255]. Although the 
exact role of tau oligomers is not clear, some studies showed that formation of aggregates has 
beneficial effect [256, 257], whereas others observed that these forms are toxic [258]. Here, 
we establish that ∆tau exerts a toxic effect on neurons in vivo. Since a co-aggregation between 
full-length tau and ∆tau was observed in brain homogenates from mutant mice, it would be 
interesting to determine the exact role of ∆tau in the formation of tau oligomers. In this light, 
it is planned to investigate the levels of the different isoforms (3R/4R) of tau as well as of the 
murine endogeneous tau in P62, ALZ17xTAU62 and P301SxALZ31 mice. Formation of tau 
oligomers may also derive from an imperfect clearance of misfolded tau protein by the 
ubiquitin-proteasome or the chaperone systems [251, 256]. Hence, futher studies may test 
whether increasing their activity in P62 mice would limit the accumulation of toxic tau and 
thereby ameliorate the phenotype of the mice. 
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Outlook: what are the consequences of endogenous murine tau protein expression on the 
phenotypes of transgenic mouse models? 
This general question underlines the potential importance of murine tau protein in transgenic 
mice expressing wild type or mutant, human forms of tau. A previous study, analyzing the 
consequences of the breeding of the AD mouse model Tg30 with mice depleted for Tau 
(TauKO), suggested that the murine tau protein has an anti-aggregation role and thus limits 
the phenotype of transgenic mouse models for tauopathies [259]. Based on this observation, it 
would be interesting to determine the role of the endogenous murine tau for the evolution of 
tau pathology and the severe phenotype of P62 mice. Breeding of TAU62 mice with TauKO 
mutant animals may be conducted, before crossing the resulting mice with P301S animals. 
The new mice obtained would allow to determine the impact of ∆tau without endogenous tau 
and see whether its toxicity is aggravated. So far, the mechanism by which endogenous tau 
limits tau aggregation is unknown, and it remains essential to elucidate the question. It is 
known that the N-terminal region of the murine and human tau proteins only share 75% of 
homology, while C-terminal domains show an almost perfect homology [260]. One can thus 
hypothesize that the protective effect of mouse tau may reside on its N-terminal region, which 
may limit the aggregation of tau protein. Depletion of this form in our mouse models may 
therefore reveal futher neuronal alteration, which may mimic more efficiently the 
pathomechanisms at play in human diseases. 
 
 
Identifying the cellular events underlying neuronal dysfunction in tauopathies by using 
a novel, severe mouse model for tauopathies 
 
The development of a novel, severe model for tauopathies allowed us to elucidate the 
mechanisms associated with tau toxicity in vivo. Future challenges will aim to dissect the 
molecular pathways and cellular processes by which Δtau causes the massive, widespread, 
neurological changes observed in mutant mice.  
 
Microtubule destabilization and impaired axonal transport as primary events in tauopathies 
Tau associates with microtubules and participates in their stability and dynamics [261]. 
Through this tight association, tau proteins also play an important role in microtubule-
dependent trafficking of organelles in cells and are determinant for the efficient axonal 
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transport of intracellular components, such as mitochondria, ER and lysosomes [262]. 
Destabilization of the microtubules is a consequence of tau hyperphosphorylation, which 
provokes a lost of its affinity for binding and leads to traffic impairments. However, recent 
works suggested that increased affinity and binding to microtubules would rather be the cause 
for the altered kinesin-dependent traffic in cells [263]. It remains unclear what corresponds to 
these ‘hyperbound’ forms of tau [264] and how they form; in this hypothesis, 
hyperphosphorylation of tau may constitute an adaptative, protective process to limit the 
binding of tau to the microtubules. Another gain of pathological function hypothesis proposes 
that increase in the ability of tau to bind to kinesin would block the interaction of the motor 
protein with cargoes and/or microtubules, and thus impair axonal transport [36, 265, 266]. 
Altered axonal transport has been implicated in the pathogenesis of different 
neurodegenerative disorders [267, 268] and was related to the abnormal accumulation of 
neurofilaments in axons of motor neurons in AD, PD and ALS [269-271].  
 
Interestingly, P62on mice displayed signs of microtubule destabilization and axonal 
transport disruption, which are likely caused by Δtau toxicity. Further investigations remain to 
be conducted to determine the mechanisms leading to these defects in detail. To this end, it 
would be interesting to assess the effect of microtubule stabilizers, such as Paclitaxel and 
Epothilone D [272-275], as microtubule stabilizing agents were recently shown to partly 
rescue tau induced axonal transport deficits in other models [272-274]. The affinity of Δtau 
and tau oligomers for tubulin and kinesin may also be studied in order to better understand the 
origin of the defects. Immunoprecipitation and co-immunohistochemistry may also give an 
idea of the interaction between tau, microtubules and motor proteins in the brain of P62 mice. 
Moreover, deregulation of the interaction between kinesin and cargoes has been related to tau-
mediated mislocalisation of the c-Jun N-terminal kinase interacting protein 1 (JIP1) in the 
soma, which may constitute another event at play in axonal transport deficits in tauopathies 
[276]. Therefore, one might test the localisation of JIP1 in these mice to see whether it is 
implicated in the defects observed. It could be also interesting to test the interaction between 
phospho-tau and JIP1 in order to determine how hyperphosphorylated tau impair axonal 
transport by its implication with kinesin. Lastly, it has been suggested that JNK pathway is 
involved in the regulation of microtubule stability in neurons and promotes kinesin-mediated 
fast axonal transport, thereby contributing to neuron function and synaptic plasticity [277]. 
JNK protein belongs to MAPK family and seems to play a role in the pathogenesis of AD by 
targeting neurofilaments [278]. Its phosphorylation induces tau pathology in PS1/APP 
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transgenic AD model [279], and it has been observed that phospho-tau colocalizes with 
activated form of JNK [280, 281]. Since the mechanism behind the hyperphosphorylation of 
tau is still unclear, an imbalance between kinases such as JNK and phosphatases has been 
suggested to play a role in tau pathology. For these reasons, analysis of JNK pathway and its 
involvement in neuronal dysfunction in P62on mice would be relevant.  
 
Neuronal alteration relies on impaired axonal transport: mitochondrial dysfunction, synaptic 
disorganisation and Golgi fragmentation 
Several reports established that transport deficits are responsible for mitochondria 
mislocation, identified as an early, key component in the neurodegenerative cascades [282-
284]. Mitochondrial homeostasis is essential in neurons, which have high-energy requests and 
prolonged processes, hence requiring organized, efficient organelle traffic [285, 286]. 
Mitochondria dysfunction may be responsible for synaptic impairment and synapse loss, early 
observed in AD [287, 288], and seems to be targeted by toxic truncated forms of tau [289]. In 
parallel, there is evidence that fragmentation of Golgi apparatus (GA) also occurs at early 
stage in many neurodegenerative diseases [290]. GA is involved in transport, processing and 
targeting of proteins to the dendrites and axon in order to maintain cell polarity [291]. Thus, 
dysfunction of the GA machinery impairs a regulated system involved in protein sorting in 
neuronal compartments. Several studies using in vitro and in vivo models suggested that 
accumulation and hyperphosphorylation of tau induce GA fragmentation in hippocampus and 
that this process is not caused by apoptosis. Moreover, these morphological changes of GA 
were shown to develop before the formation of tangles [290].  
 
Interestingly, in P62 mice, histological features e.g. swollen and fragmented GA as 
well as accumulation of mitochondria in the hippocampus of the mice, were observed in the 
absence of tangles. Additional experiments, focusing on the fission/fusion processes of 
mitochondria, the expression of specific components involved in the tricarboxylic acid (TCA) 
cycle and oxidative phosphorylation (OXPHOS) systems, as well as the production of ROS, 
might help to better characterize the mitochondrial dysfunction in P62 mice, and their 
consequences on cell homeostasis. Regarding GA alteration, it could be of interest to confirm 
that GA fragmentation is not related to neuron apoptosis in this model. Lastlty, synaptophysin 
proteins, which play a role in synaptic function, also accumulated in the hippocampus of 
paralyzed P62 mice and sorting of VAMP2 (or synaptobrevin II), one of synaptophysin 
binding partners, was altered. These preliminary data suggested that missorting of synaptic 
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proteins in the GA could affect synapse function by depleting newly synthetized vesicular 
proteins. Quantification of functional synapses and identification of the binding partners of 
synaptophysin in P62 mice may help to understand the molecular mechanisms at play in the 
control of vesicle recycling and their alterations in AD. Such changes occurring early during 
the progression of the pathology could reveal new therapeutic targets. 
 
What is causing muscle atrophy in tauopathy mouse models? 
P62on mice developed a rapidly progressive hind limb palsy associated with severe muscle 
wasting. Histology revealed marked muscle fibre atrophy where both fibre types were 
severely affected and display angulated profiles. These findings were consistent with a 
neurogenic atrophy. Several reports have already described that muscle disuse causes severe 
muscle atrophy, which was related to an important activation of the catabolic pathways, the 
ubiquitin-proteasome (UPS) and the lysosome-autophagy process, in muscle tissue. Among 
the molecular mechanisms shown to mediate these changes, activation of FoxO signalling and 
inhibition of the mTORC1 pathway were of central importance [292].  
FoxO (Forkhead box O) factors constitute positive regulators of the two proteolytic 
pathways by promoting the transcriptional expression of atrogenes (encoding the E3 ubiquitin 
ligase, MurF1 and Atrogin1) and autophagy-related genes (such as LC3 and Bnip3) [293, 
294]. Inversely, mTORC1 increases protein synthesis and inhibits autophagy induction in 
muscles [295]. While induction of the proteasome system leads to muscle wasting, both 
increased and reduced autophagy flux were shown to impair muscle homeostasis and cause 
muscle atrophy [296-298]. Excessive induction of autophagy leads to the elimination of 
fraction of cytoplasm and to muscle degeneration, as observed, for instance, in merosin-
deficient congenital myopathies (MDC1A) [299]. In contrast, inhibition of autophagy 
conducts to the detrimental accumulation of vacuoles and abnormal organelles as observed in 
collagen VI-related myopathies [298, 300, 301]. Functional defects of axonal transport seem 
to be responsible for muscle wasting in a variety of neurodegenerative diseases such as ALS 
[302], AD [303] and HD [207]. In these pathologies, FoxO/mTORC1 signalling, as well as 
the UPS and autophagy processes have been implicated in the appearance of muscle atrophy 
[304].  
Here, it would be interesting to investigate whether the UPS activity and the 
autophagy flux are modified in muscles from P62on, compared to control mice. In this line, 
analysis of autophagy markers, such as LC3 or p62 proteins, as well as quantification of the 
transcriptional expression of atrogenes could be performed. Furthermore, the mTORC1/FoxO 
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signalling, as well as other signalling, including HDAC5/Myostatin [305] or TWEAK/Fn14 
[306] related to denervation-induced proteolysis, could be studied in muscles from P62on to 
determine the upstream events causing muscle atrophy. Lastly, since muscle atrophy was 
widely restored following extinction of Δtau expression, it will be of major interest to identify 
the processes involved in this gain of muscle mass. In particular, re-activation of mTORC1 
may participate in this hypertrophy but the up-stream events leading to its activation remain to 
be fixed. Observation of centronuclear fibers in muscles from P62on-off mice also suggested 
that activation of satellite cells may be important in the hypertrophy process, by forming new 
fibers or enlarging pre-existant, atrophic fibers. Immunohistochemistry against myogenic 
markers, such as Pax7, MyoD, Myogenin or embryonic myosin heavy chain, may help to 
better understand the mechanisms at play in the restoration of muscle fibers [307-310]. 
 
Outlook: The role of autophagy in neuronal dysfunction 
Impairment of autophagy in AD has been widely described [203] and considered to be 
responsible for the accumulation of misfolded and aggregated proteins. Reduced autophagy 
flux was related in AD to decreased expression of Beclin1, an essential protein for autophagy 
processing [206] and abnormal activation of the JNK signalling, which would cause inhibition 
of FoxO factors and repression of autophagy-related genes [311]. Altered lysosome-mediated 
clearance of autophagosomes may also be responsible for the accumulation of autophagy-
related vesicles in AD and may be caused by the inefficient traffic of lysosomes within 
neurons. Moreover, macroautophagy and chaperone-mediated autophagy are involved in the 
degradation of different forms of tau and fragmented tau may also derive from imperfect 
autophagy processing [312]. Importantly, while autophagy blockade would promote the 
accumulation of tau aggregates, increased levels of tau protein may further alter axonal 
transport and thereby the autophagy flux.  
 In P62 mice, it is of major importance to test whether Δtau expression or the early 
formation of soluble oligomers of tau is sufficient to impact on the autophagy flux. In 
complement to experiments testing the axonal transport in P62 mice, western blot and 
immunohistochemistry against autophagy markers, including LC3 and p62, will allow to 
identify potential dysfunction in the flux. In this light, we have treated P301S mice with either 
rapamycin or trehalose and we showed that these treatments have beneficial effects [313, 
314]. Treating P62 mice with drugs inducing (e.g. rapamycin) autophagy will also bring 
insight on the process at play in the specific degradation of Δtau and oligomers.  
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Rationale for the development of therapeutic strategies for tauopathies: what we learnt 
from our mouse models?  
 
Up to now, the current therapies for AD addressed only symptomatic aspects and notably tried 
to delay the cognitive decline of affected patients. Since Aß accumulation was considered as 
the central upstream event leading to neurodegeneration in AD, most of the strategies were 
developed either to reduce Aß formation or to promote its clearance. But these clinical trials 
so far mainly failed to ameliorate the neuropathology and the degeneration of the neurons 
[315]. Most importantly, these therapies could not prevent the progression of concomitant tau 
pathology, once initiated. Design of new therapies targeting tau pathology now constitutes 
another interesting approach for AD and other tauopathies. 
 
A promising observation: the phenotype of tau transgenic mice is reversible 
As observed in other models [316], the severe phenotype and the histopathological features 
observed in P62on mice are largely reversible when the expression of ∆tau is suppressed. In 
particular, the accumulation of AT8 phosphorylated tau and tau oligomers are reversed in 
P62on-off mice. Moreover, the defects in GA, mitochondria mislocation and the altered sorting 
of synapse-associated proteins are not longer present in these mice, although more detailed, 
quantitative experiments remain to be done to confirm these observations. Hence, these data 
revealed that the toxic effect of ∆tau in association with mutated full-length tau can be 
reversed even after the onset and progression of the pathological changes. 
 
Rationale for the development of therapeutic strategies targeting the inhibition of tau 
fragmentation 
Based on our results, it appears obvious that ∆tau elements, when combined with different tau 
isoforms, are more toxic than full-length tau and exacerbate tau aggregation. Proteins 
inducing neurodegeneration are the substrates for many proteases such as caspases, calpains 
or cathepsins: in HD brain, caspase-3 cleaves huntingtin fragments before the clinical onset 
[317, 318], and in AD brain, the cleavage of tau proteins is initiated by caspase-3 or -6 in both 
early and late NFT stages as well as during cognitive decline  [74, 75, 319]. One might 
consider the use of inhibitors of caspase-3 or calpains, such as minocycline, a second 
generation of tetracycline, in AD pathology [320]. Recent studies described the beneficial 
effect of minocycline in primary cortical neurons: the cleavage of tau by caspase-3 is reduced 
as well as Aß-mediated activation of caspases. Similar observations have been made in mice 
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expressing human tau, where tau phosphorylation and cleavage were reduced upon treatment 
with minocycline [321, 322]. These data hence suggest that targeting the proteolytic activity 
involved in tau truncation may constitute a relevant therapeutic approach for tau pathology.  
 
Rationale for the pursuit of therapeutics countering tau aggregation 
In proteinopathies, such as AD, PD and HD, abnormal accumulation, aggregation and 
removal of proteins, constitute a specific, detrimental event associated with the pathogenesis 
and the cognitive deficits. Preventing tau aggregation or oligomerization may therefore 
constitute a promising option to limit tau toxicity and neuronal dysfunction associated with 
tauopathies.  
The efficiency of different inhibitors of amyloid and tau aggregation has already been 
assessed in in vitro or in vivo AD models. For instance, the epigallocatechin gallate, a green 
tea derived polyphenol, efficiently limits amyloid-β aggregation in vitro and neutralizes 
amyloid-β oligomers [323-326]. The substance is also sufficient to restrict tau aggregation 
and particularly its oligomerization in vitro [326]. Other plant derived substances with in vitro 
proven anti-amyloid aggregation capacity include cinnamon extracts [327] and Tannic acid 
[328]. The phenylthiazolyl-hydrazide BSc3094 [329], Methylene blue [330] and Curcumin 
[331] also had positive effect on amyloid-β and/or tau accumulation, as well as on memory 
deficits in  transgenic tau mouse model. 
Based on these previous reports and on the severe phenotype observed in P62on mice, 
the ability of different inhibitors of tau aggregation to prevent or limit the toxicity of Δtau and 
the associated neuronal alteration in mutant mice could be tested. Treating these mice with 
different pharmacological drugs may help to determine whether inhibiting the aggregation of 
tau would prevent the onset of the pathology and, more specifically, which pathological 
cellular events can be restored.  
 
Inducing autophagy as a promising therapeutical option for tauopathies 
In parallel of therapeutic options targeting the formation of tau and amyloid-β aggregates, 
promoting the clearance of tau protein represents another effective and realistic strategy for 
dementia treatment. As described before, a downward cycle between formation of tau 
aggregates and impairment in autophagy is likely at play in a majority of neurodegenerative 
diseases. For these reasons, drug-induced up-regulation of autophagy has been widely tested 
in animal models for tauopathies and envisioned for AD, PD or HD. 
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One part of my thesis aimed to determine if autophagy stimulation would promote tau 
clearance in tau transgenic mice and could ameliorate their neurodegenerative phenotype. To 
this end, P301S mutant mice were treated with two distinct autophagy-inducing agents: i) 
rapamycin, a well-known inhibitor of the mTORC1 pathway and FDA-accepted 
pharmacological drug [313] and ii) trehalose, a mTORC1-independent activator of autophagy. 
Rapamycin treatment significantly delayed the progression of tau pathology and the 
associated histopathological and biochemical changes in P301S mice [313]. While aged 
mutant mice treated with saline sham solution developed robust tau tangle disease, tangle 
formation and accumulation of sarcosyl-insoluble tau were largely prevented in rapamycin 
treated mice. Comparably, trehalose also improved neuronal survival in the brain of P301S 
mice and reduced the number of AT100 positive neurons as well as the amount of insoluble 
tau protein. [332].  
Although these results open promising avenues regarding potential, efficient therapeutic 
strategies toward AD and other tauopathies, further complementary investigations remain to 
be conducted. For instance, we have not assessed in details whether rapamycin also 
ameliorated behavioural and functional parameters. Furthermore, one limitation of these 
treatments was the absence of effect in the brainstem and most probably in spinal cords as 
seen with trehalose. Additional experiments might be done to determine why the induction of 
autophagy had no effect on the spinal cord and why the motor deficit was not reversed in 
threhalose-treated mice. One possible explanation may come from the strong expression of 
mutated tau and the associated formation of tangles, which may be resistant to autophagy-
mediated clearance. It could be also interesting to investigate the efficiency of axonal 
transport in P301S mice, treated or not with rapamycin/trehalose drugs, to determine whether 
autophagy induction restores the process. 
Lastly, our results may be even more instructive on the protective effect of autophagy 
induction by treating, as mentioned above, the severely affected P62 mice. Analysis of the 
molecular and cellular consequences of pharmacological drug promoting autophagy in these 
mice will help to determine the benefits of such treatment and their limits.  
 
Together, the insights gained by our current observations and the proposed 
perspectives shall contribute to a better understanding of the pathomechanisms leading to 
tauopathies and the development of novel therapeutic approaches. In long term, other 
therapeutic strategies, such as immunotherapy targeting tau oligomers [333] may be tested in 
the P62 model. Hence, our novel P62 mouse model offers a unique configuration to test new 
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therapeutic strategies and unravel the different molecular events conducting to the onset and 
the progression of tauopathies and AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
 
 
 
 
 
 
Figure 11: Schematic overview on the pathology of tau protein in neurodegeneration 
and on the treatment strategies to reduce tau pathology 
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MATERIALS and  METHODS 
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Animal model  
 
Inducible Δtau expressing TAU62 transgenic mice have been generated by co-injection of two 
Thy 1.2 minigenes based constructs into C57BL/6J oocytes. The Thy 1.2-tTS construct was 
obtained by replacing exon 2 of the murine Thy 1.2 promoter by a tetracycline controlled 
transcriptional silencer element (tTS). The Thy 1.2-TRE-Δtau construct contained a 
tetracycline responsive element (TRE) upstream of the human wild-type Δtau cDNA encoding 
amino acids 151 to 421 of a 3-repeat domain spanning human wild-type tau fragment (3R0N 
tau151-421). A total of 6 positive transgenic founder TAU62 mice (C57BL/6J-TgN(tTS-Thy1-
Δtau151-421) were identified and the inducible expression of human Δtau was assessed by 
western blot and immunohistochemistry. Lines 62-2 and 62-48 exhibited comparable and 
robust Δtau expression without leakage upon doxycycline withdrawal. All quantitative 
experiments were performed with mice of the TAU62-48 line, abbreviated TAU62 mice 
(C57BL/6J-TgN(tTS-Thy1-Tau) 62). TAU62-2 mice were used in order to rule out an 
insertion side effect causing the drastic motor phenotype observed in P301Sx TAU62/48 
double transgenic mice. 
 For the generation of ALZ31 wild-type human 3R0N tau transgenic mice (C57BL/6J-
TgN(Thy1-ALZ) 31), 0N3R human cDNA was cloned into a standard neuron-specific Thy 
1.2 promoter element and injected into C57BL/6J oocytes. 
 ALZ17 wild-type human 2N4R tau transgenic mice (C57BL/6J-TgN(Thy1-ALZ) 17) 
generation has been described previously [243]. Briefly, cDNA encoding the longest human 
tau isoform has been subcloned into a murine Thy 1.2 gene. Subcloning htau40 cDNA by 
using XhoI restriction site produced the tau expression construct, ALZ17 transgene. After 
microinjection into pronuclei of B6D2F1 x B6D2F1 embryos, the founders were analysed by 
PCR and then intercrossed with C57BL/6J mice to obtain strains 
 Generation of P301S mutant 0N4R tau transgenic mice (C57BL/6J-TgN(Thy1-
hTauP301S)) has been described previously [165]. Shortly, cDNA encoding the shortest human 
four-repeat tau isoform (383 amino acids isoforms of human tau) was used to obtain the 
P301S mutation. After subcloning the mutated cDNA into a murine Thy 1.2 genomic 
expression vector, this tau construct was produced by subcloning P301S htau43 cDNA using 
XhoI restriction site. Transgenic mice were generated by microinjection into pronuclei of 
(C57BL/6J x CBA/ca) F1 generation. PCR analysis was performed done to identify the 
founders and these were interbred with C57BL/6J mice to obtain strains. 
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 P301SxTAU62 double transgenic mice have been obtained by crossing P301S mice 
with ∆tau transgenic mouse lines. All double transgenic mice were heterozygous for the 
transgenes of interest. Chow containing 500mg/kg doxycycline was provided ad libitum to 
induce Δtau expression. All animal experiments were approved by the local Ethics and 
Animal Care and Use Committees. 
 
 
 
  
Figure 12: Generation of TAU62 mice 
In Tau62 mice, neuronal ΔTau expression was driven by an inducible Thy1.2 promoter element under 
a tetracycline controlled transcriptional silencer element (tTS). 
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Figure 13: Mice used to study the effect of ∆tau and the corresponding breeding (P62, 
ALZ31xP301S and ALZ17xTAU62) 
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Genotyping 
 
Lysis buffer 
Concentration Supplier
Tris 100 mM (pH 8.5) Biomol # 08003
EDTA 5 mM Fluka BioChemika # 03690
NaCl 200 mM Merck # 1.06404.10 000
SDS 0.20% Bio Rad # 161 0301  
 
Pieces of mouse ears were incubated in lysis buffer containing 0.1 mg/ml Proteinase K 
(Macherey-Nagel # 740506.75) in Eppendorf Thermomixer comfort shaker (650 rpm, 55°C 
over night (O/N)). The solution was centrifuged (13000rpm, 5 min) and 550µl of the 
supernatant was transferred into 500µl isopropanol. The solution was mixed by inverting and 
centrifuged (13000 rpm, 10 min). The pellet was washed with 75% ethanol and centrifuged 
again (13000 rpm, 10 min). DNA was consequently dried on Eppendorf Thermomixer 
comfort shaker (55°C, 5-10 min) and resuspended with 250µl dH2O. DNA was dissolved by 
agitation at 50°C 1h before performing the PCR. 
 
PCR Master Mix for 25µl reaction volume: 
 
Concentration Supplier
2X TaqDNA polymerase
QIAGEN PCR buffer
3 mM MgCl2
400 µM dNTP (each)
Forward primer 10 pmol Eurofins MWG/opreon
Reverse Primer 10 pmol Eurofins MWG/opreon
DNA 2 µl
Master Mix QIAGEN # 200403
 
 
Primer pair TauF151 detect the ∆tau allele (383 bp length) and primer pair P301S detected 4R 
tau allele (600 bp length). 
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PCR amplification protocol for genotyping 
 
TauF151 program:  
Step 1: 95°C for 2 min 
Step 2: 95°C for 1 min 
Step 3: 60°C for 1 min 
Step 4: 72°C for 2 min 
Step 5: 72°C for 10 min (final extension) 
 
Steps 2-4 were repeated for 30 cycles. 
 
P301S program: 
Step 1: 95°C for 4 min 
Step 2: 95°C for 1 min 
Step 3: 60°C for 1 min 
Step 4: 72°C for 3 min 
Step 5: 72°C for 10 min (final extension) 
 
Steps 2-4 were repeated for 30 cycles. 
 
PCR products were loaded on 1.5 % agarose gels and run at 150 Volt. 
 
Primers for genotyping (all sequences are written 5’ ! 3’) 
 
Forward primer Reverse primer
TauF151 GTG GAT CTC AAG CCC TCA AG GGC GAC TTG GGT GGA GTA
P301S GGT TTT TGC TGG AAT CCT GG GGA GTT CGA AGT GAT GGA AG  
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Behavioural assessment 
Phenotypic characterisation included the observation of motor behaviour (gait ataxia and 
tremor) by testing hind limb reflexes at ages of 21 days and after switching off the expression 
of ∆tau. Quantitative motor testing was performed on the grid test.  
For grid testing, mice were placed on a vertical mesh grid and the latency to fall of the grid 
was measured. Non-paralyzed mice attached to the grid climb towards the upper end of the 
grid and explored the whole grid, while paralyzed mice fall of the grid within the observation 
period of 180 seconds.  
 
 
Figure 14: Picture of grid-test used to analyse motor phenotype. 
 
 
Histology and immunohistochemistry  
Mice were anaesthetized with a mixture of 100mg/kg ketamine (Ketalar®, Pfizer) and 
10mg/kg xylazine (Rompun® 2%, Bayer #79762704) by intraperitoneally and after deep 
sleeping, mice were injected by sodium pentobarbital (Pentothal® 0.5g, Ospedalia AG #6900) 
(100mg/kg) and transcardially perfused with 0.01M cold phosphate-buffered saline (PBS, 
Bichsel #1000326). 
 
Theses sections describe the principles for staining paraffin embedded samples. 
 
Brain, Spinal cord and nerve preparation 
After perfusion, the spinal cord, sciatic nerve and the brain were quickly removed and one 
half of the brain was immersion fixed in 4% paraformaldehyde O/N and embedded in 
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paraffin. Paraffin sections were deparaffinised in Xylol (Biosystems #253-VI53TE) for 20 
min, rehydrated in 100% EtOH for 3 min, then two times for 3 min in 96% EtOH and two 
times for 3 min in 70% EtOH. After rehydration in histological grade ethanol, sections were 
washed in PBS. In order to mask antigenic sites, antigen retrieval were performed in Citric 
acid buffer pH 6.0 (Pro Taps®  # 400300692) according to the primary antibody 
manufacturer’s recommendation. After blocking in normal horse serum for anti-rabbit (Vector 
Laboratories #S-1000) or in 2.5% normal horse serum (Vector Laboratories #S-2012) for 30 
min at room temperature (RT), sections were incubated O/N at 4°C with primary antibody. 
The next day, the sections were washed in Tris/PBS solution three times for 5 min and then 
incubated with ImmPRESTM Reagent peroxidase for anti-mouse antibody (Vector 
Laboratories #MP-7402) or Biotinylated anti-rabbit IgG (H+L) (Vector Laboratories # BA-
1000) for 30 min at RT. After the end of incubation time, the sections were washed with 
Tris/PBS three times for 5 min and developed by using chromogen ImmPACTTM NovaREDTM 
Peroxidase substrate kit (Vector Laboratories #SK-4805). After application of chromogen, the 
sections were washed with PBS to stop the reaction and then the slides were counterstained 
with hematoxyline (J.T. Baker #3873). Finally, sections were rehydrated in 70% ethanol for 1 
min, both two times in 96% and 100% EtOH and finally in xylol, before to apply Pertex 
mounting medium (Biosystems #41-4012-00) 
 
Gallyas silver staining 
After deparaffinisation and rehydration the sections were incubated in 3% Periodic Acid 
(Sigma #P7875) for 30 min at RT. Then, the slides were washed in dH2O, one time for 2 min 
and followed by incubation in 1% Alkaline Silver solution composed of 1M sodium 
hydroxide (Merck #106498); 0.6M potassium iodide (Merck # 105043); 1% silver nitrate 
solution (Merck #101512), for 10 min at RT. During this meantime, solution ABC were 
prepared as followed: 
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Concentration Supplier
Sodium Carbonate Anhydride 0.5 M Merck #106392
Ammonium nitrate 24 mM Fluka #09890
Silver Nitrate 0.01 M Merck #101512
Tungstosilicic Acid Hydrate 3.5 mM Aldrich #95395
Ammonium nitrate 24 mM Fluka #09890
Silver Nitrate 0.01 M Merck #101512
Tungstosilicic Acid Hydrate 3.5 mM Aldrich #95395
Formalin Solution 0,26% Merck #104003
Solution A
Solution B
Solution C
 
 
After incubation in ABC solution, the sections were treated with 0.5% Acetic Acid (Merck 
#100063) to block the reaction during 30 min in RT. After that, during 2 min (not too long), 
the slides were washed in dH2O and incubated in 5 % Sodium thiosulfate (Merck #106516) 
for 2 min in RT. They were then washed in cold tap water for 2 min at RT and nuclei were 
stained with hematoxyline for 5-15 sec. The sections were washed again in cold tap water for 
few minutes and in HCl for 5-15 sec, followed by washing in hot tap water for few minutes. 
Finally, the sections were dehydrated in EtOH (70%, 96% and 100%) and xylol (Biosystems 
#253-VI53TE) before to apply Pertex mounting medium (Biosystems #41-4012-00). 
 
Improved Thioflavin-S staining (adapted from A. Sun et al., JHC 2002) 
Before to start the staining, paraffin sections were deparaffinised and rehydrated as described 
before. First of all, it is important to quench the auto-fluorescence, the slides were incubated 
in 0.3% KMnO4 (Riedel-deHaën # 31404) for 4 min at RT and washed in water. After that, 
the sections were treated with a solution of bleaching solution, composed of both 1% K2S2O5 
(Merck # 105057) and Oxalic acid (Merck #100495), until the brown colour was removed 
from the tissue (20-40 sec), followed by a washing step with water. The sections were 
incubated in 1% sodium Borohydride (NaBH4, Sigma #452882) (which is prepared 2h before 
use) for 5 min at RT. After reducing background auto-fluorescence, the slides were washed 
three times with dH2O and were stained with 0.01% Thioflavin-S solution (Sigma # T1892), 
50% ethanol (Pharmacy USB) in the dark for 8 min. Again, the sections were washed two 
times in 80% EtOH for 10 sec and three times in large volumes of dH2O. Following the 
washing step, the sections were incubated in a high concentrated phosphate buffer, containing 
411mM NaCl (Merck # 106404), 8.1mM KCl (Merck # 104936), 30mM Na2HPO4 (Merck 
#106580), 5.2mM KH2PO4 (Merck #104873), pH 7.2, at 4°C for 30 min or more and after 
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the end of the incubation time, the slides were rinsed with dH2O and finally, mounted using 
glycerine and kept in dark. 
 
Hematoxylin and Eosin Staining 
After deparaffinisation and rehydratation two times in 100% EtOH, two times in 96% and 
then one time in 70% EtOH for 3 min respectively, the sections were rinsed in cold tap water 
and stained in hematoxylin for 5-8 min. After washing in cold tap water and decolorizing 
shortly in alcohol-HCl (Pharmacy USB), the slides were washed again in cold tap water and 
blueing for 10 min in warm water and immersed in 1% erythrosine B solution (RAL diagnosis 
#361990) for 2-3 min. After this incubation time, the sections were washed shortly in cold tap 
water, dehydrated in gradient EtOH  (one time in 70%, two times in 96% and two times in 
100%) and finally cleared in xylol before to apply Pertex mounting medium. 
 
Holmes Silver Nitrate-Luxol Fast Blue staining 
 
Concentration Supplier
Boric acid 1,24% Merck #165
Dinatriumtetraborat (Borax) 1,90% Merck #
Silver nitrate 1% Merck #1.01512
Pyridin solution 10% J.T.Baker #8073
Sodium sulfite 0.8M Merck #1.06657
Hydrochinon 90mM Merck #8.22333
Gold chloride 0,25% Sigma-Aldrich #HT1004
Acid oxalic 2% Merck #1.00495
Sodium thiosulfate 5% Merck #1.06516
Luxol fast blue 0,1% Medite #1B-389
Ethanol 96% Pharmacy USB
Acetic acid 10% Merck #100063
Impregnation solution
Reduction solution
Luxol Fast Blue solution
 
 
The sections were deparaffinised and rehydrated as describe before and placed in 20% Silver 
nitrate solution (Merck #1.01512), for 90 min in the dark at RT. The slides were washed in 
dH2O three times and incubated in impregnation solution at 37°C O/N. Next day, sections 
were placed onto filter paper to remove superfluous fluid and transferred directly in reduction 
solution for 10 min. Afterwards, the sections were washed in tap water for 5 min and rinsed 
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slides were placed in dH2O. During 5 min, the sections were moved in 0.25 % Gold chloride 
solution and then rinsed in dH2O for 10 min. The wash slides were incubated in 2% Acid 
oxalic for 10 min and when the axons were thoroughly blue-grey, the reaction were stopped 
by rinsing the sections in dH2O. After that, the slides were placed in 5 % sodium thiosulfate 
solution for 5 min and again rinsed in tap water before placing the slides briefly one time in 
70% and two times in 96% EtOH. Next the sections were incubated for 2 hours at 60°C in 
Luxol fast blue solution and briefly washed two times in 96% EtOH to remove excess stain, 
then placed in running cold tap water for 5 min and transferred into dH2O. For the 
differentiation, the slides were placed in 0.1% Lithium carbonate for few seconds and 
distained in 70% EtOH before to be washed in dH2O. Finally, the slides were immersed in 
Cresyl violet solution for 10 min at RT and washed first two times in 96% EtOH for few 
seconds to remove excess stain and then in two times in 100% EtOH before to place in xylol 
and apply Pertex mounting medium. 
 
Masson Trichrome staining (Nerve) 
Concentration Supplier
Solution I
Hematoxyline 33 mM Merck #1.04302
Ethanol 96% Pharmacy USB
Solution II
Iron (III) chloride 32 mM Merck #1.05512
Acid-HCl 25% Merck #1.00316
Solution I
Fuchsin acid 17 mM Merck #7629
Acetic acid 1% Merck #1.00063
Solution II
Ponceau 23 mM Chroma #1B 205
Acetic acid 1% Merck #1.00063
Aniline blue 34 mM Chroma #1B 501
Acetic acid 2,5% Merck #100063
Weigert's Iron Hematoxylin solution I
Ferric chloride solution
Acid fuchsin Ponceau
Aniline blue solution
 
 
The sections were deparaffinised and incubated in Weigert’s Iron Hematoxylin solution for 1 
min and washed in running cold water followed by warm water for 5-10 min. After that, 
slides were placed in Acid fuchsin Ponceau solution for 5 min, followed by washing in tap 
water. Then, the sections were incubated in 1% Acid Phosphomolibdic (Merck #1.00532) for 
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5 min and Aniline blue solution was added directly on the slides for 3 min (without discarding 
the 1% Acid Phosphomolibdic) under shaking. Afterwards, the sections were rinsed three-five 
times in dH2O and briefly (5 sec) transferred in 1% acetic acid. Finally, the rinsed slides were 
dehydrated two times in absolute EtOH, then in xylol, and coverslipped. 
 
Muscles preparation 
After perfusion, whole gastrocnemius (GC), soleus (Sol), tibialis anterior (TA) and extensor 
digitorum longus (EDL) were removed and embedded on a small mound of O.C.TTM 
compound (Tissue-Tek® Sakura #4583) that is placed on a cork disc and snap frozen in liquid 
nitrogen cooled isopentane, and stored at -80°C. Coronal sections were cut into 10-12µm 
thick cryosections with a cryostat (HydraxC, Histocom AG) maintained at - 20°C. 
 
 
Myosin-ATPase (Adenosintriphosphatase) staining (pH4.2) 
 
This section describes the procedure for staining frozen sections of O.C.T embedded samples. 
 
Concentration Supplier
Sodium acetate 0.1M Merck # 6265
Sodium barbiturate (Veronal) 0.1M Sigma # 32001
Veronalacetate buffer pH 4.2 0.1M Sigma # 32001
HCl 0.1M
Sodium barbiturate (Veronal) 0.1M Sigma # 32001
CaCl2 0.03M Merck #1.02378
Adenosin-5-triphosphate disodium (ATP) 4.5mM Fluka # 02060
Cobalt chloride 2% Merck # 2539
HCl 0.1M
NaOH 1M Merck 1.06498
Ammonium sulfide solution 21% Sigma # 09981
Veronalacetate buffer (stock solution)
Veronal Ca ATP pH 9.4 solution
ATP pH 4.2 solution
Veronal Ca buffer (stock solution)
 
Before cryosectioning, the samples were equilibrated O/N at -20°C, and then placed into the 
cryostat for minimum 20 minutes. The samples were mounted on the round metallic mount of 
the cryostat with O.C.T and the sections were cut at 10µm and then collected on warm slides 
at RT. Before to proceed the staining, the sections must be dry at least 1h at RT. The slides 
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were directly transferred in ATP pH 4.2 solution for 10 min at RT and placed shortly for 
washing in Veronal-Ca pH 9.4 buffer. After what, the sections were incubated in Veronal-Ca-
ATP pH 9.4 solution for 45 min at RT. Then, the slides were washed two times in tap water 
and directly moved in dH2O before transferring in 2% Cobalt Chloride for 5 min. After three 
washing in tap water, the sections were placed in Ammoniumsulfide solution for 14 sec and 
finally the slides were rinsed before to be rehydrated in ascending EtOH (one time in 70%, 
two times in 96% and two times in 100%) and transferred in xylol and apply Pertex mounting 
medium. 
 
Semithin sections for Sciatic nerve 
This procedure is for staining semithin sections of resin embedded samples. 
Sciatic nerves were dissected at the upper thigh and nerves were fixed for at least 2-3h in 2.5 
% of Glutaraldehyde (Fisher Scientific # BP 2548-1) in RT and washed in 0.01M PBS 
overnight. After incubation in PBS, 1 % Osmium tetroxide  (Oxkem Limited 10x1g) was 
added and incubated for 2h in RT. Tissue were washed in histological grade ethanol (70%, 
80%, 90% and two times in 100%) for 20 min each and two times in Acetone (Merck # 
1.00014) for 30 min. After this washing step, tissue were incubated in Acetone-Durcupan 
(1:1) solution for 60 min and after in Acetone-Durcupan (1:3) O/N at 4°C. Later, the tissue 
were mounted in Durcupan resin, containing 150ml of Durcupan A (Fluka #44611), 150 ml of 
Durcupan B (Fluka #44612), 3.1 ml of Durcupan C (Fluka #44613), 4 ml of Durcupan D 
(Fluka #44614), and cooked at 60°C for 2-3 days and processed for light microscopy. Semi-
thin section of the nerve was performed and ultrathin section (1.5 µm) was cut using a glass 
trip, which was equipped with a Reichert-Jung apparatus. 
 
Para-Phenylendiamin staining (p-phenylendiamine) 
 
After collecting the ultrathin cryosections on the slides and dried on warm plate, the sections 
were incubated in 1% p-Phenylendiamine (Sigma #P-6001) solution for 2-3 hours. Later, the 
slides were rinsed six-ten times in dH2O and dried at RT. 
 
Electron microscopy protocol (Spinal Cords) 
After deep anaesthesia with a mixture of 100mg/kg ketamine (Ketalar®, Pfizer) and 10mg/kg 
xylazine (Rompun® 2%, Bayer #79762704) intraperitoneally and sodium pentobarbital 
(Pentothal® 0.5g, Ospedalia AG #6900) (100mg/kg) injection, mice were transcardially 
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perfused with 0.01M cold phosphate-buffered saline (PBS, Bichsel #1000326) for 2-4min 
under hood and proceeded without pause with fixative solution composed of 2% PFA 
(Pharmacy USB); 2% Glutaraldehyde (Fisher Scientific #BP 2548-1); 0.1M PBS pH 7.4 
(Bichsel # 1000326); for 1h. After perfusion, the brain and spinal cords were removed and 
postfixed in the same fixative for 1h in RT and the tissue were rinsed in 0.01M of PBS. Then 
the tissue were reduced in 1% Osmiumtetroxid and 1.5% Potassium Ferrocyanide for 40 min 
and after the tissue were transferred in 1% Osmiumtetroxid for 40 min. Following washing 
step, the tissue were dehydrated in an ascending series of EtOH and aceton, then embedded in 
Epon. During dehydration, the sections were treated with 1% uranyl acetate in 70% ethanol 
for 60 min. Sections were cut with a microtom Ultracut E from Leica and collected on single-
slot grids, stained 6% Uranyl acetate for 60 min and with lead acetat for 2 min, and examined 
with a Morgagni FEI 80kV electron microscope. 
 
Sarkosyl extraction 
Extraction buffer 
Concentration Supplier
Tris 25 mM (pH 7.4) Biomol # 08003
NaCl 150 mM Merck # 1.06404.10 000
EDTA 1 mM Fluka BioChemika # 03690
EGTA 1 mM Sigma # E3889
Sodium pyrophosphate 5 mM Sigma # P8010
PhosSTOP®, Phosphatase inhibito cocktail tablets 1 tablet Roche # 04906837001
Sodium fluoride 30 mM Merck Suprapur # 1.06450.0025
Complete Mini, Protease inhibitor cocktail tablets 1 tablet Roche # 04693124001
Phenylmethyl sulfonyl fluoride (PMSF) 1 mM Sigma # P-7626
Leupeptine 10 µg/ml Sigma # L-2884
Aprotinine 10 µg/ml Sigma # A-1153
Pepstatine 10 µg/ml Sigma # P-5318  
 
A68 Buffer 
Concentration Supplier
Tris 10 mM (pH 7.4) Biomol # 08003
NaCl 800 mM Merck # 1.06404.10 000
Sucrose 10% Fluka BioChemika # 03690
EGTA 1 mM Sigma # E3889
Phenylmethyl sulfonyl fluoride (PMSF) 1 mM Sigma # P-7626
Leupeptine 10 µg/ml Sigma # L-2884
Aprotinine 10 µg/ml Sigma # A-1153
Pepstatine 10 µg/ml Sigma # P-5318  
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Phosphatase and protease inhibitors were freshly added to the extraction and A68 buffer. 
 
 
Following PBS (Bichsel #1000326) perfusion, one half of the mouse brain was dissected into 
forebrain and brain stem and immediately frozen in liquid nitrogen. Sarkosyl extraction was 
performed as described previously [95]. The brain tissue was homogenized in 3X volume of 
cold Extraction buffer (w/v) by using ultraturrax T8 (IKA labortechnik) and briefly sonicated 
(Bandelin SONOPLUS, 90% power, 10 % cycle, 10 sec pulses) Then the samples were 
centrifuged at 80 000g (28 000rpm) for 15 min by using ultracentrifuge (Beckman Coulter, 
OptimaTM L-70K Ultracentrifuge) by using SW55Ti rotor (Beckman Coulter #99E3241). The 
supernatant was collected to use for the analysis of soluble tau and the remaining pellets are 
homogenized in A68 buffer (w/v). Samples were centrifuges at 5 000 rpm for 20 min and 1% 
of sarkosyl (N-laurylsarcosine, Sigma #L74414) added for 1h30 at 37 °C in thermoshaker 
(Eppendorf Thermomixer comfort shaker) under shaking (max rpm). Samples were then 
centrifuged at 80 000g (28 000rpm) for 30 min and the pellet is resuspended in 150µl/g of 
tissue 50mM Tris HCl pH 7.4, considered as sarkosyl insoluble tau.  
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Figure 15: Schematic representation of sarkosyl extraction procedure 
 
Western Blot analysis 
Following PBS (Bichsel #1000326) perfusion, one half of the mouse brain was dissected into 
forebrain and brain stem and immediately frozen in liquid nitrogen. The brain tissue was 
homogenized in 1:10 volume of TBS-Complete buffer, containing 20mM Tris pH 7.5 
(Biomol #08003); 137mM NaCl (Merck #1.06404); 1 tablet of complete mini, protease 
inhibitor cocktail tablets (Roche # 04693124001); by using Ultraturrax T8 (IKA labortechnik) 
and then sonicated (Bandelin Sonopuls) at 90% power, 10% cycle and 10 pulses. The samples 
were centrifuged at 5000 rpm for 30 min and the supernatant was collected and aliquoted. 
 
Western blot was performed with the NuPAGE® System from Invitrogen, all materials and 
reagents were purchased from Invitrogen, BioRad and Amersham. 
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Gels were loaded with 10µl molecular weight marker and an appropriate amount of protein 
diluted in TBS-Complete buffer and incubated with 5 µl NuPAGE LDS sample buffer (# 
NP0007), 2 µl NuPAGE reducing agent (# NP0004) was used to work under reducing or non-
reducing conditions. 
 
Reagent Reduced Sample Non-reduced Sample
Sample x µl x µl
NuPAGE® LDS Sample Buffer (4X) 5 µl 5 µl
NuPAGE® Reducing Agent (10X) 2 µl  --
Deionized Water x µl x µl
Total Volume 20 µl 20 µl  
 
Samples were heated for 5 min at 95°C and quickly spin down and then loaded onto a gel. 
The proteins were separated on 7% Tris-acetate gels at 125V for 90 min. NuPage gels were 
carefully removed from the cassette and after activation of PVDF membrane (# RPN303F, 
Amersham Biosciences) in methanol for 30 seconds and 5 min in transfer buffer, NuPage gels 
were transferred onto PVDF membranes at 30V for 2h at RT by using the XCell IITM Blot 
Module. Unspecific binding epitopes were blocked with 5% non-fat milk in PBS-T (0.01M 
PBS pH 7.4; 0.05 % Tween-20 (Calbiochem # 655205)) for 1h at RT and incubated with 
appropriate dilution of primary antibody O/N at 4°C on a shaker. After washing three times 
with PBS-T for 5 min at RT, membranes were incubated with horseradish peroxidase (HRP)-
conjugated anti-mouse or -rabbit secondary antibody for 1h at RT. Then, membranes were 
washed three times with PBS-T for 5 min at RT and detected by electrochemiluminescence 
(ECL) (GE Healthcare, AmershamTM ECLTM #RPN2209). 
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The following antibodies were used for immunohistochemistry and western blot. 
 
Statistical analysis was performed using IBM® SPSS® Statistics Version 19 for t-tests and 
ANOVA. 
 
Antibody Species Specificity dilution Source
Tau-C3 Mouse Detection of caspase-cleaved Tau (truncated at Asp421) WB 1:1000; IHC 1:1000 Santa Cruz Biotechnology, Inc, Dallas, Texas #sc-32240
AT8 Mouse Detection of PHF-tau (Ser202/Thr205) WB 1:1000; IHC 1:800 Pierce, Rockford, IL #MN1020
AT100 Mouse Detection of PHF-tau (Ser212/Thr214) WB 1:1000; IHC 1:500 Pierce, Rockford, IL #MN1060
PHF-1 Mouse Phosphoserine 396/404 WB 1:2000; IHC 1:1000 Peter Davies, Albert Einstein College of Medecine, Bronx, NY
MC1 Mouse Detection of aa's 5-15, 312-322 IHC 1:100 Peter Davies, Albert Einstein College of Medecine, Bronx, NY
RD3, clone 8E6/C11 Mouse Human tau, recognize 3R, residue 209-224 WB 1:4000; IHC 1:3000 Millipore Corporation, Billerica, MA #05-803
RD4, clone1E1/A6 Mouse Human tau and mouse, recognize 4R, aa 275-291 WB 1:4000; IHC 1:100 Millipore Corporation, Billerica, MA #05-804
HT7 Mouse Human tau, PHF-tau, residue 159-163 WB 1:4000; IHC 1:800 Pierce, Rockford, IL #MN1000
2F11 Mouse Axons of CNS, PNS, react with NF-L(70KDa) IHC 800 Dako, Glostrup, DK #M0762
NF200 Mouse Neurofilament heavy protein IHC 1:100 Probst et al., 2000, Acta Neuropathol
GFAP Mouse Mature astrocytes IHC 1:500 LabVision (Thermo Fisher Scientific Inc. Kalamazoo, MI #MS-1407-R7
Synaptophysin Mouse Specific for presynaptic vesicles IHC 1:1000 Millipore Corporation, Billerica, MA #MAB5258
MG160 Rabbit Golgi apparatus IHC 1:1000 Nicholas Gonatas, Pathology and Laboratory Medicine, University of Pennsylvania, PA
VAMP2/Synaptobrevin 2 Rabbit Detection of fusion of transport vesicles IHC 1:1000 Synaptic system, Goettingen, Germany # 104 202
ß-actin Mouse Specific for actin WB 1:5000 Sigma-Aldrich, Saint Louis, MO #A5316
T49 Mouse Specific for rodent tau WB 1:10 000 Virginia Lee, CNDR, University of Pennsylvania School of Medicine, Philadelphia, PA
Cox subunit 1a Mouse Mitochondrial staining IHC 1:200 Abcam plc, Cambridge, UK #ab14705
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